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The Quality of Life Among Lymphedema Patients 
Due to Lymphatic Filariasis in Three Rural Towns in Haiti 
Koji Kanda 
ABSTRACT 
The worldwide eradication of lymphatic filariasis has recently started with two 
strategies, interruption of transmission and morbidity control. One of the most endemic 
countries, Haiti has experienced successful interventions through national and 
international efforts, but the morbidity control is still hindered by a lack of adequate 
information on quality of life (QOL) issues among those suffering from the chronic 
manifestations of the disease such as lymphedema. In addition, previous interventions 
have been focused primarily in a single community where an established lymphedema 
treatment clinic serves as a national reference center, so it is critical to expand programs 
to other areas in Haiti.  
The purpose of the study was to understand the issues of morbidity control and 
QOL among lymphedema patients due to lymphatic filariasis in three rural Haitian towns. 
Secondary data (n = 316) collected in an ongoing filariasis support group project was 
analyzed in terms of socio-demographic characteristics, including gender  age, and 
regional perspectives. Also, two different commercial QOL instruments (EuroQol, CDC 
Healthy Days) and a subjective well-being assessment tool (CES-D) were introduced to 
describe their QOL and mental health status, respectively. The reliability and validity of 
 ix
the measurements were established at the same time.    
Regional differences were evident in patients’ illness history, knowledge of the 
illness, self-care and self-efficacy for legs, and major QOL indicators related to physical 
and mental health. Age of patients also influenced foot size, illness stage, and the QOL 
scores. However, other socio-demographic factors were poorly associated with filariasis-
related variables, including gender. The commercial QOL instruments and a standardized 
mental health tool satisfied a reasonable level of reliability and validity. Though 
additional discussion is needed regarding the validation of the mental health scales 
between EuroQol and the other instruments, they nevertheless offer utility for enhancing 
the quality of morbidity control programs.  
These findings offer a significant contribution for the development of filariasis 
prevention programs such as community-based morbidity control and support group 
activities in Haiti, as well as other areas of the filariasis-endemic world.  
330 words 
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Chapter One 
Introduction 
Lymphatic filariasis (LF) is among the most common vector-borne diseases in 
tropical regions. Above a billion people are at risk and over 120 million people are 
infected with parasites in more than 80 countries in Africa, Asia, Central and South 
Americas, and the Pacific Islands (World Health Organization [WHO], 2000a). Of those, 
44 million people are suffering from symptomatic conditions such as lymphedema and 
hydrocele.  
Lymphatic filariasis is one of six eradicable tropical diseases worldwide (Center 
for Disease Control and Prevention [CDC], 1993). In 1998, WHO started the Global 
Programme to Eliminate Lymphatic Filariasis (GPEFL), an initiative aimed at complete 
eradication of filariasis by 2020. The program is based on two strategies: interruption of 
transmission and morbidity control. The interruption of transmission is designed for at-
risk and asymptomatic populations, and fairly achievable by several substrategies such as 
mass drug distribution and diethylcarbamazine (DEC)-fortified salt intake in endemic 
areas. The other approach, morbidity control, is targeted for those who live with chronic 
manifestations due to lymphatic filariasis. The control strategy includes adequate health 
education, compliance with hygiene regimens, and related efforts. However, it is still 
hindered by a lack of adequate information on quality of life (QOL) issues, which could 
lead to more suitable, effective guidelines for morbidity control. Particularly, since 
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filariasis is greatly associated with different socio-demographic variables (King & 
Freedman, 2000) and its clinical conditions are diverse by region or even within the same 
community (Dreyer, Figueredo-Silva, Neafie, & Addiss, 1998), providing appropriate 
morbidity control programs is a challenge in endemic areas including Haiti, which has 
one of the highest prevalence rates worldwide.  
One of the most common symptomatic manifestations due to LF is lymphedema. 
The non-fatal body disfigurement causes a huge burden of disability among infected 
people over decades. Currently about 15 million people are living with lymphedema 
worldwide. In one filariasis endemic area of Haiti, it is estimated that more than 20% of 
the population are carriers of microfilaremia (Pan American Health Organization 
[PAHO], 2001), and approximately 5% of women suffer from a severe form of 
lymphedema called elephantiasis (Eberhard, Walker, Addiss, & Lammie, 1996). 
Lymphedema is also often associated with the comorbidity of hydrocele and/or acute 
attacks. Such conditions execerbate daily life, but little research has been conducted on 
QOL among lymphedema patients. In Haiti, a morbidity control program has been in 
operation for almost a decade, at Ste. Croix Hospital in Leogane, and new treatment 
programs have recently been initiated in a few other areas of high endemicity. Therefore, 
understanding the issues of disabilities and the QOL among lymphedema patients due to 
LF would provide timely insights for improving morbidity control in other filariasis 
endemic areas in Haiti. 
 There are several objectives in this study. The first objective is to observe the 
association of filariasis-related variables among filariasis-related lymphedema in three 
rural Haitian towns. The association between the disease and socio-demographic 
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indicators is complicated because it is known that the prevalence and characteristics of 
filariasis varies by region or even within the same community (Dreyer et al., 1998) and 
that different populations infected with the same parasite can have very different clinical 
manifestations of the infection (Ottesen, 1987). Also, gender poses an important but 
complicated issue in LF and that there are no consistent results from an epidemiological 
standpoint. Above all, since it has been reported that there is higher prevalence of LF 
among women in Haiti (Lammie, Addiss, Leonard, Hightower, & Eberhard, 1993), 
attention to male Haitian patients has been very limited. Thus, careful consideration of 
socio-demographic variables would be significant for understanding of regional filariasis 
problems and the development of future morbidity control plans in the new communities. 
The other objective is to introduce and evaluate QOL measures among 
lymphedema patients due to LF. The QOL assessment procedure is now well established 
in chronic diseases. Though LF is categorized as an infectious disease, the symptomatic 
manifestations are chronic. Particularly, lymphedema due to LF is considered one of the 
most severe chronic disabilities among infectious diseases. Therefore, the application of 
the common generic QOL instruments such as the CDC Healthy Days Scales and 
EuroQol Instrument (EuroQol) would be an innovative approach to assess the QOL 
among the filariasis-related lymphedema patients. Also, a subjective well-being 
assessment tool for mental health, Center for Epidemiologic Studies Depression Scale 
(CES-D) would provide supplemental information for morbidity control. In order to fit 
these tools into Haitian cultures, it is important to establish the reliability and validity of 
the measurements prior to the assessment. Since there is no gold standard for QOL 
assessment for LF, the findings would be a significant contribution to future guidelines 
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for QOL assessment of LF as well as provide background information for the morbidity 
control programs. 
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Chapter Two 
Review of Literatures 
General Background - Epidemiology, Etiology, Treatment, and Prevention 
 Lymphatic filariasis is one of the most common vector-borne diseases in tropical 
regions. More than a billion people are at risk and over 120 million people are infected in 
more than 80 countries in Africa, Asia, Central and South Americas, and the Pacific 
Islands, (WHO, 2000a; WHO, 2002a). In particular, more than 40% of infected people 
live in India, and one-third in Africa. Filariasis is caused by eight different parasitic 
nematode worms: Brugia malayi, Brugia timori, Mansonella ozzardi, Mansonella 
perstan, Mansonella streptocerca, Loa loa, Onchocera volvulus, and Wuchereria 
bancrofti (King & Freedman, 2000). Of those, W. bancrofti, B. malayi, and B. timori are 
responsible for the infection in the lymphatic system of humans. W. bancrofti accounts 
for 90% of all infections of LF. It occurs in most tropical and subtropical filariasis 
endemic regions. On the other hand, the prevalence of brugian filariasis is limited to 
Asia. B. malayi is found from India in the west to South Korea in the northeast and 
Indonesia in the southeast (King & Freedman, 2000). B. timori is located only in eastern 
Indonesia. Brugian filariasis accounts for 13 million among all filarial-infected people. 
Figure 1 shows endemic countries of LF worldwide. 
Figure 1. Lymphatic Filariasis Endemic Countries (WHO, 2002a) 
 
 6
7 
The disease is transmitted by several kinds of mosquitoes. W. bancrofti is 
transmitted by Culex quinquefasciatus, Anopheles, and Adeles. Anopheles is also 
responsible for B. malayi transmission as well as Coquilletidia and Mansonia. B. timori is 
transmitted by Anopheles barbirostris (King & Freedman, 2000).  
The life cycle of the filarial parasite is identical to other vector-borne diseases. 
When the female mosquitoes ingest microfilariae with blood from infected humans, the 
microfilariae develop into infective filariworm larvae in the thoratic muscles of the 
mosquitoes, and travel to the lymphatics through the bloodstream. Then the larvae enter 
the human body when the mosquitoes feed on blood. In the lymphatic system, the larvae 
develop into adult worms and the female worms yield microfilariae, which reach the 
bloodstream again after the 6 – 12 months incubation period.  
Infected persons show one or more conditions after the incubation period. The 
conditions are divided into three stages: aymptomatic damage to the lymphatic system 
and kidneys, acute attacks of filarial fever, and chronic conditions such as elephantiasis 
and hydrocele. Asymptomatic infection is identified by the observation of millions of 
microfilariae in the blood vessel or adult worms in the lymphatic system without the 
onset of symptoms. The damage to the lymphatic system may enhance a risk of acute 
attacks such as acute adenolymphangitis (ADL). Kidney damage may cause blood and 
protein loss in the urine. Clinically asymptomatic microfilaremia is the most common 
manifestation of bancroftian filariasis, but a large proportion of infected people do not 
show any symptomatic sign (King & Freedman, 2000). It is estimated that 120 million 
people have asymptomatic conditions worldwide (WHO, 2000b). 
An acute episode is characterized by severe pain and inflammation of skin, lymph 
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nodes, and lymphatic vessels, often accompanied by fever, nausea, and vomiting. It is 
triggered by bacterial infections, which enter through breaks in the skin. ADL appears not 
only during the asymptomatic stage but also during the onset of chronic conditions. The 
attack usually lasts 5 - 7 days and usually occurs several times each year. Though some 
people have only a few attacks in their lifetime, they are likely to have experienced 
asymptomatic or subclinical conditions for years prior to the acute attack (King & 
Freedman, 2000). The progression of elephantiasis and fibrosis is typically observed 
during the attack. In the world, 15 million people are currently suffering from acute 
attacks (WHO, 2000b). 
Because the disease is rarely fatal, chronic symptoms are the severe burdens of 
infected people. The major symptoms include adenopathy, genital manifestations, 
lymphedema, and tropical pulmonary eosinophilia. Adenopathy is a painless enlargement 
of a lymph node due to the presence of adult worms in the lymphatic vessel, but lymph 
node enlargement may be the only clinical symptom in infected people, regardless of the 
presense of microfilaremia (Dreyer et al., 1998). Genital manifestations include 
hematuria, hydrocele, chylocele, chyluria, lymphedema and elephantiasis of the scrotal 
wall, penis, and lymph scrotum. In particular, hydrocele is the most common genital 
impairment among males. Hydrocele is a symptom that the sac around the testes becomes 
inflated like a baloon with a volume of fluid inside. It is estimated that 25 million men 
suffer from hydrocele worldwide (WHO, 2000b). Chylocele also shows the same 
disfigurement of genitalia, but intestinal chyle are included inside of the sac. It is less 
frequent than hydrocele. Chyluria and hematuria may happen among infected people. In 
some cases, chyle and blood are present in the urine. Lymphedema is a lymphatic 
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dysfunction which dilates the lymphatic vessels due to filarial infections. It appears most 
frequently on the lower extremities of the legs, and the severe condition called 
elephantiasis includes dermatosclerosis and papillomatous lesions as well as the swelling 
of a part of or an entire body. Currently 15 million people worldwide are impaired by 
lymphedema/elephantiasis (WHO, 2000b). Tropical pulmonary eosinophilia is an 
asthma-like symptom with paroxymal nocturnal cough and anorexia, but its frequency is 
relatively unusual (Dreyer et al., 1998). 
The strategy of the treatment and prevention of LF is well established. WHO 
(2000a) recommends annual, single-dose, two-drug regimens of diethylcarbamazine 
(DEC) with albendazole or ivermectin to get rid of microfilariae from the blood. For the 
infected surface areas, maintaining rigorous simple hygiene by careful cleansing is 
extremely helpful in managing the chronic condition and preventing acute attacks. Also, 
protecting the surface from mosquito bites by the use of bednets, insecticides, and 
repellents is effective for interruption of larvae transmission. Likewise, the control of 
mosquito-favorable environments such as large areas of water is also helpful. Surgical 
operation is another option for treatment of chronic conditions. However, though it is 
technically feasible and great improvement of the conditions can be expected, most 
endemic areas usually face financial limitations and inadequate medical resouces so that 
the operation is often not practical. DEC-fortified salt intake is also useful and cost-
effective for future prevention. 
Lymphatic filariasis is also called one of six eradicable diseases in the world 
(CDC, 1993). WHO has recently initiated the Global Programme to Eliminate Lymphatic 
Filariasis (GPEFL) to achive complete eradication of filariasis by 2020. The strategy of 
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the global elimination program includes two cost-effective and socially-responsible 
components: interruption of transmission, and morbidity control. The interruption of 
transmission is fairly achievable because humans are the only reservoir of W. Bancrofti, 
which is responsible for 90% of all parasites causing LF (Ottesen, 2000). Also, the 
transmission of the filarial worm is less frequent than with other parasite diseases 
(Ottesen, 2000). Thus, WHO designed the strategic procedures to interrupt transmission 
in two steps; districts in which lymphatic filariasis is endemic must be identified, and 
then community-wide (mass treatment) programs implemented to treat the entire at-risk 
population (WHO, 2000a). In most countries, one time annual simultaneous single dose 
administration of two drugs, 400 mg albendazole plus 6 mg/kg DEC, will be effective. 
The areas where either onchocerciasis or loiasis may also be endemic require the same 
regimen but use 200 mcg/kg ivermectin instead of DEC for 4-6 years. An alternative 
community-wide regimen is to provide common table/cooking salt fortified with DEC in 
the endemic region for a period of one year (WHO, 2000a). This mass treatment gives 
equal effectiveness to at risk populations. 
On the other hand, morbidity control is targeted for those suffering from chronic 
conditions. Since the non-fatal disease often causes both suffering and disability among 
patients for a long time, it is necessary to alleviate their conditions. There are several 
approaches to morbidity control, but WHO (2000a) states that it will be necessary to 
implement community education programs to raise awareness in affected patients. This 
would promote the benefits of intensive local hygiene and the possible improvement, 
both in the damage already occurred, and in preventing painful, acute episodes of 
inflammation and future infection (WHO, 2000a). Also, the creation of hope and 
  11
understanding among the patients and their communities are additional important factors 
for morbidity control.  
 
 
Lymphedema 
 Lymphedema is one of the commom chronic symptoms among LF patients 
(Figure 2). It is currenly estimated that 15 million people are living with lymphedema due 
to lymphatic filariasis worldwide (WHO, 2000b). The disease is caused by the presence 
of adult worms in the lymphatic vessels. It is sometimes triggered by physical events 
such as injury or pregnancy. The worms dilate the lymphatic vessels and make the 
lymphatic system malfunction. Lymphedema usually occurs in the lower extremities, but 
it also appears in the arms, breast, and urogenital organs. In the presence of the symptom 
on lower legs, Dreyer, Addiss, Dreyer, and Noroes (2002) categorized its symptom into 
seven stages (Table 1, Appendix A). Most conditions are either of stage 1, 2, or 3, but 
sometimes more extreme cases can be detected. 
Table 1. Lymphedema Stage and Its Characteristics (Dreyer et al., 2002). 
Lymphedema Stage Characteristic 
Stage 1 Swelling goes away overnight. 
Stage 2 Swelling does not go away overnight. 
Stage 3 Shallow skin folds. 
Stage 4 Knobs. 
Stage 5 Deep skins folds. 
Stage 6 Mossy lesions. 
Stage 7 Unable to care for self or perform daily activities. 
 
 
 Figure 2. A Condition of Lymphedema. 
 
 
 
Like other filariasis symptoms, the prevalence of lymphedema increases as 
infected people get older. Shriram, Murheker, Ramaiah, and Sehgel (2002) found that the 
increase was stable between 20 and 30 years of age, but that it became significant 
afterwards. The prevalence of the disease is also associated with gender. However, the 
effects are not consistent. Lammie et al. (1993) found that the incidence of lymphedema 
was 5 – 10 times greater among females than males in Haiti. On the other hand, in India, 
more males experienced lymphedema than females (Shriram et al., 2002). Acute attacks 
frequently occurred among lymphedema patients. In Tanzania, 61.3% of lymphedema 
patients developed ADL (Gasarasi, Premji, Mujinja, & Mpembeni, 2000). Also, ADL 
was more common among patients with lymphedema than hydrocele in Ghana (Gyapong, 
Gyapong, & Adjei, 1996b). In addition, recurrent bacterial infections facilitated the 
progression of lymphedema to elephantiasis (Dreyer et al., 1998). Comorbidity of 
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lymphedema and other chronic symptoms, especially hydrocele in male, is another 
concern. In eastern India, Shriram et al. (2002) reported that 15.9 % of hydrocele patients 
had lymphedema, and 90 out of 565 (12.4 %) of male filariasis patients had both 
hydrocele and lymphedema in the southern state of Tamil Nadu (Ramaiah et al., 2000). 
Regular, intensive hygiene is a critical part of the prevention and treatment of 
lymphedema. Though drug therapy such as albendazole and DEC is effective as an anti-
parasitic treatment, daily washing and drying is extremely important for minimizing the 
chance of future acute attacks and maximizing the degree of elephantiasis improvement. 
Elevation of the legs is also an important exercise for alleviating the condition. In 
addition, patient education is critical for changing fatalistic beliefs about the disease and 
maintaining their motivation to follow the regimen (WHO, 2000a). Surgical procedures 
are limited in resource poor, filarial endemic settings. 
 
 
Four Aspects of Lymphatic Filariasis 
 As mentioned above, morbidity control is one of two pillars of eliminating LF 
globally. WHO (2000b) categorized suffering and disability of LF into four different 
aspects: physical, social, psychological, and economic.  
 Physical components of disability include asymptomatic or symptomatic body 
conditions such as acute inflammatory attacks, disfigurement of the body, decreased 
mobility and function of limbs, obesity, and hidden disease (WHO, 2000b). The acute 
attack is a painful bacterial infection of the skin and superficial tissues. The incidence 
increases as they get older, with a peak in the 50s (Gasarasi et al., 2000; Gyapong et al., 
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1996b). The impairment of the body influences daily activities, especially among female 
patients. Ramaiah, Vijay Kumer, Ramu, Pani, and Das (1997) found that women 
suffering from chronic conditions had significant difficulties in domestic chores. Also, 
there is a tendency for women to refrain from traveling due to the physical impairment 
(Bandyopodhyay, 1996; Coreil, Mayard, Louis-Charles, & Addiss, 1998; Ramaiah et al., 
1997). 
In addition to the physical burdens, there are huge negative impacts on social, 
psychological, and economic conditions among chronic patients. From a social 
perspective, malfunction of the body increases the difficulty of self-care. Although it is 
unusual to have a self-untreatable condition, the limitation of the body function enhances 
the stress of care in daily lives. Patients also suffer from shame, stigma, and 
discrimination due to disfigurement of the body. In Haiti, patients reported negative 
effects of their illness on family relations, and they experienced at least some sort of 
discrimination in the community (Coreil et al., 1998). Also, women experienced 
embarrassment, shame, cultural constraints, and social taboos preventing them from 
seeking help (Bandyopodhyay, 1996). People from the community often refuse to marry, 
sit beside, or eat with LF affected persons (Rauyajin, Kamthornwachara, & Yablo, 1995). 
Those suffering from genital impairment experience sexual disability. Above all, those 
with hydrocele experience severely impaired sexual function as well as decreased work 
capacity, and it has apparently negative effects on the QOL for the patients, families, and 
communities (Ahorlu, Dunyo, Asamoah, & Simonsen, 2001). Also, unmarried men with 
hydrocele found it difficult to find a spouse due to the condition, and married men 
experienced various degree of sexual dysfunction (Gyapong, Gyapong, Weiss, & Tanner, 
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2000). 
Related to the social aspects, psychological burdens also influence patients’ lives. 
It is significant to observe the negative consequence in mental health. Typically, people 
suffer from depression, passivity, hopelessness, and fatalism, in some cases even leading 
to suicide (WHO, 2000b). Such phenomena might happen among both patients and 
family members. However, low-cost psychosocial interventions such as support groups, 
offer significant benefits and satisfaction in allevieting the psychological burden of 
disease as well as improvement in QOL for people with LF in developing countries 
(Coreil, Mayard, & Addiss, 2003). 
Finally, economic limitation is the other negative aspect of LF. Because of the 
nature of the disease, it significantly affects poor people. The impairment minimizes both 
quantity and quality of work among infected people. A large number of acute patients are 
completely absent from their jobs during the onset of attacks, usually 3 - 4 full days 
(Gasarasi et al., 2000; Gyapong, Gyapong, Evans, Aikins, & Adjei, 1996a; Ramaiah et 
al., 2000). Though the coping mechanism works among chronic patients, they also fail to 
pursue their works at the same level as before (Babu et al., 2002; Gyapong et al., 1996a; 
Ramaiah et al., 2000). In India, for example, 32 % of the total days suffering from attacks 
are considered as a loss of any economic work among chronic patients due to lymphatic 
filariasis, and a loss of work is significant in those with lymphedema only, those with 
hydrocele only, and those with both lymphedema and hydrocele (Ramaiah et al., 2000). 
Women’s productivities are also impaired by the disease in endemic regions 
(Bandyopodhyay, 1996; Coreil et al., 1998). Level of absenteeism is influenced by 
disease conditions as well as other personal characteristics such as age, gender, and 
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family type (Babu et al., 2002). Since the disease manifestations are more prevalent 
among householders, the family suffers from income shortage. In India, about 7 % of 
household income goes for the treatment of LF, and the cost of hydrocele surgery 
exceeds more than one-third of the average household income (Babu et al., 2002). 
Therefore, economic loss eliminates the possibility of recovery and threatens daily life. 
Then the economic difficulty indirectly affects negatively on social and psychological 
impairment among both patients and family (Babu et al., 2002). As a result, a single 
disease causes a vicious cycle of physical, social, psychological, and economic burdens. 
 
 
Haiti 
The Republic of Haiti is located on the island of Hispaniola, surrounded by the 
islands of Cuba and Jamaica on the west and Puerto Rico on the east. Haiti occupies a 
land area of 27,700 km2 on the western-third of the island, and the rest is governed by the 
Dominican Republic. The nation consists of nine departments, 133 minicipalities, and 
561 districts, with a total of 8.2 million people (PAHO, 1998; WHO, 2002b). Because of 
the high fertility rate (4.4 per woman), children under 15 years old accounts for 40 % of 
the total population (PAHO, 2003). On the other hand, people over 65 only account for 4 
% due to low life expectancy at birth (52.8 years in males and 56 years in females) 
(PAHO, 2003). Haiti is also one of the most densely populated countries in Central and 
Latin Americas. Owing to the small territory with rapid increase of the population, the 
population density is 260 inhabitants per km2 nationwide and 885 inhabitants per km2 of 
cultivated land, as of 1995 (PAHO, 1998).  More than one-third of the total population 
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(34.7%) are living in the capital, Port-au-Prince, and there is a tendency toward rapid 
increase of the urban population in recent years (PAHO, 1998). This basic demographic 
information is summarized in Table 2.  
Table 2. Demographic Profile in Haiti. (PAHO, 1998; WHO, 2002b; PAHO, 2003) 
Country name The Republic of Haiti 
Location N 19”00, W 72”25, western one-third of Hispaniola 
Land area 27,700 km2  
Capital Port-au-Prince 
Administrative divisions 9 departments, 133 minicipalities, 561 districts 
Population  8.2 millions (1997) 
15 years or younger 42 % 
16-64 years 54 % 
65 years or older 4 % 
% living in capital 34.7 % 
Total fertility rate (TFR) 4.4 
Population density (nationwide) 260 people per km2 (1995) 
(cultivated land) 885 people per km2 (1995) 
Life expectancy at birth 52.8 years in male, 56 years in female 
 
Haiti is categorized as one of the least developed countries in the world. Social 
service infrastructure is poorly established or nonexistent. All types of infrastructure such 
as water, sewage and sanitation systems, enviromental pollution due to the rapid increase 
of motor vehicles, and road networks are definitely inadequate (PAHO, 2003). Moreover, 
due to the chronic political instability and economic crisis, the actual gross domestic 
product showed decline to 1980’s level in late 1990s, and the unemployment rate 
exploded instead (PAHO, 1998; World Bank, 2002). Currently, more than 80% of the 
total population is below the poverty line (World Bank, 2002). The gross domestic 
product (GDP) per capita was US$460 in 1999 (World Bank, 2002), or 1,094 
international dollars in 2000 (WHO, 2002b), both of which are the least amount in the 
Americas. 
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There is no systematic method to collect, process, and disseminate information on 
mortality in Haiti (PAHO, 1998). However, it is estimated that nearly one-half of all 
deaths happen during the first five years of life due to diarrheal diseases, acute respiratory 
infections, and malnutrition (PAHO, 1998). Vaccine-preventable diseases such as 
measles, diphtheria, and neonatal tetanus are still prevalent due to unsatisfactory 
vaccination rates. In 2000, vaccination coverage of measles, DTP3, and BCG was 75%, 
45%, and 55%, respectively (PAHO, 2003). As a result, a certain number of vaccine-
preventable diseases occur intermittantly. For adolescents and adults, both communicable 
and noncommunicable diseases are common. Tropical vector-borne diseases such as 
malaria and dengue fever as well as lymphatic filariasis are endemic. Malaria is found 
throughout the country but its occurrence is more frequent in rural coastal areas, varying 
year to year in relation to season and the amount of rainfall (PAHO, 1998). In 1999, 973 
cases and 59 deaths attributed to Plasmodium falciparun were reported (PAHO, 2003). 
Likewise, dengue fever has been prevalent particularly in urban areas, though the 
epidemiological data are insufficient to estimate its magnitude (PAHO, 2003). The 
outbreak of more severe forms of dengue, including dengue hemorrhagic fever and 
dengue toxic shock symdrome, is a constant threat throughout the country (PAHO, 1998). 
Other communicable diseases such as tuberculosis, HIV/AIDS, sexually transmitted 
diseases (STDs), and zoonoses are also found all over the country. However, poor 
surveilance systems often cause underestimation in the entire nation. 
Haiti is one of the most endemic countries with lymphatic filariasis. The presence 
of bancroftian filariasis in Haiti originated from the history of African slave trade (King 
& Freedman, 2000). Although the exact nationwide prevalence is unknown, it is 
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estimated that more than 20 % of the population in most coastal cities are carriers of 
microfilaremia (PAHO, 2001). In the city and surrounding areas of Leogane, for example, 
the prevalence of microfilaremia is about 25 %, approximately 5 % of women have a 
chronic symptom of elephantiasis, and the prevalence of hydrocele among men is up to 
30% (Eberhard et al., 1996). Recently a filariasis mapping for children has completed 
(Beau de Rochears et al., in press). It shows that two major areas, Leogane and areas 
surrounding of Port-au-Prince, and the North Department, record the highest prevalence 
of microfilaremia. 
 
 
Factors Associated with Lymphatic Filariasis and Lymphedema 
There are complicated issues in socio-demographic variables associated with 
lymphedema due to LF. Age is greatly associated with the onset of symptoms. The 
identification of both microfilaria and symptomatic conditions is rare in early childhood, 
but the incidence increases as people get older (Gasarasi et al., 2000; Gyapong et al., 
1996b; Hyma, Ramesh, & Gunasekaran, 1989; King & Freedman, 2000; Shriram et al., 
2002; Weerasooriya, Weerasooriya, Gunawardena, & Samarawickrema, 2001). Likewise, 
the prevalence of lymphedema also increases as infected people get older. Shriram et al. 
(2002) found that, although the increase was stable between 20 and 30 years of age, it 
became significant afterwards.  
On the other hand, the gender profile remains unclear. It is generally held that 
more females suffer from lymphedema than males. In Haiti, Lammie et al. (1993) found 
that the incidence of lymphedema was 5 – 10 times higher among females than males. 
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However, the tendency seems inconsistent in other areas of the world. Shriram et al. 
(2002) showed that more males experienced lymphedema than females in India. No 
significant gender differences were observed among elephantiasis patients with filarial 
fever in Sri Lanka (Weerasoriya et al., 2001). The unclear gender perspective also tends 
to occur in other filariasis conditions. Several studies mentioned that men generally had 
higher microfilaremia levels and some clinical features such as hydrocele than women 
(King & Freedman, 2000; Weerasooriya et al., 2001). Gasarasi et al. (2000) found that 
males experienced acute attacks more often than females in Tanzania; however, females 
had higher prevalence of acute attacks than males in Ghana (Gyapong et al., 1996b). 
Thus, the gender perspective is one of the important factors for consideration in LF 
elimination. More issues related to gender will be discussed in later chapters. 
Socioeconomic status (SES) is an another important factor in LF. Filariasis 
principally affects persons of the lowest SES, especially those who are unable to protect 
themselves from mosquitoes sufficiently and/or who live in the mosquito-favorable 
environments (King & Freedman, 2000). Educational status as well as employment status 
of the household-head were positively associated with protection against mosquito vector 
contacts (Mwobobia & Mitsui, 1999). Place of residence is also a source of variation. It is 
known that the prevalence and characteristics of LF varies by region or even within the 
same community (Dreyer et al., 1998). Also, different populations infected with the same 
parasite can have very different clinical manifestations of the infection (Ottesen, 1987). 
In Haiti, most research has been conducted in the city and surrounding areas of Leogane 
only. Thus, different aspects of lymphatic filariasis would be observed within the country.  
In terms of knowledge of the illness, the lack of current knowledge about filariasis 
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is a significant risk factor for higher rates of morbidity among those affected. Reports 
from several countries indicate that poor knowledge about LF significantly execerbates 
conditions and contributes to high risk behavior (Ahorlu et al., 1999; Eberhard et al., 
1996; Gyapong et al., 1996a; Rauyajin et al., 1995). Particularly, in spite of the obvious 
recognition of both acute and chronic symptoms, there is almost no understanding of the 
etiology of these conditions and the role of mosquitoes that transmit the disease in Haiti 
(Coreil et al., 1998; Eberhard et al., 1996). In addition, the lack of knowledge is less 
likely to promote self-care practice at home. Since the simple daily care is important for 
the alleviation of the leg condition, the lack of knowledge would lead to the poor 
compliance and the lower self-efficacy of the self-care regimen at home, and therefore 
the QOL among patients would remain lower in their later life. However, there is little 
research about this issue and a more in-depth understanding is needed. 
Certain occupations contribute to the high prevalence of LF. Because the 
distribution of the disease is in rural areas of the developing world, those engaging in 
agricultural-related work using water have higher chances of exposure. Particularly, it 
was reported that the rainy season was associated with more frequent episodes of acute 
attacks (Gasarasi et al., 2000; Gyapong et al., 1996b). Thus, the type of occupation and 
the prevalence of filariasis seems to be related. However, there is no information about 
such relationships in Haiti.  
As mentioned in the section on lymphedema, comorbid conditions related to 
filariasis are likely to affect lymphedema patients. An acute attack is one of the most 
common complications. In Tanzania, 61.3 % of lymphedema patients developed ADL 
(Gasarasi et al., 2000). Also, ADL is more frequent among patients with lymphedema 
  22
than hydrocele in Ghana (Gyapong et al., 1996b). In addition, recurrent bacterial 
infections facilitate the progression of lymphedema to elephantiasis (Dreyer et al., 1998).  
 
 
Gender Perspective 
The gender perspective is an important aspect of LF. There is a lot of controversy 
regarding gender differences in LF. From an epidemiological standpoint, the prevalence 
of infection is often higher among men than women during the childbearing years 
(Dreyer et al., 1998). Also, males have higher microfilaremia levels and clinical 
symptoms because of a frequent consequence of hydrocele (King & Freedman, 2000; 
Weerasooriya et al., 2001); in contrast, females experience a higher incidence of 
lymphedema and ADL (Gyapong et al., 1996b; King & Freedman, 2000). However, the 
opposite results have also been reported in different regions (Gasarasi et al., 2000). These 
outcomes indicate that the risk factors of infection by gender vary by location.  
Though several studies have focused on females, there has been little attention to 
the disease among males in Haiti. At the same time, QOL among chronic patients is also 
a gender sensitive issue. Because the nature of the body disfigurement differs by gender, 
it affects their QOL in a different manner. Above all, because of higher prevalence of 
chronic conditions and social ignorance about the disease among females, research 
among males is quite limited. The dominant symptomatic condition among males, 
hydrocele, also makes it difficult to intervene in some cultures because of the location of 
the disfigurement. Therefore, this study also aims at a gender comparison of filarial 
infection on risk factors and QOL. 
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Quality of Life 
Lymphatic filariasis is known as the disease which is the second leading cause of 
disability worldwide (WHO, 1995). Since mortality is rarely an issue in filariasis, acute 
attacks and several chronic conditions greatly affect their QOL. One of the obviously 
negative aspects is that acute attacks and clinical manifestations limit physical activity. 
Reports in endemic countries indicate that both acute and clinical manifestations 
significantly hamper daily activities of infected people, especially women engaging in 
housework such as cooking, cleaning, washing and bringing up children (Ramaiah et al., 
1997; Ramaiah et al., 2000). Male patients also go through the impairment of sexual 
function due to hydrocele (Ahorlu et al., 2001). In the Haitian case, more than 70 % of 
patients with lymphedema in Haiti experienced limited physical activities due to acute 
attacks (Dahl, 2001). In relation to physical activities, economic loss is another burden 
among infected persons. Many studies show that symptomatic conditions forced people 
to reduce their economic productivity or even stay at home all the time. In particular, 
those with ADL are affected much more severely. Although chronic patients are usually 
capable of maintaining their economic activities at some level (Gyapong et al., 1996a), it 
is almost impossible for those with ADL to have any income during the period of 
symptoms (Ahorlu et al., 1999; Babu et al., 2002; Gyapong et al., 1996a; Ramaiah et al., 
1997; Ramaiah et al., 2000). However, it is still significant that there is a regional 
difference in loss of work based on gender (Babu et al., 2002; Ramaiah et al., 2000). In 
addition, since the economic loss not only reduces their income but directly increases the 
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proportion of treatment cost in a family, patients’ health-seeking behavior is restricted 
(Gyapong et al., 1996a). Hence, they are more likely to endure their painful conditions. 
Psychosocial burden and QOL are strongly related in filariasis patients. Social 
stigma and discrimination prevent them from participating in the community and society 
as well as induce mental and psychological stress among them due to their abnormal 
physical features (Bandyopadhyay, 1996; Coreil et al., 1998). Patients with hydrocele 
also face a severe psychosocial burden (Ahorlu et al., 2001; Gyapong et al., 2000). 
However, surgical repair of hydrocele greatly improves QOL both physically and 
mentally, even though its cost is prohibitive in resource poor countries (Ahorlu et al., 
2001). Physical disability also makes a negative psychosocial impact on not only patients 
per se but also their family and community. Coreil et al. (1998) found that patients 
experienced difficulties in maintaining a good relationship with their family, and that the 
family underwent social discrimination and ostracism from the community. Therefore, 
QOL among lymphedema patients is likely to be considered poor. 
On the other hand, effective morbidity control programs have a great impact on 
communities. Coreil et al. (2003) reported that successful support group activities in a 
filariasis endemic area of Haiti showed significant improvement on patients’ QOL. 
However, even if the treatment regimen of lymphedema was well introduced in the 
community, patients often felt unconfortable following some practices such as bandaging 
and elevation of the legs due to discomforts, pain, itching, and tightness of bandages 
(Coreil et al., 1998). Therefore, it is important to make an additional control strategy by 
careful understanding of QOL among them.   
There is no gold standard in QOL assessment for chronic patients due to 
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lymphatic filariasis. Several different QOL measurement forms for chronic diseases have 
been established and widely available over the last few decades. Yet, there are challenges 
for QOL assessment of lymphedema patients due to LF by using health-related QOL 
measurements. The latest try attempted QOL assessment of the introduction of hygiene 
and skin care regimens in Guyana, using the Dermatology Life Quality Index (DLQI) 
(McPherson, 2003). It was concluded that the improved DLQI scores after the regimen 
indicated that the morbidity management by trained nurses was an effective intervention 
to enhance their QOL. However, the sample size was small (n=15), and the validity and 
reliability of the measurement was established only when lymphedema was considered as 
a skin disease.  
Another QOL study among lymphedema patients was conducted by the 
Nottingham Health Profile (NHP) to evaluate conservative treatment for general chronic 
lymphedema patients rather than lymphedema due to LF (Sitzia & Sobrido, 1997). 
However, the reliability and validity of the questionnaires was not established, and the 
study concluded that the first part of NHP was less useful for QOL assessment among 
them so that the authors recommended other assessment tools such as the SF-36, the 
MOS 36-item short-form health survey (Ware & Sherbourne, 1992).  
Pereira de Godoy, Braile, de Fatima Godoy, and Longo (2003) recently examined 
the QOL among lymphedema patients with the SF-36. Though the objective of the 
assessment was designed not only for those due to LF but for general lymphedema 
patients, the researchers concluded that both physical and mental health as well as social 
interaction among the lymphedema group showed a statistically significant lower QOL. 
However, in addition to the small sample size (n=23), neither does Haitian Creole version 
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of SF-36 exist in QualityMetric, Co. Ltd, the organization which retains the right to 
access SF-36, nor have translation efforts among researchers been accepted. Therefore, it 
is currently impossible to conduct the QOL assessment among Haitian lymphedema 
patients with the SF-36. 
Therefore, it would be beneficial to introduce other QOL assessment tools among 
lymphedema patients. Considering the characteristics of the disease manifestation, there 
are several generic instruments which could apply to Haitian lymphedema cases. One of 
the most commonly used instruments is the EuroQol Instrument, developed by the 
EuroQol Group, a consortium of five European countries in 1987. It is designed to 
examine the feasibility of jointly developing a standardized non-disease-specific 
instrument for describing and valuing health-related QOL (Brooks, 1996). The test 
consists of two parts: EuroQol five-demension health scale (EQ-5D) and EuroQol Visual 
Analogue Scale (EQ-VAS). EQ-5D consists of five questions from five different health-
related concepts each: mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. Each question has three different answers, and respondents have to 
choose one of them, on the basis of the current day’s health status. Thus, there are 35 = 
243 possible combinations to describe one’s health. These outcomes are weighted by 
EuroQol group guidelines. On the other hand, the EQ-VAS measures one’s overall health 
status by pointing a 20cm vertical visual analogue scale, which ranges from zero as a 
worst imaginable health state to 100 as a best imaginable health state. Like EQ-5D, EQ-
VAS also assesses current health status. A number of researchers have used the EuroQol 
in QOL assessment for various chronic diseases (e.g. Fransen & Edmonds, 1999; Hurst, 
Kind, Hunter, & Stubbing, 1997; Konig et al., 2002; Myers & Wilkes, 1999). 
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Another widely used form is the CDC Healthy Days questionnaire, developed by 
CDC (2000). It is a compact set of measures about recent perceived physical and mental 
health status and activity limitation. The latest version of the questionnaire consists of 
three parts: four general questions of self-determined health condition, five measures of 
acitvity limitation, and five additional statements regarding QOL. The first four core 
questions assess self-rated general health status, the duration of the unhealthy condition 
regarding physical and mental health, and the length of activity limitation due to both 
poor physical and mental health. Each question except the first one requires the answer 
during the past 30 days. The second part, five measures of acitvity limitation, assesses the 
major cause and duration of limitation and how it affects people's routine and personal 
care only if they have any activity limitation. The last part evaluates the length of 
unhealthy days due to pain, depression, anxiety, sleeplessness, and vitality within last 30 
days. CDC (2000) indicates that the Healthy Days measures are useful for identifying 
health disparities, tracking population trends, and building broad conditions around a 
measure of population health compatible with the definition of health by WHO. 
Particularly, the questionnaires are more focused on activity liminations so that the 
context would be suitable for the evaluation of lymphedema-oriented QOL.  
For assessing QOL in mental health, Center for Epidemiologic Studies 
Depression Scale (CES-D) developed by Radloff (1977) in National Institute of Mental 
Health is widely used. It is a 20-question self-reporting scale to evaluate one’s depressive 
condition in the past week by four simple scores. Most of the above questionnaires ask 
about negative experiences but some assess positive atittudes of respondents. 
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Reliability and Validity of the Quality of Life Measurements 
Since the reliability and validity of the generic QOL instruments are not yet 
established in filariasis-endemic Haitian communities, it is important to assure the quality 
of the measurements prior to a survey administration. Reliability is the extent to which a 
measure yields consistent results. In other words, it looks at the extent to which scores are 
free of random error. Ary, Jacobs, and Razavieh (2002) explains that three different 
consistency measures or reliability coefficient (rxy) are widely used for reliability 
measurement: 1) test-retest coefficient; 2) alternate-form coefficient; and 3) internal-
consistency coefficient. The test-retest coefficient is one derived from correlating 
individuals’ scores on the same test in two different administrations with a certain 
interval. The alternate-form coefficient comes from correlated individuals’ scores on 
different sets of equivalent items. The calculations of these two coefficients require 
laborious works due to at least two administrations of the same test or two equivalent test 
forms. On the other hand, the internal-consistency coefficient is based on the relationship 
among scores derived from individual items or subsets of items within a single test so 
that only one administration of the test is necessary. Common measurements for internal-
consistency coefficients are coefficient alpha developed by Cronbach (1951) and the 
Spearman-Brown formula for split-half reliability methods. 
Although reliability is related to the consistency of a scale as a measure of a 
specific variable, validity is associated with its adequacy. DeVellis (2003) summarizes 
that validity mainly consists of three categories: content validity, criterion-related 
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validity, and construct validity. Content validity is the extent to which a specific set of 
measurements reflects a content domain. It is often easier to assess it when the domain is 
clearly defined, but more difficult when measuring attributes such as beliefs, attitudes, or 
disposition due to their ambiguous conceptualization (DeVellis, 2003). Criterion-related 
validity is the extent to which a measure is empirically associated with another measure 
or procedure, such as a gold standard in that field. Thus, it is used to demonstrate the 
accuracy of a measure used in a study. Construct validity is the extent to which a question 
correlates with other measures that it should correlate with. It indicates how much a 
theoretical construct or hypothesis agrees with a specific measurement. It can be 
subcategorized into convergent validity and discriminate validity. Convergent validity 
looks at how much theoretically related measures agree with one another. Discriminant 
validity, on the other hand, indicates how much theoretically unrelated measures show a 
lack of the relationship with one another.  
For the EuroQol, Brooks (1996) summarized the following issues. He notes that 
the test-retest reliability for the standard EuroQol questionnaires for the general Dutch 
population could be established by the generalizability study, a study focused on 
determining to what extent scores are comparable across different levels of a facet (van 
Agt, Essink-Bot, Krabbe, & Bonsel, 1994). They concluded that four different versions of 
questionnaires generated stable valuations over time. Good test-retest reliability 
(Intraclass Correlation Coefficient [ICC] = 0.78) was also obtained for the visual 
analogue scale of EuroQol instrument among healthy British people (Gudex, Dolan, 
Kind, & Williams, 1996). For those suffering from chronic conditions such as rheumatoid 
diseases and inflammatory bowel disease, ICCs of 0.70 - 0.85 indicated that there was 
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moderate to high level reliability of the EuroQol questionnaire (Fransen & Edmonds, 
1999; Hurst et al., 1997; Konig et al., 2002).  
On the other hand, Brazier, Jones, and Kind (1993) made a comparison of the 
validity between the EuroQol instrument and the SF-36. They concluded that there was 
reasonable evidence for construct validity in the EuroQol dimension responses and the 
total scores, by comparing the percentages of each health problem with socio-
demographic variables such as age. Also, the authors figured out that convergent and 
discriminant validity had a reasonable agreement between EuroQol and SF-36 in the 
general population. Although the outcome of EuroQol was less variable than SF-36 due 
to the limited number of questionnaires and answers, they suggested that it was more 
applicable for a general population and suitable for those with major morbidity. The 
validity studies were performed for several chronic disease conditions, and similar 
performances of construct and criterion-related validity were observed (Fransen & 
Edmonds, 1999; Hurst et al., 1997; Konig et al., 2002; Myers & Wilks, 1999). However, 
the results were not consistent by the type of disease, possibly because of ceiling effects 
due to the simplicity of the questionnaires in EuroQol. Myers and Wilks (1999) suggested 
that the EuroQol was a useful rapid-assessment means for chronic fatigue syndrome 
patients, and Coons, Rao, Keininger, and Hays (2000) indicated that EQ-5D was 
generally a preference-based measure designed to summarize the QOL. However, no 
investigation has been conducted in lymphatic filariasis or chronic lymphedema. 
There is much less discussion of reliability and validity of the CDC Healthy Days 
instrument, but CDC has documented relevant studies in the publication “Measuring 
Healthy Days”. It reported that good internal consistency reliability was established 
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among 2400 Norwegian adults (CDC, 2000, p.17). Also, acceptable test-retest reliability 
was found among Americans who suffered from known disabilities (CDC, 2000, p.17). 
Validity of the measurements was more carefully examined in various situations (CDC, 
2000, pp.15 - 19). Good construct validity was established in studies of statewide normal 
adults, low-income elderly, those with disabilities, and low-income older male minorities, 
especially in terms of socio-demographic status and disease conditions. Also, acceptable 
or good correlations with SF-36 and CES-D questionnaires were found in several health-
related domains. However, like the EuroQol, the application of the CDC Healthy Days is 
a challenge in the Haitian LF cases. 
In contrast, such arguments for CES-D have been active for more than two 
decades. Radloff (1977) reported in his article that very high internal consistency was 
established by different types of reliability measurements among general population and 
psychiatric patients. He found that reliability coefficients of from 0.77 to 0.92 were 
obtained by coefficient alpha, split-halves r, and spearman-brown methods. Also, 
moderate but stable test-retest reliability was observed in different intervals of retest 
administrations. All but one gained the range of 0.45 - 0.70 on 2, 4, 6, and 8 weeks 
intervals of mail back administrations and 3, 6, and 12 months of reinterviews. The 
author also showed substantial to excellent evidence of criterion-related validity and 
construct validity. Criterion-related validity was established by looking at patterns of 
correlations with other self-report measures such as the Lubin and Bradburn Negative 
Affect scale. Though the result was at an acceptable level, comparisons with the variety 
of self-reported measures helped document concurrent and discriminant validity. In 
addition, overall construct validity was established by examining correlations with 
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clinical ratings of depression and by relationships with other variables such as socio-
demographic indicators. Therefore, CES-D is a strong indicator for looking at current 
mental health status so that the questionnaires are expected to be applied well among the 
lymphedema patients in Haiti.  
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Chapter Three 
Methods 
Study Design 
The thesis is based on the analysis of secondary data obtained from a cross-
sectional, correlational study along with a descriptive epidemiological survey. A cross-
sectional study is a field study that collects data about activities, events, or other 
experiences at a single point of time. It is easier and less expensive to perform than 
longitudinal studies, and allows us to generate and test hypotheses. The disadvantages are 
that it cannot establish temporal relationships between variables, there are potential biases 
in the selection of the population/sample, and it cannot control potential confounders. 
However, the study also allows researchers to evaluate multiple risk factors and 
outcomes. A correlational study is a study that describes and postulates the associations 
between variables of interests by using correlation coefficients. It is useful to obtain a 
first look at the population, but does not control for potential confounding factors. 
Finally, a descriptive study is a study that describes the existing distribution of variables 
without regard to causal associations. Therefore, the thesis intends to investigate 
associations between socio-demographic variables and filariasis-related variables among 
Haitian patients and to describe the QOL among them at a certain point in time. 
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Objectives 
The purpose of the study consists of two main objectives. The first objective is 
to observe the association of filariasis-related variables among lymphedema patients. The 
variables include demographic characteristics, illness history, knowledge of lymphedema, 
and self-care practice and behavior related to the illness. The risk factors for the filarial 
infection have been identified through various international studies; however, risk factors 
are sensitive to the environment and people’s life style (King & Freedman, 2000). Also, 
different populations infected with the same parasite can have very different clinical 
manifestations of the infection (Ottesen, 1987). Moreover, Haiti is a country mixing 
western hemisphere with indigenous culture so that it is anticipated that any demographic 
variables, knowledge about the disease, or their unique daily custom and behavior may 
influence the disease. This cross-sectional correlational study also includes the 
consideration of regional differences and gender perspectives. The prevalence and 
characteristics of LF can vary by region or even within the same community (Dreyer et 
al., 1998). Above all, since there is no research on the regional comparisons of LF in 
Haiti, the assessment of multiple communities is noteworthy for future filariasis 
management in Haiti. There are some differences known about the clinical manifestations 
and social and behavioral factors by gender (Bandyopadhyay, 1996; Coreil et al., 1998), 
but they are still poorly understood. In Haiti, there has been no systematic comparison of 
gender perspectives, especially no representative information on men with LF in Haiti. 
Therefore, understanding the gender perspective of lymphatic filariasis is significant for 
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morbidity management. It will be clarified by careful consideration of demographic, 
social, and behavioral factors associated with the disease. 
 The other objective is to evaluate the QOL among lymphedema patients. As 
mentioned above, morbidity control is one of two main strategies for the global 
elimination of LF. However, since there are few systematic QOL assessments of 
lymphedema due to various limitations such as sample size and reliability and validity of 
the measurements, the obtained information has limited utility for morbidity control. 
Therefore, a general introduction of the QOL assessment is highly recommended. 
To fulfill the primary objective, secondary data collected for the ongoing project 
called Evaluation of Support Groups in the Management of Lymphedema Caused by 
Lymphatic Filariasis was used. The survey form was created on the basis of the 
questionnaires previously used in a survey in Leogane. In the project, the form was 
designed for the assessment of background information about LF in three rural Haitian 
towns. The data includes socio-demographic information, illness history, foot exam, 
knowledge of the illness, self-care practice, and self-efficacy of the care. The form can be 
viewed in Appendix B. Regional assessments and gender comparisons were achieved by 
the evaluation of each questionnaire by regions and gender, respectively.  
The second objective, the QOL assessment is also a part of the ongoing project, 
but establishing the reliability and validity of the instruments is an original work for this 
thesis. The generic QOL tools include the CDC Healthy Days Survey and EuroQol. CES-
D, Center for Epidemiologic Studies Depression Scale was also applied for a future 
reference of mental health assessment of lymphedema patients. Due to the high illiteracy 
rate, interviews were conducted by trained personnel using Creole-language forms. Also, 
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since there are few representative reports of reliability and validity of the questionnaires 
among lymphedema patients, a basic discussion of these issues was considered through 
application of commonly used validation procedures.  
Therefore, following research questions will be of interest in this research. 
Research questions 
1. How is the condition of LF manifested in three rural Haitian towns? 
1.1. To what extent does place of residence influence lymphedema conditions? 
1.2. To what extent are socio-demographic variables such as age, gender, and SES 
associated with lymphedema conditions? 
1.3. What is the knowledge of the illness and history of the illness? 
1.4. How does the lymphedema condition interact with the frequency of comorbid 
condition such as acute attacks? 
 
2. How do patients’ health-related behaviors affect morbidity control in their daily lives? 
2.1. How do LF patients seek treatment for their legs?  
2.2. How do place of residence, SES, and the cost of medication affect on treatment-
seeking behavior? 
2.3. To what extent do previous illness history and knowledge of the illness interact 
with help-seeking behavior?  
2.4. What is the effect on self-efficacy? 
 
3. How does the condition of lymphedema affect quality of life? 
3.1. To what extent does the difference of the place of residence influence on QOL? 
3.2. To what extent are differences of socio-demographic variables such as age, gender, 
and SES associated with the QOL among lymphedema patients? 
3.3. To what extent are differences observed between lymphedema stage and QOL, 
such as morbidity, physical limitation, and anxiety/depression? 
3.4. What is the association with knowledge of the illness and illness history? 
3.5. To what extent do simultaneous symptoms exacerbate QOL? 
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4. To what extent do the generic QOL assessment tools for chronic diseases have 
reliability and validity for measuring QOL among lymphedema patients due to LF in 
Haiti?   
 
 
Population and Sample Size 
The dataset came from an ongoing research project titled Evaluation of Support 
Groups in the Management of Lymphedema Caused by Lymphatic Filariasis. A 
collaboration between Haitian and US public health institutions expanded the successful 
support group intervention among lymphedema patients in Leogane, Haiti, which was 
funded by WHO (Coreil et al., 2003). The dataset included background information 
among LF patients living in one of the most LF endemic areas located north of the 
nation’s capital. Thus, the dataset was primarily aimed to provide the baseline 
information prior to support group introduction in the new areas.  
The data were collected in three localities, Arcahaie, Cabaret, and La Plaine. 
Arcahaie is a coastal town situated 30 miles north of the capital, Port-au-Prince. Cabaret 
is another community located between Port-au-Prince and Arcahaie. Both towns are 
situated on or near the main northern highway Route National No. 1 within 
L’arrondissement d’Arcahaie (District of Arcahaie). Particularly, Cabaret is just right of 
the main highway so that it is more urbanized than Arcahaie. However, sampling in 
Cabaret included more residents from the rural zones so that the effect of urbanization 
seems to be lower. On the other hand, La Plaine is a dispersed area that is a part of La 
Commune de Delmas, (Delmas County) on or near Route National No. 1. The community 
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of Delmas is one of six communities in L’arrondissement de Port-au-Prince (District of 
Port-au-Prince), which includes the metropolitan area. Therefore, residents in La Plaine 
have greater access to the capital due to its closeness to the metropolitan area. The 
locations of these localities except La Plaine are available in Appendix C. Though the 
exact population size in each town is unknown, it is estimated to be 100,000 for Arcahaie, 
60,000 for Cabaret, and 10,000 for La Plaine. The target population was lymphedema 
patients of all ages. The prevalence of lymphedema is poorly understood because there is 
no case reporting on surveillance in these areas. However, Beau de Rochars et al. (in 
press) figured out that these communities were in three of the most filariasis endemic 
areas in the country, based on the national mapping of infected school children. The 
towns are also located in one of two regions which have the highest prevalence of 
microfilaremia. Therefore, analysis of the data collected in these towns would be one of 
the most representative information about LF in Haiti. 
The sample size of the project was based mainly on the information collected on 
the preliminary census in early 2003. At that time, at least 60 and 25 adult lymphedema 
patients were found in Arcahaie and Cabaret, respectively. Since the census was 
conducted in a short period of time with a minimum effort, it was anticipated that many 
more people suffering from lymphedema were collectible as samples. Also, population 
data were unavailable so that the statistical calculation of the sample size was impossible. 
Thus, the sample size was based on resources available for the study and patients 
available in the study site. Fortunately, a total sample of 316 were able to be collected , 
including 123 in Arcahaie, 72 in Cabaret, 120 in La Plaine, and 1 unknown site.  
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Sampling Method 
 The sample was based on the availability of patients. Since the study was focused 
on a particular condition of a single disease and there was no list or information of the 
study population, non-probability sampling was conducted instead of probability 
sampling. Non-probability sampling is one of two sample selections that researchers can 
make a subjective decision for the characteristics of samples. It is especially appropriate 
when resources for samples are limited, the members of a population are difficult to 
identify, or the list of a population is unavailable. Because samples cannot be collected by 
random selection such as probability sampling, it is difficult to reduce or eliminate 
potential biases and confounders. There are several types of non-probability samplings. 
Henry (1990) lists six major designs of non-probability sampling: convenience, most 
similar/dissimilar, typical cases, critical cases, snowball, and quota. Of those, the 
approach in this project was more likely to be convenience sampling – that a group of 
individuals who are available for a study, or quota sampling – that interviewers select a 
member of samples until filling out quota.  
Interviews were conducted in the infectious disease department of the local 
hospital in Arcahaie and the public clinic in Cabaret and La Plaine, or in people's homes. 
It was restricted by person-to-person interview only, due to the nearly 50% of nationwide 
illiteracy rate. A team of trained interviewers conducted the interviews. A small 
refreshment and transportation fee was provided at the end of the interview. Informed 
consent was obtained prior to the data collection.  
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Measurement 
The questionnaires used in this study had two different formats. The first form, 
Filariasis Baseline Evaluation Survey, was a set of questions adapted from a previous 
filariasis survey in Leogane, Haiti. It consists of six different categories: demographics, 
illness history, foot exam, knowledge about the illness, self-care practices for leg, and 
self-efficacy. All the items were written in both English and Haitian Creole, although the 
instruments were administered in Creole only. The contents of each category are 
summarized in Table 3. Also, the full questionnaires are available in Appendix B. 
Table 3. Brief Summary of the Survey Categories and Questionnaires. 
Demographic: address, gender, age, 
marital status, general information about 
their living children, religion, occupation, 
educational level, literacy, economic scale.  
Illness history: age of first awareness of 
the illness, first impression of the illness, 
recognition of the first symptom, 
treatment of the illness, precautions taken 
with one’s foot, number of acute attacks in 
the past year, presence of comorbidity of 
lymphedema and acute attacks. 
Foot exam: the sizes of foot (10cm from 
toe), ankle (10cm from floor), and leg 
(20cm from floor) for both limbs, the stage 
of illness (stage 1 to 7, from mild to 
severe), location and condition of lesions. 
Knowledge about the illness: what the 
respondent thinks is the cause of the 
illness, which care options can help one's 
lymphedema, which care options can be 
done to help prevent acute attacks and 
what treatments are available, what kinds 
of care can be provided to ease one's acute 
attacks. 
Self-care practice for legs: what kinds of 
practices and how often one does each for 
self-care of the legs daily, once a week, 
once a month, or less often. 
Self-efficacy: how confident they feel in 
their ability to practice all the care 
techniques available to take care of their 
legs. 
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The other form was a combination of two generic QOL assessment tools, the 
CDC Healthy Days Survey and EuroQol, and a subjective well-being assessment tool, 
CES-D. All were translated by researchers who engaged in research on LF in Haiti. As 
mentioned in the previous chapter, these forms were designed for assessing one's general 
health condition. Particularly, the CDC Healthy Days is more focused on activity 
limitation, CES-D is a common mental health indicator, and the EuroQol evaluates five 
health dimensions of mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. The forms are available in Appendix B. 
 
 
Reliability and Validity 
 In order to confirm to what extent the measurements have reliability, coefficient 
alpha or Cronbach alpha was calculated. One of the reasons that the Cronbach alpha was 
selected is that this is a cross-sectional study. Since the project was only a single time 
administration, test-retest reliability could not be introduced. The second reason is that, 
due to the limited period of survey administration and no alternative equivalent 
assessment tools, alternate-form reliability was excluded for reliability measurement. In 
addition, it was impossible to use the Kuder-Richardson Procedure because there were no 
dichotomous measures in the questionnaires. Therefore, the internal-consistency 
reliability formula was used to confirm the reliability of the instruments. The formula for 
coefficient alpha is as follows: 
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α = (K/(K-1))*((sx2 - ∑ si2 ) / sx2 ), 
where,       K = number of items on the test 
               Sx2 = variance of the test scores for all K-items 
              ∑ Si2 = sum of variances of the item scores. 
 
There are some limitations for these tests. Coefficient alpha assumes that the 
items on the form are homogeneous. Since EuroQol and the CDC Healthy Days are 
designed for evaluating one's general health, the questionnaires include different domains 
of health status such as physical and mental health and disability. Thus, overall alpha 
might be lower than expected. 
 On the other hand, establishing validity required more elaborate procedures. 
Criterion-related validity was observed by comparing a single domain in one form with a 
related from in another, EuroQol and the CDC Healthy Days. Also, CES-D is a mental 
health measurement only so that the questionnaires in CES-D were used in comparison 
with comparable domains in the other two forms. The approach to construct validity was 
dependent on the previous findings or constructs that have already been established in the 
literature, because it is impossible to prove the validity of a measure. According to the 
literature review in the previous chapter, the relationships between certain characteristics 
of the symptoms and a dimension of the questionnaires would be expected. For example, 
since people with lymphedema in Haiti experienced limited physical activities due to 
acute attacks (Dahl, 2001), they would be expected to claim more activity limitations in 
the CDC Healthy Days. It has been reported that women with abnormal physical features 
due to lymphedema experience mental and psychological stress (Bandyopadhyay, 1996; 
Coreil et al., 1998). This suggests that they would have a higher score on the 
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anxiety/depression scale in EuroQol and CDC Healthy Days and in many of the 
questionnaires in CES-D. Also, SES would be expected to affect responses to the 
questionnaires. Thus, construct validity was established by analyses of the hypotheses 
shown above by using statistical tests such as correlational analysis. Lastly, convergent 
and discriminant validity was established by comparing the most similar and dissimilar 
health domains of the questionnaires of one form with another. For example, the EQ-VAS 
scale in EuroQol and self-determined overall health condition in the CDC Healthy Days 
should be correlated each other because both domains address the general health of 
respondents. Likewise, mobility questions in EuroQol also should be correlated with 
activity limitation questions in the CDC Healthy Days. On the other hand, there should be 
no or weak relationships between anxiety and depression scales and physical health 
status. Content validity was not examined because it is beyond the purpose of this thesis.   
 
 
Data Analysis 
All the data were analyzed using SAS version 8.02 (SAS Institute Inc, Cary, NC). 
The Filariasis Baseline Evaluation Survey was described by simple descriptive statistics. 
Each category was summarized by variables of interest for a general profile of the 
sample. Some of the categories such as knowledge about the illness, self-care practices 
for legs, and self-efficacy were utilized as QOL measurements so that simple bivariate 
statistical analysis such as t-test, correlation, chi-square test, and others as appropriate 
were performed between variables of interest including socio-demographic indicators and 
self-care practices for leg. On the other hand, scores from the QOL measurements were 
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analyzed by following the guidelines for each QOL evaluation instrument, in addition to 
the establishment of reliability and validity discussed in the previous section. The 
variables investigated in the Filariasis Baseline Evaluation Survey were used for further 
analyses of QOL. For instance, the scores obtained in the QOL instruments were 
examined by variables of interest such as age and gender, and compared by simple 
statistical tests to observe the differences between them.  
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Chapter Four  
Results 
General Information 
 The research was reviewed and approved on February 17, 2004, for ethics in 
human subject research by the Institutional Review Board at University of South Florida.  
 
 
Demographics 
Table 4 shows the demographic characteristics by gender and regions. Of 316 
total respondents, there were 255 (80.7 %) females and 61 (19.3 %) males, and 120 
people lived in Arcahaie, 72 in Cabaret, and 123 in La Plaine (1 missing). The gender 
proportion was slightly different among towns. There were 2.78 times more females than 
males in Cabaret, but 6.23 times in La Plaine. The mean age was 44.52 years. No 
significant age differences were found for either gender or regions. There was almost no 
previous visit of Ste. Croix Hospital in Leogane, where a lymphatic filariasis treatment 
program is currently available. 
The demographic characteristics were nearly identical for males and females as 
well as across towns. Statistically significant differences were found only in marital 
status between gender (χ2=14.89, df=6, p=0.02), occupation by gender (χ2=90.07, df=5, 
p<0.01) and regions (χ2=44.26, df=10, p<0.01), and working days per week by gender 
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(T=-3.11, df=81.7, p<0.01) and regions (F=8.76, df=2, 19, p<0.01). In marital status, 
plase was the most common status in both genders, but the proportion of single 
respondents was also the highest among males. Type of occupation varied by gender. 
More than 35 % of respondents were engaged in vending at home or market, but it was 
exclusively a female-dominated job. On the other hand, agriculture-related work was 
more common among men. This fact may affect the difference on working days per 
week. However, there was no significant gender difference in average income. The 
regional differences were also obvious in occupation. There were more vendors in 
Arcahaie and La Plaine, but more farmers in Cabaret, probably due to the difference in 
gender distribution. Working days per week were also different by region (F=8.76, df=2, 
194, p<0.01); however, no significant regional differences were found in average income.
Table 4. Demographic Characteristics of Lymphedema Patients (#: 1 missing, *: % total, *: different between gender (p<0.05), **: 
different among towns (p<0.05), US $1 = 42.5 Haitian Groude (Gde) as of 2/18/04). 
 Gender Town #   Total 
Male     Female Arcahaie Cabaret La Plaine
Number of respondents (N (%*))  316 (100)    61 (19.3)  255 (80.7)  120 (38.1)    72 (22.9)  123 (39.1) 
Age (mean ± SD (range)) 44.5 ± 18.4 
(9 – 95)  
43.5 ± 20.7 
(9 – 95) 
44.8 ± 17.9  
(9 – 90 ) 
43.5 ± 18.5 
(10 – 90) 
44.9 ± 17.7  
 (12 – 86) 
45.1 ± 18.9 
      (9 – 95) 
Visit of Ste.Croix Hospital (n)      3      0      3      2      0      1 
Married    47 (14.9)    10 (16.4)    37 (14.5)    18 (15.0)      8 (11.1)    21 (17.1) 
             Plase  115 (36.4)    17 (27.9)    98 (38.4)    36 (30.0)    31 (43.1)    48 (39.0) 
Live together      9 (2.9)      2 (3.3)      7 (2.8)      4 (3.3)      3 (4.2)      2 (1.6) 
In relationship    21 (6.7)      5 (8.2)    16 (6.3)    10 (8.3)      4 (5.6)      7 (5.7) 
            Single    44 (13.9)    17 (27.9)    27 (10.6)    17 (14.2)      7 (9.7)    20 (16.3) 
Separated/divorced    41 (13.0)      5 (8.2)    36 (14.1)    20 (16.7)    10 (13.9)    10 (8.1) 
Marital status 
(n (% N)) ** 
            Other    36 (11.4)      5 (8.2)    34 (13.3)    15 (12.5)      9 (12.5)    15 (12.2) 
Those who have living children  
(n (%*)) 
 239 (75.6)    36 (59.0)  203 (79.6)    84 (70)    58 (80.6)    96 (78.1) 
Number of living children  
(mean ± SD (range)) 
  2.8 ± 2.5 
(0 – 11) 
  2.5 ± 2.6 
(0 – 8) 
   2.9 ± 2.5  
(0 – 11) 
  2.5 ± 2.5  
(0 – 9) 
  2.8 ± 2.3  
(0 – 8) 
  3.1 ± 2.7  
(0 – 11) 
Age of oldest child  
(mean ± SD (range)) 
25.1 ± 13.7 
(0 – 65) 
25.2 ± 13.0    
(2 – 55) 
 25.1 ± 13.9  
(0 – 65) 
25.6 ± 14.2 
(1 – 65) 
25.1 ±13.6 
(0 – 55) 
24.6 ± 13.5  
(1 – 60) 
Age of youngest child  
(mean ± SD (range)) 
15.8 ± 11.0  
(0 – 50) 
13.4 ± 10.0    
(0 – 35) 
 16.3 ± 11.2 
(0 – 50) 
16.8 ± 10.6 
(2 – 46) 
14.8 ± 12.1 
(0 – 46) 
15.6 ± 10.9 
(0 – 50) 
Number of children who go/went to 
school (mean ± SD (range)) 
  1.5 ± 1.9  
(0 – 11) 
  1.5 ± 2.0  
(0 – 7) 
   1.5 ± 1.9  
(0 – 11) 
  1.3 ± 1.7 
(0 – 6) 
  1.5 ± 2.0 
(0 – 7) 
  1.6 ± 2.1 
(0 – 11) 
 
(Continued on the next page)
 47
Table 4 (Continued). 
 
Gender  TownTotal 
Male     Female Arcahaie Cabaret La Plaine
Catholic 156 (49.4)   32 (52.5)  124 (48.6)   56 (46.7)   34 (47.2)   66 (53.7) 
          Protestant 121 (38.3)   18 (29.5)  103 (40.4)   45 (37.5)   29 (40.3)   46 (37.4) 
       Voodooist   11 (3.5)     1 (1.6)    10 (3.9)     5 (4.2)     2 (2.8)     4 (3.3) 
Religion  
(n (% N)) 
   No religion or other   27 (8.5)   10 (16.4)    18 (7.1)   14 (11.7)     7 (9.7)     7 (5.7) 
Farmer   44 (13.9)   28 (45.9)   16 (6.3)   20 (16.7)   20 (27.8)     4 (3.3) 
Seller at home   66 (20.9)     1 (1.6)   65 (25.5)   18 (15.0)   16 (22.2)   32 (26.0) 
Seller at market   52 (16.5)     0 (0)   52 (20.4)   30 (25.0)     9 (12.5)   13 (10.6) 
Tailor / seamstress   17 (5.4)     2 (3.3)   15 (5.9)     4 (3.3)     1 (1.4)   11 (8.9) 
Unemployed   90 (28.5)   13 (21.3)   77 (30.2)   31 (25.8)   19 (26.4)   40 (32.5) 
Occupation 
(multiple 
answers) 
(n (% N)) * 
** 
Other   64 (20.3)   21 (34.4)   43 (16.9)   23 (19.2)     9 (12.5)   32 (26.0) 
Number of working days per week 
(mean ± SD) * ** 
 5.2 ± 2.0  5.9 ± 1.5  5.0 ± 2.1  4.4 ± 2.2  5.6 ±1.7  5.6 ± 1.8 
Income per day (Gde (US$)) 332.2 ($7.8) 415.1 ($9.8) 309.5 ($7.3) 416.5 ($9.8) 350.8 ($8.3) 250.5 ($5.9) 
Able to read and write (n (% N)) 192 (60.8)   41 (67.2) 151 (76.1)   74 (61.7)   38 (52.8)   79 (64.2) 
Number of school years completed 
(mean ± SD (range)) 
 3.9 ± 4.3  
   (0 – 15) 
 4.1 ± 4.3    
   (0 – 14) 
 3.8 ± 4.3 
      (0 – 15) 
 4.4 ± 4.5 
      (0 – 15) 
 2.9 ± 4.0 
      (0 – 14) 
 3.9 ± 4.3      
   (0 – 14) 
Radio 238 (75.3)    44 (72.1) 194 (76.1)   98 (81.7)   52 (72.2)   88 (71.5) 
Storage set 121 (38.3)   21 (34.4) 100 (39.2)   55 (45.8)   27 (37.5)   38 (30.9) 
Living room   69 (21.9)    11 (18.0)   58 (22.8)   18 (15.1)   16 (22.2)   35 (28.5) 
Number of 
people 
having: 
(n (% N)) Bicycle/motorcycle 141 (44.6)   31 (50.8) 110 (43.1)   76 (63.3)   35 (48.6)   30 (24.4) 
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Illness History 
In order to describe the first experience of the illness and its related health 
behaviors that respondents had, the responses regarding illness history were described in 
Table 5 - 8. A chi-square test was conducted to look at gender and regional differences at 
the significance level of α = 0.05. 
Table 5 shows the age at which the respondent first noticed symptoms and what 
the perceived illness was. The mean age was 28.0 years old, and this was consistent for 
gender and regions. About a quarter (24.4 %) of respondents thought that the illness was 
a chill, followed by bad blood, gland, magical powder, and sprain. Also, 14.9 % of 
respondents couldn’t identify the illness. Surprisingly, only 2 people were able to 
recognize the illness as filariasis. A significant difference was observed both in gender 
(χ2=16.83, df=7, p=0.02) and towns (χ2=42.42, df=14, p<0.01). Those who answered bad 
blood were dominated by females, and more people in Cabaret thought it was gland 
rather than blood. 
 Table 6 describes the first symptom noticed. Swollen foot, swollen gland, and 
pain were common symptoms reported. There was a significant regional difference 
(χ2=55.61, df=12, p<0.01). More people in La Plaine experienced fever, headache, and 
hot foot than those in other towns. However, no significant gender differences were 
found. 
 Table 7 shows how people treated the illness at that time. Nearly half of them 
relied on traditional medication such as an herbal remedy. Also, Western medicine was 
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an alternative choice (95 or 30.1 % of them visited a hospital/clinic or health center and 
83 or 26.3 % went to the pharmacies). Although no significant gender differences were 
found in their help-seeking behavior (χ2=13.35, df=7, p=0.06), females were more likely 
to follow traditional medicine. Regional differences were also evident (χ2=67.55, df=14, 
p<0.01). People living in Arcahaie preferred traditional healers, but those in La Plaine 
were dependent more on health professionals as well as herbal remedies and use of 
cupping/leeches. 
 Table 8 describes what precautions people usually take with their affected legs. 
Keeping clean/hygiene, wash/soak/soap legs, herbal remedy, and wearing 
sandals/socks/stockings/shoes were the most common precautions taken. However, some 
of those who answered “other” practiced contradictory precautions such as exposing legs 
to cold water or washing legs with cold water or urine, instead of avoiding cold water or 
washing legs with hot water. There was no significant gender difference in precautions 
taken, but regional differences were significant (χ2=50.74, df=20, p<0.01). People in 
Arcahaie preferred to use herbal remedies, pomade, and leg covering such as sandals and 
stockings. Avoiding cold water and something cold or wet was a more common 
precaution in Cabaret. On the other hand, those in La Plaine tried to band, wrap, tie legs, 
not to walk on ground with bare feet, and to keep clean by washing legs more than 
residents of other areas.
Table 5. The First Impression of the Illness (multiple responses, *:1 missing, **: different between gender (p<0.05), ***: different 
among towns (p<0.05)).  
Gender   Town* Total  
(N=316) Male 
(N=61) 
Female 
(N=255) 
Arcahaie 
(N=120) 
Cabaret 
(N=72) 
La Plaine 
(N=123) 
Age of first awareness of the 
illness (mean ± SD (range)) 
28.0 ± 15.6 
 (1 – 95) 
27.1 ± 18.4 
 (1 – 95) 
28.2 ± 14.8 
 (1 – 78) 
27.3 ±14.6 
(4 – 72) 
27.1 ± 15.3 
(3 – 72) 
29.4 ± 16.8 
(1 – 95) 
Chill 77 (24.4) 16 (26.2) 61 (23.9) 32 (26.7) 15 (20.8) 30 (24.4) 
Gland 62 (19.6) 15 (24.6) 47 (18.4) 13 (10.8) 23 (31.9) 26 (21.1) 
Magical powder 56 (17.7) 13 (21.3) 43 (16.9) 32 (26.7)   4 (5.6) 20 (16.3) 
Sprain 54 (17.1) 12 (19.7) 42 (16.5) 18 (15.0) 13 (18.1) 23 (18.7) 
Filariasis   2 (0.6)   1 (1.6)   1 (0.4)   0 (0)   1 (1.4)   1 (0.8) 
Don’t know 47 (14.9)   7 (11.5) 40 (15.7) 17 (14.2) 15 (20.8) 14 (11.4) 
Blood 70 (22.2)   2 (3.3) 68 (26.7) 27 (22.5)   4 (5.6) 39 (31.7) 
First 
impression of 
the illness 
(n (% N)) ** 
*** 
Other 53 (16.8)   8 (13.1) 45 (17.7) 21 (17.5) 10 (13.9) 22 (17.9) 
 
 
Table 6. The First Symptom Noticed (n (% N), multiple responses, *:1 missing, **: different among towns (p<0.05)). 
 Gender Town* **    Total
(N=316) Male 
(N=61) 
Female 
(N=255) 
Arcahaie 
(N=120) 
Cabaret 
(N=72) 
La Plaine 
(N=123) 
Swollen foot 266 (84.2) 53 (86.9) 213 (83.5) 100 (83.3) 55 (76.4) 110 (89.4) 
Pain 179 (56.7) 31 (50.8) 147 (57.6)   65 (54.2) 33 (45.8)   80 (65.0) 
Swollen gland 190 (60.1) 43 (70.5) 147 (57.6)   51 (42.5) 49 (68.1)   89 (72.4) 
Fever 141 (44.7) 29 (47.5) 112 (43.9)   39 (32.5) 23 (31.9)   78 (63.4) 
Headache   47 (14.9)   8 (13.1)   39 (15.3)     5 (4.2)   5 (7.0)   37 (30.1) 
Hot foot  115 (36.4) 18 (29.5)   97 (38.0)   30 (25.0) 14 (19.4)   71 (57.7) 
Other   70 (22.2) 12 (19.7)   58 (22.7)   36 (30.0) 14 (19.4)   20 (16.3) 
 
 51
Table 7. Treatment Choice (n (% N), multiple responses, *:1 missing, **: different among towns (p<0.05)). 
 Gender Town* **    Total
(N=316) Male 
(N=61) 
Female 
(N=255) 
Arcahaie 
(N=120) 
Cabaret 
(N=72) 
La Plaine 
(N=123) 
Traditional healer   33 (10.4)   7 (11.5)   26 (10.2) 22 (18.3)   3 (4.2)   8 (6.5) 
Herbal remedy 143 (45.3) 22 (36.1) 121 (47.5) 54 (45.0) 22 (30.6) 67 (54.5) 
Pomade   49 (15.5) 11 (18.0)   38 (14.9) 23 (19.2) 10 (13.9) 16 (13.0) 
Herbal leaves on legs   31 (9.8)   3 (4.9)   28 (11.0) 16 (13.3)   9 (12.5)   6 (4.9) 
Cupping / leeches   51 (16.1)   7 (11.5)   44 (17.3) 11 (9.2)   2 (2.8) 38 (30.9) 
Pharmaceutical medicine   83 (26.3) 21 (34.4)   62 (24.3) 31 (25.8) 24 (33.3) 28 (22.8) 
Health professional   95 (30.1) 18 (29.5)   77 (30.2) 18 (15.0) 20 (27.8) 57 (46.3) 
Other   49 (15.5)   2 (3.3)   47 (18.4) 15 (12.5) 14 (19.4) 19 (15.4) 
 
 
Table 8. Precaution for Legs (n (% N), multiple responses, *:1 missing, **: different among towns (p<0.05)). 
 Gender Town* **   Total 
(N=316) Male 
(N=61) 
Female 
(N=255) 
Arcahaie 
(N=120) 
Cabaret 
(N=72) 
La Plaine 
(N=123) 
Avoid cold water/something cold/being wet 34 (10.8)   5 (8.2) 29 (11.4)   9 (7.5) 14 (19.4) 11 (8.9) 
Band/bandage, wrap, tie legs 25 (7.9)   1 (1.6) 24 (9.4)   6 (5.0)   3 (4.2) 16 (13.0) 
Do not walk (put legs) on ground (mud) 33 (10.4)   5 (8.2) 28 (11.0)   8 (6.7)   3 (4.2) 22 (17.9) 
Keep clean/hygiene, wash/soak/soap legs 58 (18.4)   9 (14.8) 49 (19.2) 19 (15.8)   7 (9.7) 32 (26.0) 
Herbal remedy (leaves/herbs) 56 (17.7) 11 (18.0) 45 (17.6) 28 (23.3)   9 (12.5) 19 (15.4) 
Take medicine (komprime/flanax/dolex, etc,) 22 (7.0)   4 (6.6) 18 (7.1)   8 (6.7)   8 (11.1)   6 (4.9) 
Put pomade 47 (14.9) 10 (16.4) 37 (14.5) 23 (19.2) 13 (18.1) 11 (8.9) 
Raise legs 20 (6.3)   4 (6.6) 16 (6.3)   6 (5.0)   3 (4.2) 11 (8.9) 
Put sandal/socks/stocking/shoes 58 (18.4) 14 (23.0)     44 (17.3) 30 (25.0) 13 (18.1) 15 (12.2)
Nothing 68 (21.5) 12 (19.7) 56 (22.0)    28 (23.3) 16 (22.2) 23 (18.7)
Other 94 (29.7) 16 (26.2) 78 (30.6)    39 (32.5) 20 (27.8) 35 (28.5)
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Table 9 shows the history of acute attacks in the previous year. To determine 
gender and regional differences, the following statistical tests were used as appropriate: 
T-test, F-test, and chi-square test. The criterion of significance is α = 0.05. Most people 
(94.6 %) experienced at least one attack in the previous year. Each attack lasted 10.6 days 
on average. Females had a significantly longer attack period than males (T=-2.59, 
df=298, p=0.01). People sought treatment in nearly half of the attacks. Of those, more 
than one-third of people went to a clinic, and 12.6 % visited an herbalist. The other sites 
mostly consisted of health centers or pharmacies. Regional differences were significant 
(χ2=16.87, df=8, p=0.03). Particularly, people in Arcahaie preferred the herbalist, but 
those in Cabaret visited pharmacies more often. Approximately 5.1 days had elapsed 
between the onset of the illness and the visit to health facilities, and there was a 
significant gender difference (T=2.99 df=213, p<0.01); interestingly, females stayed at 
home longer, though they had a longer attack period. In each attack, people visited health 
care facilities about 2.5 times, averaging 7.7 hours for a trip and 25.2 Gde (US $0.59) for 
each transportation fee. About 30 % of respondents received help from others during the 
visit to health facilities, and most helpers were family members. Besides accompanying 
the patient to the clinic, helpers mainly took over patients’ routine household chores and 
prepared and administered medicine, herbal remedies, and some other common 
treatments for lymphedema. The average cost of consultation per visit was 54.01 Gde 
(US $1.27), and for each attack the total average cost was 130.49 Gde (US $3.07). These 
fees include the cost of consultation only and exclude the cost of treatment. The 
consultation in Cabaret seemed to be less expensive.  
 54
About three-quarters (74.4 %) of people who went to health care facilities 
obtained medicine. Also, 25.6 % of them received herbal remedies or pomade. Most of 
the tests/exams were blood exams. The cost was dependent on the type of treatment. The 
treatment related to Western medicine (test/exam and shot/injection) was more expensive 
than other traditional procedures, except for herbal remedies. However, the average cost 
of treatment was inconsistent among its type, possibly due to the large number of missing 
responses. On the other hand, people selected herbal remedy more often than medicine 
when they made a treatment at home. More than two-thirds of people chose pharmacy 
medicines (flanax, komprime) or a common antibiotic (ampicillin). A significant 
difference was present both among gender (χ2=16.48, df=7, p=0.02) and towns (χ2=81.11, 
df=14, p<0.01). Particularly, females relied more on indigenous treatment such as herbal 
remedy or leg washing. Also, in comparison with people in Arcahaie and Cabaret, those 
in La Plaine were more concerned about the treatment for legs generally, especially 
washing legs, taking medicine, and raising legs.  
In more than 40 % of attacks, people received some help from a third person 
during the illness. Mostly, family members or relatives took over respondents’ daily 
housework and assisted in their treatment, including herbal remedies, soaping legs, and 
use of pomades. No gender difference was found in the type of help sought. In contrast, 
regional differences were noted (χ2=13.32, df=2, p<0.01). Particularly, in comparison 
with the other cities, people in La Plaine sought more help in daily activities than the 
treatment for legs. Also, in 58 % of attacks, the respondents weren’t able to engage in 
their work activities during the illness. The average number of missing days was 11.7 
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days, which indicates that they were unable to work during the entire period of the attack. 
There were neither significant gender nor regional differences.  
Table 9. History of Acute Attacks (#: 1-3 missing, *: difference between gender (p<0.05), **: difference among towns (p<0.05), ***: 
The average cost of treatment obtained in health settings was calculated only for total due to a small number of the valid 
sample). 
Gender Town#  Total 
(N = 316) 
 
Male 
(N = 61) 
Female 
(N = 255) 
Arcahaie 
(N = 120) 
Cabaret 
(N = 72) 
La Plaine 
(N = 123) 
People who had acute attacks during the 
past year (n (% N), T=total attacks) 
 299 (94.6) 
    T = 462 
    58 (95.1) 
     T = 93 
 241 (94.5) 
    T = 369 
 113 (94.1) 
     T = 187 
  69 (95.8) 
    T = 106 
 116 (94.3) 
     T = 166 
Number of attacks (mean ± SD)   1.5 ± 0.8    1.6 ± 0.8   1.4 ± 0.8   1.5 ± 0.8   1.5 ± 0.8   1.3 ± 0.7 
Duration of attack (mean days ± SD) *  10.6 ± 11.9    8.6 ± 6.3 11.1 ± 13.0 10.9 ± 10.5   9.2 ± 6.7 11.0 ± 15.6 
Clinic  165 (35.7)     44 (47.3)  121 (32.8)    66 (35.3)    39 (36.8)    60 (36.1) 
Herbalist    58 (12.6)     11 (11.8)    47 (12.7)    30 (16.0)    11 (10.4)    17 (10.2) 
Voodoo priest      7 (1.5)       1 (1.1)      6 (1.6)      5 (2.7)      1 (0.9)      1 (0.6) 
Other site    47 (10.2)     11 (11.8)    36 (9.8)    15 (8.0)    19 (17.9)    13 (7.8) 
Location of 
treatment sought 
(n (% T), 
multiple 
responses) ** Nowhere  212 (45.9)     32 (34.4)  180 (48.8)    79 (42.2)    42 (39.6)    88 (53.0) 
Days spent before Rx (mean ± SD) *   5.1 ± 8.1    3.2 ± 2.7   5.6 ± 9.1   5.6 ± 9.3   3.2 ± 4.2   5.7 ± 8.5 
No time    50 (10.8)     12 (12.9)    38 (10.3)    18 (9.6)    16 (15.1)    16 (9.6) 
No money    57 (12.3)     12 (12.9)    45 (12.2)    19 (10.2)    17 (16.0)    21 (12.6) 
Can’t go out    31 (6.7)     10 (10.8)    21 (5.7)    15 (8.0)      1 (0.9)    15 (9.0) 
Treatment at home    23 (5.0)       2 (2.2)    21 (5.7)      8 (4.3)      5 (4.7)    10 (6.0) 
Other    44 (9.5)       7 (7.5)    37 (10.0)    14 (7.5)    11 (10.4)    16 (9.6) 
Reasons for 
days spent 
before treatment 
(n (% T), 
multiple 
responses) Missing, not applicable  278 (60.2)     24 (25.8)  133 (36.0)  122 (65.2)    60 (56.6)    96 (57.8) 
Number of visits for the same attack  
(mean ± SD) ** 
  2.5 ± 1.7    2.3 ± 1.7   2.6 ± 1.8   2.4 ± 1.5   2.1 ± 1.5   2.9 ± 2.2 
Accompanied to health centers (n (% T))  146 (31.6)    37 (39.8)  109 (29.5)    70 (37.4)    32 (30.2)    44 (26.5) 
Of those, by family / relative (n (% above))  122 (83.6)    32 (86.5)    90 (82.6)    58 (82.9)    27 (84.4)    37 (84.1) 
Time to arrive at the place (hours ± SD)   7.7 ± 23.7   7.6 ± 10.5   7.7 ± 26.7   6.7 ± 10.1   9.6 ± 11.6   7.6 ± 39.5 
Paid for transportation (n (% T))  132 (28.6)    33 (35.5)    99 (26.8)    59 (31.6)    32 (30.2)    41 (24.7) 
(Continued on the next page) 
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Table 9 (Continued). 
Gender Town#  Total 
(T = 462) Male  
(T = 93) 
Female 
(T = 369) 
Arcahaie 
(T = 187) 
Cabaret 
(T = 106) 
La Plaine 
(T = 166) 
Sought care at health center (H (%)) 250 (54.1) 61 (65.6) 189 (51.2) 108 (57.8) 64 (60.4)   78 (47.0) 
Number of consultation visits per 
attack (mean ± SD)** 
  2.9 ± 4.9   3.2 ± 6.6   2.7 ± 4.1   2.0 ± 1.4   2.1 ± 3.4   4.6 ± 7.6 
Cost per visit (mean Gde ± SD) ** 54.0 ± 87.5 51.2 ± 72.7 55.0 ± 92.4 66.5 ± 99.2 25.7 ± 28.4 62.8 ±101.0 
Cost for total (mean Gde ± SD) 130.5 ± 244.7 162.4±332.4 119.6±206.7 163.8±305.5 86.1±177.9 174.9±191.8 
Shot / injection   55 (22.0),  
163.6 ± 232.8 
18 (29.5)   37 (19.6)   15 (13.9) 24 (37.5)   16 (20.5) 
Medicine 186 (74.4),  44 (72.1) 
174.5 ± 271.1 
142 (75.1)   82 (75.9) 42 (65.6)   62 (79.5) 
Herbal remedy   64 (25.6),  
145.6 ± 208.4 
11 (18.0)   53 (28.0)   33 (30.6) 11 (17.2)   20 (25.6) 
Cupping / leech   30 (12.0),   
 65.9 ± 85.7 
  2 (3.3)   28 (14.8)   10 (9.3)   0 (0)   20 (25.6) 
Pomade   64 (25.6),    
 76.2 ± 148.9 
12 (19.7)   52 (27.5)   21 (19.4) 20 (31.3)   23 (29.5) 
Massage   14 (5.6),      
 52.5 ± 130.6 
  0 (0)   14 (7.4)     0 (0)   0 (0)   14 (17.9) 
Bandage   23 (9.2),      
 34.3 ± 39.8 
  0 (0)   23 (12.2)     1 (0.9)   0 (0)   22 (28.2) 
Test / exam   20 (8.0),    
314.2 ± 434.8 
  3 (4.9)   17 (9.0)     5 (4.6)   1 (1.6)   14 (17.9) 
Other   11 (4.4),       
380 ± 0 
  1 (1.6)   10 (5.3)     5 (4.6)   1 (1.6)     5 (6.4) 
Treatment 
obtained in 
health setting 
(n (% H) * **, 
cost (gde) ± 
SD, multiple 
responses) 
*** 
Missing 34 (13.6),N/A   8 (13.1)   26 (13.8)     0 (0) 10 (15.6)   24 (30.8) 
(Continued on the next page) 
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Table 9 (Continued).  
Gender Town#  Total 
(T = 462) Male  
(T = 93) 
Female 
(T = 369) 
Arcahaie 
(T = 187) 
Cabaret 
(T = 106) 
La Plaine 
(T = 166) 
Took medicine 125 (27.1) 27 (29.0)   98 (26.6)   37 (19.8) 12 (11.3)   76 (45.8) 
Herbal remedy 214 (46.3) 34 (36.6) 180 (48.8)   80 (42.8) 47 (44.3)   84 (50.6) 
Pomade 132 (28.6) 16 (17.2) 116 (31.4)   54 (28.9) 32 (30.2)   46 (27.7) 
Washed legs 183 (39.6) 33 (35.5) 150 (40.7)   52 (27.8) 27 (25.5) 101 (60.8) 
Raised legs   94 (20.3) 18 (19.4)   76 (20.6)   24 (12.8) 14 (13.2)   56 (33.7) 
Prayed   56 (12.1)   1 (1.1)   55 (14.9)     5 (2.7)   2 (1.9)   46 (27.7) 
None   20 (4.3)   4 (4.3)   16 (4.3)     6 (3.2) 10 (5.3)     4 (2.4) 
Other   63 (13.6)   6 (6.5)   57 (15.4)   25 (13.4) 10 (5.3)   28 (16.9) 
Self-care at 
home (n (% 
T)) * ** 
Missing   76 (16.5) 22 (23.7)   54 (14.6)   33 (17.6) 29 (27.4)   14 (8.4) 
People received help (n (% T)) ** 193 (41.8) 41 (44.1) 152 (41.2)   76 (40.6) 31 (29.2)   86 (51.8) 
by family/relative (n (% above)) 166 (86.0) 35 (85.4) 131 (86.2)   64 (84.2) 28 (90.3)   74 (86.0) 
People who couldn’t work during the 
attack (n (% T)) 
270 (58.4) 59 (63.4) 211 (57.2) 105 (56.1) 71 (67.0)   91 (54.8) 
Days missing work (mean ± SD) ** 11.7 ± 22.7 10.0 ± 25.2 12.2 ± 21.8 9.3 ± 9.5 6.4 ± 5.7 19.6 ± 37.8 
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Table 10 shows respondents’ treatment for legs in the previous attack. About 50 
% of the respondents purchased goods for their treatment and prevention. Forty percent 
of those who purchased goods obtained sandals, and 36.4 % applied pomades. T-test 
indicated that the cost of sandals was more than twice as expensive as that of pomades at 
the significance level of α = 0.05 (T=4.48, df=166, p<0.01), but there was no significant 
difference in purchase history between gender. In contrast, regional preferences were 
apparent (χ2=20.51, df=6, p<0.01). Particularly, those in Cabaret preferred pomade over 
use of a bandage. 
 Table 11 describes people’s daily activities. Among five different categories, 
more than half of them engaged in washing clothes, going shopping, and going to church. 
Including go selling, however, these activities were exclusively women’s roles (χ2>7.4, 
df=1, p<0.01, and RR>2.2). Unlike gender differences, regional differences were less 
obvious. Only the numbers of people going shopping and selling were significantly 
higher in Arcahaie than in the other towns. The average days of the activities were also 
calculated. Going selling occurred much more often than other activities. This is probably 
related to source of income. 
Table 10. Materials Purchased (n (% N), multiple answers, #: 1 missing, *: different among gender (p<0.05)). 
 Gender Town#   Total
(N = 316) Male 
(N = 61) 
Female 
(N = 255) 
Arcahaie 
(N = 120) 
Cabaret 
(N = 72) 
La Plaine 
(N = 123) 
Cost (gde ± SD (range)) 
People who bought 160 (50.6) 31 (50.8) 129 (50.6) 66 (55.0) 40 (55.6) 54 (43.9) 123.2 ± 131.7 (0 – 1000)* 
Shoes/sandals    90 16   74 44 10 36 159.5 ± 119.9 (0 – 500)* 
Pomade   82 18   64 32 24 26   68.5 ±   66.3 (0 - 350) 
Bandage   23   5   18   8   1 14   68.8 ±   52.0 (0 – 175) 
Other   30   7   23   9 11 10 205.7 ± 274.9 (0 – 1000)* 
 
 
Table 11. Daily Activities (n (% N), mean days per week ± SD), *: frequency different between gender (p<0.05), **: frequency 
different among towns (p<0.05), #: days different between gender (p<0.05), ##: days different among towns (p<0.05), &: 1 
missing). 
Gender  Town &  Total  
(N=316) Male 
 (N=61) 
Female  
(N=255) 
Arcahaie  
(N=120) 
Cabaret  
(N=72) 
La Plaine  
(N=123) 
Wash clothes 
* ** 
209 (66.3) 
2.3 ± 1.4 
10 (16.4) 
2.4 ± 1.1 
199 (78.4) 
2.3 ± 1.4 
72 (60.0) 
2.2 ± 1.1 
41 (57.8) 
2.0 ± 0.9 
95 (77.2) 
2.6 ± 1.8 
Go shopping * 
## 
162 (51.4) 
2.5 ± 1.7 
11 (18.0) 
3.5 ± 2.7 
151 (59.5) 
2.4 ± 1.6 
72 (60.0) 
2.1 ± 1.0 
31 (43.7) 
2.3 ± 1.0 
59 (48.0) 
3.0 ± 2.3 
Go selling * 
** # ## 
  61 (19.5) 
3.5 ± 2.2 
2 (3.3) 
    2.0 ± 0 
  59 (23.4) 
3.5 ± 2.1 
32 (26.9) 
2.2 ± 1.1 
14 (19.7) 
4.1 ± 2.0 
15 (12.3) 
5.4 ± 2.0 
Go to church * 
#  
178 (56.5) 
1.9 ± 1.6 
25 (41.0) 
1.4 ± 0.7 
153 (60.2) 
2.0 ± 1.7 
68 (56.7) 
1.8 ± 1.4 
38 (53.5) 
1.7 ± 1.2 
71 (57.7) 
2.1 ± 1.9 
Take children 
to school ** 
  68 (21.9) 
1.9 ± 1.0 
  9 (14.8) 
1.7 ± 0.7 
  59 (23.7) 
1.9 ± 1.1 
13 (10.9) 
1.8 ± 0.9 
15 (21.1) 
2.1 ± 1.3 
40 (33.6) 
1.9 ± 1.0 
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Knowledge 
Table 12 describes respondents’ knowledge of the cause of the illness. More than 
half of them did not know a cause. Only 9.8 % of them could identify that the illness was 
due to an insect bite or worms. Twenty-one people thought that the illness was related to 
blood. Under the chi-square test, there was no gender difference in knowledge; however, 
regional differences were evident (χ2=31.52, df=10, p<0.01). People living in Arcahaie 
reported more knowledge about the cause of the illness.  
 
Table 12. Cause of Illness (n (% N), multiple responses, *: 1 missing, **: different 
among towns (p<0.05)). 
Gender Town* **  Total  
(N=316) Male 
 (N=61) 
Female  
(N=255) 
Arcahaie 
(N=120) 
Cabaret 
 (N=72) 
La Plaine 
(N=123) 
Insect bite or 
worms 
 31  
(9.8) 
  5  
(8.2) 
 26 
(10.2) 
16 (13.3)   5 (6.9) 10 (8.1) 
Magic  33 
(10.4) 
  8  
(13.1) 
 25  
(9.8) 
23 (19.2)   3 (4.2)   7 (5.7) 
Sprain or foot 
injury 
 30  
(9.5) 
  4  
(6.6) 
 26 
(10.2) 
12 (10.0)   9 (12.5)   9 (7.3) 
Chill  43 
(13.6) 
13  
(21.3) 
 30 
(11.8) 
22 (18.3)   8 (11.1) 13 (10.6) 
Other  41 
(13.0) 
  6  
(9.8) 
 35 
(13.7) 
22 (18.3)   9 (12.5) 10 (8.1) 
Do not know 177 
(56.0) 
31  
(50.8) 
146 
(57.3) 
50 (41.7) 43 (59.7) 83 (67.5) 
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Foot Size and Illness Stage 
To observe the lymphedema condition and determine the relationship between 
this condition and the variables of interest, T-test and F-test were used for foot size, and 
the chi-square test was conducted for illness stage. The level of significance is α = 0.05 
for all tests.  
Table 13 presents the results of a foot exam. The mean foot size was 24.6 cm for 
right and 24.8 cm for left. The ankle size was 26.2 cm for right and 27.0 cm for left. The 
size of the leg was 35.5 cm for right and 35.9 cm for left. Due to the nature of physical 
appearances, t-test revealed that there were significant differences in foot and leg sizes 
between genders (all p-values < 0.01); however, interestingly, the sizes of legs, which 
measured 20 cm above the ground, were significantly larger among females than males. 
There were no significant differences in ankles by gender. Also, there were no significant 
differences among towns, except left foot was larger in La Plaine (F=3.65, df=2, 309, 
p=0.03). 
Table 14 and Figure 3 show the distribution of illness by stage. More than two-
third of people’s legs were categorized as stage 2 or lower, except for the left foot among 
those living in La Plaine. Some patients had lymphedema on one side only. No gender 
differences were observed for illness stage in both legs, but those who live in La Plaine 
experienced more severe symptoms of lymphedema, particularly of the left leg (χ2=13.95, 
df=2, p<0.01). 
 63
Stages and sizes of feet are also summarized in Table 15 and Figure 4, by current 
age (age group), age of onset, education, income, occupation, knowledge of the illness, 
and the number of acute attacks in the previous year. Only the number and/or proportion 
of stage 2 or lower was described in stages of illness. Current age was correlated with 
illness stage and leg size. In each foot location, the mean foot size increased with age (all 
p-values < 0.05). In particular, people in their 50s experienced more severe symptoms 
than younger cohorts. Also, the stage of the illness varied among the age groups but was 
more likely to be mild in younger groups. On the other hand, the other variables were less 
related to either stage or foot size. Significant variations were observed only for size of 
right ankle by education and knowledge of the illness, and the size of left leg by 
occupation. Therefore, other variables seem to be poorly associated with foot size and 
stage. 
 
Table 13. Foot Exam (mean cm ± SD (range), *: different between gender (p < 0.05), **: 
different among towns (p < 0.05)). 
Gender Town  Total 
Male Female Arcahaie Cabaret La Plaine 
Foot  
(right)* 
24.6 ± 3.0 
(19 - 42) 
25.8 ± 3.5 
(20 - 42) 
24.4 ± 2.8 
(19 - 40) 
24.6 ± 3.4 
(19.5 – 42) 
24.2 ± 2.7 
(20 – 35) 
24.9 ± 2.7 
(19 – 34) 
(left) * 
** 
24.8 ± 2.9 
(18.5 - 38) 
25.7 ± 2.6 
(20 - 32) 
24.6 ± 3.0 
(18.5 - 38) 
24.4 ± 3.0 
(18.5 – 38) 
24.6 ± 2.6 
(20 – 32) 
25.4 ± 3.0 
(20 – 34) 
Ankle  
(right)  
26.2 ± 4.9 
(18 - 49) 
27.1 ± 6.3 
(18 - 49) 
26.0 ± 4.5 
(18 - 45) 
26.0 ± 4.2 
(19 – 40) 
25.7 ± 4.6 
(18 – 44) 
26.8 ± 5.6 
(18 – 49) 
(left) 27.0 ± 5.4 
(17 - 57) 
27.2 ± 5.2 
(21 - 57) 
27.0 ± 5.4 
(17 - 51) 
26.5 ± 4.7 
(17 – 48) 
27.1 ± 5.2 
(18.5 – 48) 
27.4 ± 6.1 
(19 – 57) 
Leg  
(right) 
35.5 ± 5.6 
(23 - 54) 
34.1 ± 6.8 
(23 - 54) 
35.8 ± 5.3 
(24 - 54) 
35.4 ± 5.7 
(23 – 49) 
35.2 ± 5.5 
(25.5 – 53) 
35.8 ± 5.6 
(24 – 54) 
(left) * 35.8 ± 6.4 
(22.5 - 80) 
33.9 ± 5.1 
(24.5 - 52) 
36.3 ± 6.6 
(22.5 - 80) 
35.1 ± 6.0 
(22.5 – 57) 
36.1 ± 7.3 
(25.5 – 80) 
36.5 ± 6.2 
(25 – 62) 
 
 
Table 14. Stage of Illness (n (% N), *: different among towns (p<0.05)). 
Gender   Towns * 
Stage (left) 
 
Total  
(N = 314) 
Male  
(N = 59) 
Female 
 (N = 255) 
Arcahaie 
(N = 119) 
Cabaret  
(N = 71) 
La Plaine 
(N = 123) 
0 - Normal   26 (8.3)   4 (6.8)   22 (8.6)     7 (5.9)   2 (2.8) 17 (13.8) 
1 - Swelling is reversible overnight   71 (22.6) 10 (16.9)   61 (23.9)   28 (23.5) 20 (28.2) 23 (18.7) 
2 - Swelling is not reversible overnight 125 (39.8) 32 (54.2)   93 (36.5)   61 (51.3) 31 (43.7) 33 (26.8) 
3 - Shallow skin fold   58 (18.5)   8 (13.6)   50 (19.6)   17 (14.3) 15 (21.1) 25 (20.3) 
4 - Knobs   21 (6.7)   2 (3.4)   19 (7.5)     3 (2.5)   1 (1.4) 17 (13.8) 
5 - Deep skin folds     6 (1.9)   1 (1.7)     5 (2.0)     0 (0.0)   2 (2.8)   4 (3.3) 
6 - Mossy lesions     7 (2.2)   2 (3.4)     5 (2.0)     3 (2.5)   0 (0.0)   4 (3.3) 
Stage 2 or lower 222 (70.7) 46 (67.9) 176 (69.0)   96 (80.7) 53 (74.7) 73 (59.3) 
Gender Towns  
Stage (right) 
 
Total  
(N = 314) 
Male  
(N = 60) 
Female  
(N = 254) 
Arcahaie 
(N = 120) 
Cabaret  
(N = 70) 
La Plaine 
(N = 123) 
0 - Normal   43 (13.7)   8 (13.3)   35 (13.8)   14 (11.7)   4 (5.7)   24 (19.5) 
1 - Swelling is reversible overnight 106 (33.8) 25 (41.7)   81 (31.9)   46 (38.3) 28 (40.0)   32 (26.0) 
2 - Swelling is not reversible overnight   84 (26.8) 14 (23.3)   70 (27.6)   33 (27.5) 24 (34.3)   27 (22.0) 
3 - Shallow skin fold   52 (16.6)   5 (8.3)   47 (18.5)   18 (15.0) 11 (15.7)   23 (18.7) 
4 - Knobs   21 (6.7)   3 (5.0)   18 (7.1)     8 (6.7)   1 (1.4)   12 (9.8) 
5 - Deep skin folds     7 (2.2)   4 (6.7)     3 (1.2)     1 (0.8)   2 (2.9)     4  (3.3) 
6 - Mossy lesions     1 (0.3)   1 (1.7)     0 (0.0)     0 (0.0)   0 (0.0)     1 (0.8) 
Stage 2 or lower 233 (74.3) 47 (78.3) 186 (73.3)   83 (77.5) 56 (80.0)   83 (67.5) 
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Figure 3. Stage of Illness. 
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Figure 3 (Continued). 
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Figure 3 (Continued). 
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Table 15. Other Socio-demographic Variables vs. Stage of Illness (n (% N)) and Foot Sizes (mean cm ± SD) (*1: different total 
between left and right legs (N left / N right) due to the one side of leg missing among patients, *2: different among age 
group (p<0.05), *3: different among occupation (left only, p<0.05), *4: different among educational level (left only for 
stage, right only for ankle p<0.05), *5: different among knowledge of the illness (left only, p<0.05)). 
     Stage 2 or lower *2 Foot *2 Ankle *2 Leg *2    
 N Left Right    Left Right Left Right Left Right
Age group (yrs)          
19 or less 33   29 (87.9)   30 (90.9) 22.9 ± 1.9 23.2 ± 1.8 23.6 ± 2.9 23.0 ± 2.6 31.5 ± 3.7 31.5 ± 3.6
20 – 29 42   37 (88.1)   36 (85.7) 23.9 ± 2.1 23.7 ± 2.2 25.0 ± 3.9 24.6 ± 3.4 35.0 ± 4.4 34.8 ± 4.2
30 – 39 49   35 (71.4)   39 (79.6) 25.5 ± 2.9 24.8 ± 3.1 27.8 ± 5.8 26.2 ± 3.6 36.8 ± 5.6 35.7 ± 4.4
40 – 49 63   44 (69.8)   45 (71.4) 25.0 ± 2.5 24.8 ± 2.9 27.5 ± 5.6 27.1 ± 5.7 37.2 ± 7.4 36.7 ± 6.1
50 – 59 52   32 (61.5)   33 (63.5) 25.5 ± 3.6 26.1 ± 3.8 28.3 ± 5.6 28.2 ± 5.2 37.5 ± 6.6 37.9 ± 6.0
60 – 69 39   25 (64.1)   27 (69.2) 25.1 ± 3.0 24.2 ± 2.5 27.5 ± 4.3 26.2 ± 5.8 35.9 ± 6.9 35.1 ± 6.5
70 or more 33   17 (51.5)   21 (63.6) 25.3 ± 3.4 24.9 ± 2.8 28.4 ± 6.6 27.1 ± 4.7 35.0 ± 7.2 34.1 ± 5.3
Missing   3     3 (100.0)     2 (66.7) 23.3 ± 1.2 24.0 ± 1.0 22.0 ± 2.0 25.0 ± 2.6 32.3 ± 1.5 34.0 ± 4.4
Age of onset (yrs)          
9 or less 15     9 (60.0)   12 (80.0) 24.6 ± 3.3 23.9 ± 2.6 27.0 ± 6.5 24.7 ± 4.6 35.0 ± 6.7 34.1 ± 6.0
10 – 19 92   64 (69.6)   68 (73.9) 24.7 ± 2.7 24.7 ± 3.3 26.8 ± 5.8 26.2 ± 5.2 35.4 ± 5.8 35.0 ± 5.5
20 – 29 57   44 (77.2)   41 (71.9) 24.6 ± 2.9 24.2 ± 2.6 26.9 ± 5.3 26.2 ± 5.6 36.0 ± 6.8 36.0 ± 6.0
30 – 39 51   38 (74.5)   38 (74.5) 25.5 ± 3.2 25.7 ± 3.6 27.5 ± 3.2 27.0 ± 4.3 36.5 ± 4.9 36.7 ± 4.9
40 – 49 33   25 (75.8)   28 (84.9) 25.0 ± 3.6 24.0 ± 2.2 26.2 ± 5.3 25.5 ± 4.0 35.5 ± 6.3 34.7 ± 5.2
50 or more 29   23 (79.3)   21 (72.4) 24.2 ± 2.8 24.4 ± 1.8 25.8 ± 5.4 25.4 ± 3.2 35.0 ± 6.0 34.7 ± 5.1
Missing 37   19 (51.4)   25 (67.6) 24.9 ± 2.7 24.7 ± 3.1 28.6 ± 6.3 27.3 ± 5.6 37.3 ± 9.1 35.8 ± 6.4
 
(Continued on the next page) 
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Table 15 (Continued).  
Stage 2 or lower *4    Foot Ankle *4 *5 Leg *3   
 N Left Right    Left Right Left Right Left Right
Daily income (gde)          
25 or less   33   25 (75.7)   23 (69.7) 24.6 ± 2.4 24.8 ± 4.1 26.5 ± 5.1 25.9 ± 4.4 34.7 ± 5.9 34.2 ± 4.8 
26 – 50   28   18 (64.3)   21 (75.0) 25.1 ± 2.5 25.6 ± 3.9 27.7 ± 4.4 27.4 ± 5.3 36.9 ± 5.9 36.6 ± 6.2 
51 – 100   29 / 28   22 (75.9)   21 (75.0) 25.1 ± 3.8 24.6 ± 2.5 27.5 ± 5.4 27.1 ± 5.5 36.1 ± 6.4 36.2 ± 5.0 
101 – 200   25   13 (52.0)   18 (72.0) 26.2 ± 2.9 25.3 ± 3.0 27.5 ± 3.3 27.7 ± 6.1 36.3 ± 4.9 36.8 ± 5.4 
201 – 400   29   18 (62.1)   19 (65.5) 25.4 ± 3.3 25.0 ± 2.2 28.9 ± 9.0 26.7 ± 4.6 37.6 ± 7.6 36.7 ± 6.0 
401 or more   28   19 (67.9)   20 (71.4) 25.3 ± 2.6 24.8 ± 2.5 27.2 ± 3.7 26.1 ± 4.0 36.7 ± 4.8 36.8 ± 5.0 
Missing/refused *1 142/143 107 (75.4) 111 (77.6) 24.3 ± 2.8 24.2 ± 2.8 26.3 ± 5.2 25.6 ± 4.7 35.3 ± 6.9 34.7 ± 5.7 
Occupation          
Farmer   44   34 (77.3)   38 (86.4) 25.3 ± 2.4 25.3 ± 3.7 26.7 ± 5.2 26.8 ± 6.0 34.3 ± 5.8 34.5 ± 6.3 
Seller at home *1   66 / 65   40 (60.6)   45 (69.2) 24.8 ± 2.7 24.7 ± 2.7 26.8 ± 3.5 26.4 ± 4.0 36.0 ± 5.2 36.4 ± 5.2 
Seller at market   52   35 (67.3)   37 (71.2) 25.6 ± 3.4 25.2 ± 3.5 28.3 ± 6.7 27.0 ± 4.3 37.7 ± 7.1 37.1 ± 5.4 
Tailor / seamstress   17   12 (70.6)   11 (64.7) 25.1 ± 3.2 24.1 ± 2.0 27.9 ± 5.3 25.9 ± 3.7 38.9 ± 7.0 35.8 ± 4.5 
Other   64   51 (79.7)   54 (84.4) 24.5 ± 3.0 24.2 ± 2.6 26.6 ± 5.6 25.7 ± 5.4 35.2 ± 5.7 35.0 ± 5.6 
Unemployed *1   88 / 89   63 (71.6)   62 (69.7) 24.3 ± 2.7 24.2 ± 2.6 26.4 ± 5.2 25.8 ± 5.3 35.2 ± 6.9 34.7 ± 5.9 
Education (yrs)          
2 or less 
(preparatory)  
155 102 (65.8) 111 (71.6) 25.2 ± 3.1 24.8 ± 3.0 27.4 ± 5.2 26.7 ± 5.3 35.8 ± 7.0 35.4 ± 6.0 
3 - 4 (elementary)   33   23 (69.7)   23 (69.7) 24.5 ± 3.4 25.1 ± 3.7 27.2 ± 6.1 27.7 ± 6.3 36.5 ± 7.1 37.3 ± 7.0 
5 - 6 (intermediate)   40   25 (62.5)   33 (82.5) 24.7 ± 2.8 23.9 ± 1.7 27.7 ± 7.0 24.8 ± 2.9 36.0 ± 7.5 35.1 ± 5.8 
7 - 10 (secondary)   40   31 (77.5)   30 (75.0) 24.5 ± 2.4 24.5 ± 2.7 25.7 ± 5.1 25.6 ± 4.2 35.2 ± 4.1 35.1 ± 3.8 
11 or more (higher)   37   33 (89.2)   31 (83.8) 24.3 ± 2.8 24.3 ± 3.6 25.9 ± 3.8 24.7 ± 3.0 36.1 ± 4.8 34.9 ± 3.7 
Missing/refused     9     8 (88.9)     5 (55.6) 24.2 ± 2.2 24.4 ± 2.8 26.6 ± 3.3 27.6 ± 4.0 34.9 ± 3.1 36.0 ± 3.6 
 
(Continued on the next page) 
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Table 15 (Continued). 
Stage 2 or lower Foot Ankle Leg   
 N Left Right    Left Right Left Right Left Right
Knowledge          
Insect bite / 
worm 
31   25 (80.7)   23 (74.2) 24.5 ± 2.9 24.7 ± 2.4 26.0 ± 4.5 26.4 ± 4.6 37.3 ± 6.9 37.3 ± 5.9 
Magic 33   23 (69.7)   24 (72.7) 25.2 ± 3.4 24.8 ± 4.0 28.0 ± 7.2 26.0 ± 4.3 35.0 ± 6.4 35.1 ± 5.0 
Sprain foot / 
injury *1 
30 / 29   23 (76.7)   22 (75.9) 24.9 ± 2.6 24.3 ± 2.8 27.9 ± 5.4 25.9 ± 4.0 36.0 ± 5.0 35.7 ± 4.4 
Chill *1 41 / 42   29 (70.7)   31 (73.8) 25.0 ± 2.8 25.3 ± 3.4 27.9 ± 5.3 27.7 ± 5.6 35.8 ± 5.1 35.6 ± 5.8 
Other 41   29 (70.7)   29 (70.7) 24.6 ± 2.4 25.3 ± 4.1 27.5 ± 3.8 28.0 ± 5.6 35.9 ± 5.0 36.9 ± 6.2 
Don’t know 177 123 (69.5) 133 (75.1) 24.7 ± 2.9 24.4 ± 3.4 26.5 ± 5.1 25.6 ± 4.4 35.5 ± 6.9 34.8 ± 5.2 
Number of 
acute attacks  
         
0 16   13 (81.3)   11 (68.8) 23.8 ± 2.7 24.2 ± 2.0 25.3 ± 4.6 26.0 ± 3.2 35.1 ± 6.5 35.8 ± 5.3 
1 177 123 (69.5) 137 (77.4) 24.8 ± 3.0 24.4 ± 2.6 27.2 ± 6.0 25.9 ± 5.0 36.2 ± 7.1 35.3 ± 5.5 
2 *1 79 / 80   57 (72.2)   56 (70.0) 25.0 ± 2.8 25.0 ± 3.7 26.5 ± 4.0 26.5 ± 4.8 35.6 ± 5.2 35.6 ± 6.0 
3 39   26 (66.7)   27 (69.2) 24.5 ± 2.8 24.8 ± 3.4 27.3 ± 4.6 27.3 ± 5.1 34.9 ± 5.5 35.7 ± 5.5 
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Figure 4. Stage of Illness by Socio-demographic Variables. 
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Figure 4 (Continued). 
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Figure 4 (Continued). 
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 74
 
 
Self-care Practice and Self-efficacy 
The data regarding self-care practices and self-efficacy were analyzed to describe 
respondents’ health-related behaviors. Chi-square test was conducted to observe the 
differences of their behaviors by the variables of interest at a significant level of α = 0.05.  
Table 16 shows the number of people who currently practice self-care for affected 
legs. Hygiene, wearing shoes, and herbal remedy were among the most common self-care 
practices reported for legs. Of those, most people who answered hygiene and wearing 
shoes performed these practices as a daily care. On the other hand, the frequency of 
performing it was less often. Only about one-third of people who answered herbal 
remedy did it as a daily care. No gender differences were found, but regional differences 
were significant (χ2=58.77, df=22, p<0.01). People in La Plaine reported taking care of 
their legs more often than those in other regions.  
Table 17 shows the self-care practices associated with other socio-demographic 
variables. The table includes the five most common practices (hygiene, wearing shoes, 
elevation, herbal remedy, and pomade) due to the small number of responses in the other 
practices. The remaining practices were categorized as “other”. However, the choice of 
self-care practices was not significantly associated with the variables of interest (age 
group, age of onset, education, income, occupation, and knowledge of the illness). 
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Table 16. Gender, Town vs. Self-care Practice for Legs (n (% N), *: 1 missing, **: 
different among towns (p<0.05)). 
Gender Town* **  Total 
(N = 316) Male 
 (N = 61) 
Female  
(N = 255) 
Arcahaie 
(N=120) 
Cabaret 
(N = 72) 
La Plaine 
(N=123) 
Hygiene 202 (63.9) 36 (59.0) 169 (66.3) 68 (56.7) 44 (61.1)   92 (74.8) 
Wearing 
shoes 
238 (75.3) 41 (67.2) 197 (77.3) 77 (64.2) 54 (75.0) 106 (86.2) 
Permangan
ate 
  41 (13.0)   8 (13.1)   33 (12.9) 10 (8.3)   5 (6.9)   26 (21.1) 
Creme   49 (15.6)   4 (6.6)   45 (17.6) 16 (13.3)   5 (6.9)   27 (22.0) 
Elevation   72 (22.8)   9 (14.8)   63 (24.7) 21 (17.5) 12 (16.7)   39 (31.7) 
Massage   29 (9.2)    6 (9.8)   23 (9.0)   5 (4.2)   3 (4.2)   21 (17.1) 
Exercise   21 (6.7)   6 (9.8)   15 (5.9)   8 (6.7)   5 (6.9)     8 (6.5) 
Bandage   54 (17.1)    9 (14.8)   45 (17.6) 12 (10.0)   8 (11.1)   34 (27.6) 
Medicine   59 (18.7)  16 (26.2)   43 (16.9) 26 (21.7) 11 (15.3)   22 (17.9) 
Herbal 
remedy 
139 (44.0)  23 (37.7) 116 (45.5) 57 (47.5) 35 (48.6)   47 (38.2) 
Pomade   90 (28.5)  23 (37.7)   67 (26.3) 36 (30.0) 32 (44.4)   22 (17.9) 
Other   32 (10.1)    6 (9.8)   26 (10.2)   8 (6.7) 10 (13.9)   14 (11.4) 
 
 
Table 17. Other Socio-demographic Variables vs. Major Self-care Practices for Legs (n (% N), “other” indicates the 
sum of the rest of practices so that the number doesn’t reflect the proportion of N). 
      N Hygiene Wearing shoes Elevation Herbal remedy Pomade  Other
Age group (yrs)      
19 or less 33 20 (73.4) 23 (69.7) 8 (24.2) 17 (51.5) 11 (33.3) 34 
20 - 29 42 25 (59.5) 30 (71.4) 7 (16.7) 21 (50.0) 10 (23.8) 46
30 – 39 49 35 (71.4) 40 (81.6) 13 (26.5) 19 (38.8) 14 (28.6) 43
40 – 49 64 44 (68.8) 50 (78.1) 16 (25.0) 23 (35.9) 16 (25.0) 66
50 – 59 52 29 (55.8) 35 (67.3) 9 (17.3) 27 (51.9) 17 (32.7) 44
60 – 69 39 25 (64.1) 27 (69.2) 10 (25.6) 20 (51.3) 11 (28.2) 26
70 or more 34 25 (73.5) 30 (88.2) 9 (26.5) 12 (35.3) 9 (26.5) 25
Missing 3   2 (66.7) 3 (100.0) 0 (0)             0 (0) 2 (66.7) 1
Age of onset (yrs)  
9 or less 15   8 (53.3) 12 (80.0)    1 (6.7) 8 (53.3) 5 (33.3) 17
10 – 19 92 56 (60.9) 64 (69.6) 18 (19.6) 42 (45.7) 30 (32.6) 94
20 – 29 58 45 (77.6) 49 (84.5) 16 (27.6) 28 (48.3) 15 (25.9) 49
30 – 39 51 32 (62.7) 37 (72.5) 13 (25.5) 22 (43.1) 8 (15.7) 59
40 – 49 34 20 (58.8) 23 (67.6) 10 (29.4) 15 (44.1) 12 (35.3) 23
50 or more 29 17 (58.6) 20 (69.0) 5 (17.2) 11 (37.9) 9 (31.0) 19
Missing 37 27 (73.0) 33 (89.2) 9 (24.3) 13 (35.1) 11 (29.7) 30
Education (yrs)  
2 or less (preparatory) 157 101 (64.3) 118 (75.2) 32 (20.4) 65 (41.4) 41 (26.1) 110
3 – 4 (elementary)  33 19 (57.6) 19 (57.6) 5 (15.2) 18 (54.5) 9 (27.3) 27
5 – 6 (intermediate) 40 29 (72.5) 34 (85.0) 15 (37.5) 18 (45.0) 14 (35.0) 50
7 – 10 (secondary)  40 23 (57.5) 29 (72.5) 11 (27.5) 20 (50.0) 18 (45.0) 46
11 or more (higher)  37 28 (75.7) 31 (83.8) 9 (24.3) 15 (40.5) 5 (13.5) 41
Missing/refused 9 5 (55.6) 7 (77.8) 0 (0) 3 (33.3) 3 (33.3) 11
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Table 17 (Continued).  
 N Hygiene Wearing shoes  Elevation    Herbal remedy Pomade Other
Daily income (gde)        
25 or less 33 27 (81.8) 28 (84.8) 12 (36.4) 14 (42.4) 9 (27.3) 30
26 – 50 28 18 (64.3) 22 (78.6) 6 (21.4) 10 (35.7) 10 (35.7) 21
51 – 100 29 20 (69.0) 22 (75.9) 7 (24.1) 10 (34.5) 5 (17.2) 23
101 – 200 25 11 (44.0) 19 (76.0)    2 (8.0) 12 (48.0) 7 (28.0) 12
201 – 400 29 13 (44.8) 16 (55.2) 6 (20.7) 15 (51.7) 9 (31.0) 34
401 or more 28 14 (50.0) 18 (64.3) 6 (21.4) 10 (35.7) 9 (32.1) 27
Missing/refused 144 102 (70.8) 113 (78.5) 33 (22.9) 68 (47.2) 41 (28.5) 138
Occupation  
Farmer 44 31 (70.5) 34 (77.3) 7 (15.9) 18 (40.9) 18 (40.9) 34
Seller at home 66 44 (66.7) 52 (78.8) 20 (30.3) 31 (47.0) 14 (21.2) 55
Seller at market 52 31 (59.6) 38 (73.1) 9 (17.3) 24 (46.2) 19 (36.5) 37
Tailor / seamstress 17 12 (70.6) 15 (82.4) 6 (35.3) 6 (35.3) 3 (17.6) 22
Other 64 39 (60.9) 48 (75.0) 14 (21.9) 24 (37.5) 17 (26.6) 74
Unemployed 90 64 (71.1) 69 (76.7) 25 (27.8) 41 (45.6) 21 (23.3) 90
Illness knowledge  
Insect bite / worm 31 21 (67.7) 26 (83.4) 9 (29.0) 15 (48.4) 12 (38.7) 49
Magic 33 18 (54.5) 20 (60.6) 4 (12.1) 20 (60.6) 5 (15.2) 21
Sprain/injure foot 30 19 (63.3) 23 (76.7) 7 (23.3) 14 (46.7) 6 (20.0) 21
Chill 43 24 (55.8) 31 (72.1) 5 (11.6) 26 (60.5) 16 (37.2) 34
Other 41 16 (39.0) 21 (51.2) 9 (22.0) 20 (48.8) 12 (29.3) 32
Don’t know 177 125 (70.6) 139 (78.5) 46 (26.0) 71 (40.1) 47 (26.6) 252
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Table 18 reports other self-care practices which respondents do not currently do 
but can be done to help one’s leg. Although the number of responses was lower than that 
of self-care in general, its preference and frequency tended to be similar. Only slight 
gender differences were found in self-efficacy, but regional differences were significant 
(χ2=120.25, df=22, p<0.01). Because of the number of responses, people in La Plaine 
were much more willing to do their leg treatment. This tendency is similar to self-care 
practices currently being done for legs. People who answered other practices recorded 
120, but 53 (16.8 %) and 18 (5.7 %) people responded “nothing” and “don’t know” in 
that order. 
Other socio-demographic variables were also included in the analysis of potential 
self-care practices (Table 19). The selection of the practices was dependent on the 
frequency in Table 18 (hygiene, wearing shoes, herbal remedy, pomade, and other). The 
rest were categorized as “other2”. Unlike current self-care practices for legs, other 
practices which can be done in the future varied significantly by education (χ2=44.06, 
df=25, p=0.01) and knowledge of the illness (χ2=73.21, df=25, p<0.01). 
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Table 18. Gender, Town vs. Possible Leg Care in the Future (n (% N), *: 1 missing, **: 
different among towns (p<0.05)). 
Gender Town* **  Total 
(N = 316) Male 
 (N = 61) 
Female  
(N = 255) 
Arcahaie 
(N=120) 
Cabaret 
(N = 72) 
La Plaine 
(N=123) 
Hygiene 108 (34.2) 18 (29.5)   90 (35.3) 17 (14.2) 17 (23.6)   74 (60.2) 
Wearing 
shoes 
119 (37.7) 22 (36.1)   97 (38.0) 27 (22.5) 19 (26.4)   73 (59.3) 
Permangan
ate 
  15 (4.7)   1 (1.6)   14 (5.5)   1 (0.8)   2 (2.8)   12 (9.8) 
Creme   14 (4.4)   0 (0)   14 (5.5)   1 (0.8)   0 (0)   13 (10.6) 
Elevation   29 (9.2)   3 (4.9)   26 (10.2)   6 (5.0)   6 (8.3)   22 (17.9) 
Massage   19 (6.0)   4 (6.6)   15 (5.9)   2 (1.7)   1 (1.4)   16 (13.0) 
Exercise     3 (0.9)   0 (0)     3 (1.1)   2 (1.7)   0 (0)     1 (0.8) 
Bandage   43 (13.6)   4 (6.6)   39 (15.3) 12 (10.0)   5 (6.9)   26 (21.1) 
Medicine   50 (15.8) 13 (21.3)   37 (14.5) 21 (17.5) 16 (22.2)   13 (10.6) 
Herbal 
remedy 
114 (36.1) 18 (29.5)   96 (37.6) 49 (40.8) 21 (29.2)   44 (35.8) 
Pomade   79 (25.0) 16 (37.7)   63 (26.3) 34 (30.0) 26 (44.4)   19 (17.9) 
Other or 
don’t know 
120 (38.0) 20 (32.8) 100 (39.2) 47 (39.2) 35 (48.6)   37 (30.0) 
 
 
Table 19. Other Socio-demographic Variables vs. Possible Leg Care in the Future (n (% N), “other2” indicates the sum 
of the rest of practices so that the number doesn’t reflect the proportion of N, *: p < 0.05). 
 N Hygiene Wearing shoes Herbal remedy Pomade Other Other2 
Age group (yrs)        
19 or less 33 13 (39.4) 16 (48.5) 14 (42.4) 13 (39.4) 10 (30.3) 21
20 - 29 42 11 (26.2) 15 (35.7) 15 (35.7) 11 (26.2) 15 (35.7) 29
30 – 39 49 20 (40.8) 20 (40.8) 16 (32.7) 8 (16.3) 21 (42.9) 28
40 – 49 64 15 (23.4) 18 (28.1) 18 (28.1) 11 (17.2) 27 (42.2) 36
50 – 59 52 20 (38.5) 21 (40.4) 23 (44.2) 15 (28.9) 21 (40.4) 29
60 – 69 39 14 (35.9) 14 (35.9) 19 (48.7) 11 (28.2) 11 (28.2) 16
70 or more 34 13 (38.2) 13 (38.2) 9 (26.5) 8 (23.5) 15 (44.1) 12
Missing 3 2 (66.7) 2 (66.7)               0 (0) 2 (66.7)      0 (0) 2
Age of onset (yrs)   
9 or less 15 7 (46.7) 6 (40.0) 7 (46.7) 4 (26.5) 5 (33.3) 10
10 – 19 92 26 (28.3) 35 (38.0) 39 (42.4) 28 (30.4) 32 (34.8) 51
20 – 29 58 21 (36.2) 22 (37.9) 18 (31.0) 11 (19.0) 23 (39.7) 33
30 – 39 51 15 (29.4) 14 (27.5) 18 (35.3) 9 (17.6) 23 (45.1) 32
40 – 49 34 11 (32.4) 14 (41.2) 13 (38.2) 7 (20.6) 12 (35.3) 19
50 or more 29 4 (13.8) 14 (48.3) 11 (37.9) 9 (31.0) 9 (31.0) 14
Missing 37 14 (37.8) 14 (37.8) 8 (21.6) 11 (29.7) 16 (43.2) 14
Education (yrs) *   
2 or less (preparatory) 157 44 (28.0) 45 (28.7) 57 (36.3) 39 (24.8) 66 (42.0) 56
3 – 4 (elementary)  33 18 (54.5) 20 (60.6) 13 (39.4) 11 (33.3) 13 (34.4) 19
5 – 6 (intermediate) 40 13 (32.5) 15 (37.5) 16 (40.0) 8 (20.0) 16 (40.0) 26
7 – 10 (secondary)  40 9 (22.5) 23 (57.5) 16 (40.0) 14 (35.0) 6 (15.0) 43
11 or more (higher)  37 10 (27.0) 12 (32.4) 11 (29.7) 5 (13.5) 15 (40.5) 22
Missing/refused 9 4 (44.4) 4 (44.4) 1 (11.1) 2 (22.2) 4 (44.4) 7
 
(Continued on the next page) 
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Table 19 (Continued).  
 N Hygiene Wearing shoes Herbal remedy Pomade Other Other2 
Daily income (gde)        
25 or less 33 4 (12.1) 5 (15.2) 11 (33.3)    2 (6.1) 16 (48.5) 13
26 – 50 28 7 (25.0) 6 (21.4) 7 (25.0) 5 (17.9) 10 (35.7) 16
51 – 100 29 8 (27.6) 8 (27.6) 10 (34.5) 3 (10.3) 17 (38.6) 10
101 – 200 25 16 (64.0) 17 (68.0) 12 (48.0) 8 (32.0) 6 (24.0) 12
201 – 400 29 10 (34.5) 13 (44.8) 12 (41.4) 8 (27.6) 13 (44.0) 19
401 or more 28 15 (53.6) 17 (60.7) 7 (25.0) 9 (32.1) 14 (50.0) 21
Missing/refused 144 48 (33.3) 53 (36.8) 55 (38.2) 44 (30.6) 44 (30.6) 78
Occupation  
Farmer 44 7 (15.9) 8 (18.2) 17 (38.6) 10 (22.7) 18 (40.9) 17
Seller at home 66 24 (36.4) 25 (37.9) 21 (31.8) 12 (18.2) 29 (43.9) 37
Seller at market 52 18 (34.6) 22 (42.3) 20 (38.5) 17 (32.7) 19 (36.5) 27
Tailor / seamstress 17 7 (41.2) 7 (41.2) 5 (29.4)    1 (5.9) 10 (58.4) 18
Other 64 27 (42.2) 33 (51.6) 24 (37.5) 14 (21.9) 16 (25.0) 48
Unemployed 90 29 (32.2) 28 (31.1) 31 (34.4) 25 (27.8) 36 (40.0) 39
Illness knowledge *  
Insect bite / worm 31 12 (38.7) 15 (48.4) 13 (41.9) 11 (35.5) 8 (25.8) 34
Magic 33    2 (6.1) 4 (12.1) 12 (36.4) 12 (36.4) 15 (45.5) 7
Sprain/injure foot 30    2 (6.7) 3 (10.0) 15 (50.0) 6 (20.0) 11 (36.7) 7
Chill 43 13 (30.2) 14 (32.6) 17 (39.5) 14 (32.6) 15 (34.9) 21
Other 41 7 (17.1) 8 (19.5) 18 (43.9) 10 (24.4) 19 (46.3) 12
Don’t know 177 78 (44.1) 82 (46.3) 55 (31.1) 36 (20.3) 69 (39.0) 106
 
 
 81
 82
Table 20 shows the degree of confidence for leg care. Nearly 90 % of people 
reported that they were at least somewhat confident in their ability to care for their legs. 
Like self-care practices for legs, there were no significant gender differences, but people 
in La Plaine reported higher confidence for their leg care than those in other towns 
(χ2=21.79, df=2, p<0.01).  
 
Table 20. Degree of Confidence for Leg Care (n (% N), *: 1 missing, **: different among 
towns (p<0.05)). 
Gender Town* **  Total 
(N = 316) Male 
(N = 61) 
Female 
(N = 255) 
Arcahaie 
(N = 120) 
Cabaret 
(N = 72) 
La Plaine 
(N = 123) 
Very 
confident 
247 (78.2) 50 (82.0) 197 (77.3) 85 (70.8) 49 (68.1) 113 (91.9)
Somewhat 
confident 
or below 
  69 (21.8) 11 (18.0)   58 (22.7) 35 (29.2) 23 (31.9)   10 (8.1) 
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Quality of Life 
One of the most interesting research questions is to what extent the lymphedema 
condition affects quality of life, measured by the standardized QOL and subjective well-
being instruments. To describe it, the scores of EuroQol, CES-D, and CDC Healthy Days 
were analyzed. Also, in order to observe the association between the outcomes of the 
scales and the variables of interest, the T-test and F-test were used to compare mean 
differences. At the same time, the chi-square test was performed for the categorical 
outcome. For the criterion of significance, α = 0.05 was used.  
 
 
EuroQol 
Table 21 presents the results of the EuroQol questionnaire. More than 70 % of 
respondents reported no problems in four of five health categories. Above all, none of 
them had extreme problems in mobility or self-care. Only six people were unable to 
perform their usual activities. Also, anxiety/depression was less likely to be severe among 
them. A gender difference was found only for mobility (χ2=5.67, df=1, p=0.02). Females 
were 2.02 times more likely than males to have problems in walking (RR=2.02, 95% CI: 
1.07<RR<3.80). On the other hand, more than half of respondents felt some degree of 
pain/discomfort. Though the gender difference was not statistically significant for the 
latter variable, regional differences were prominent (χ2=19.23, df=4, p<0.01). In 
particular, respondents from Arcahaie seemed to experience more severe pain/discomfort, 
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but people in La Plaine reported less pain. A similar pattern was also found for overall 
health status (F=12.19, df=2, 312, p<0.01). Figure 5 shows the clear regional differences 
visually. Though not significant, the degree of anxiety/depression was different across 
towns (χ2=5.34, df=2, p=0.07). Thus, the results indicated that people in La Plaine 
experienced milder symptoms of LF than those in other places. 
 The results of the EuroQol scale were also compared with other socio-
demographic variables, including stage of the illness. Table 22 shows the number and 
percent of people not reporting any health problems in the five categories and the average 
health score, and Figure 6 depicts the difference of overall health status by the variables 
of interest. Of those variables, age group and educational level had a strong association 
with QOL measures. Mobility, usual activities, pain/discomfort, and overall health status 
varied significantly within them (all p-values < 0.05). Though not significant, age group 
was also associated with self-care (p-values < 0.10). In general, older people were more 
likely to report poorer health status, and people who completed more formal education 
tended to maintain better health status. Also, QOL varied by stage of the illness. There 
were significant differences in mobility and usual activities by stage of both legs (all p-
values < 0.05); however, the other health categories including overall health status varied 
significantly by stage of one leg only. The other variables had a partial impact on the 
QOL measures. Occupation seems to substantially impact mobility, usual activities, and 
overall health condition (all p-values < 0.05), but the small number of respondents in 
tailor/seamstress category and the large number in other occupation may negatively affect 
the outcomes so that it would be difficult to observe the impact of the variable correctly. 
The QOL scores were also significantly different in usual activities for age of onset, self-
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care for knowledge of the illness, and pain/discomfort for both categories (all p-values < 
0.05); however, it is difficult to observe the patterns of the scores. No differences were 
observed by income.     
Table 21. Gender, Town vs. EuroQol (#: 1 missing, *: different between gender (p<0.05), **: different among towns (p<0.05)). 
 Gender Town #   Total 
(N=316) Male  
(N=61) 
Female 
(N=255) 
Arcahaie 
(N=120) 
Cabaret 
(N=72) 
La Plaine 
(N=123) 
No problem 231 (73.1) 52 (85.3) 179 (70.2)   83 (69.2) 58 (80.6)   89 (72.4) Mobility 
(n (% N)) * Some problem   85 (26.9)   9 (14.8)   76 (29.8)   37 (30.8) 14 (19.4)   34 (27.6) 
No problem 287 (90.8) 56 (91.8) 231 (90.6) 107 (89.1) 65 (90.3) 114 (92.7) Self-care 
(n (% N)) Some problem   29 (9.2)   5 (8.2)   24 (9.4)   13 (10.8)   7 (9.7)     9 (7.3) 
No problem 233 (73.7) 45 (73.4) 188 (73.7)   84 (70.0) 57 (79.2)   91 (74.0) 
Some problem   75 (23.7) 12 (19.7)   63 (24.7)   32 (26.7) 13 (18.1)   30 (24.4) 
Unable to perform     6 (1.9)   3 (4.9)     3 (1.2)     3 (2.5)   2 (2.8)     1 (0.8) 
Ambiguous response     1 (0.3)   1 (1.6)     0 (0)     0 (0)   0 (0)     0 (0) 
Usual activities 
(n (% N)) 
Missing     1 (0.3)   0 (0)     1 (0.4)     1 (0.8)   0 (0)     0 (0) 
No problem 138 (43.7) 27 (44.3) 111 (43.5)   37 (30.8) 32 (44.4)   69 (56.1) 
Some problem 158 (50.0) 30 (49.2) 128 (50.2)   70 (58.3) 35 (48.6)   52 (42.3) 
Extreme   19 (6.0)   3 (4.9)   16 (6.3)   12 (10.0)   5 (6.9)     2 (1.6) 
Pain/discomfort  
(n (% N)) ** 
Ambiguous response     1 (0.3)   1 (1.6)     0 (0)     1 (0.8)   0 (0)     0 (0) 
No 237 (75.0) 45 (73.4) 192 (75.3)   83 (69.2) 51 (70.8) 103 (83.7) 
Moderate   63 (19.9) 14 (23.0)   49 (19.2)   25 (20.8) 18 (25.0)   19 (15.5) 
Extreme     9 (2.9)   1 (1.6)     8 (3.1)     7 (5.8)   1 (1.4)     1 (0.8) 
Anxiety 
/depression 
(n (% N))  
Missing     7 (2.2)   1 (1.6)     6 (2.4)     5 (4.2)   2 (2.8)     0 (0) 
Overall health status (mean ± SD) ** 57.1 ± 17.3 59.7 ± 22.8 56.5 ± 18.5 53.8 ± 15.5 53.2 ± 14.0 63.0 ± 18.9 
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Figure 5. Gender, Town vs. Overall Health Status by EuroQol. 
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Table 22. Filariasis Related Variables vs. People Answered No Problem in EuroQol Questionnaires (n (% N)) and EuroQol Overall 
Health Status (mean ± SD) (*1: different among age group, *2: different among age of onset, *3: different among education 
level, *4: different among occupation, *5: different among knowledge of the illness, *6: different among right leg, *7: 
different among left leg (all p<0.05)). 
 N Mobility
*1 
 Self-care Usual activities
*1 *2 
 Pain / 
discomfort *1 
*2 
Anxiety / 
depression 
Overall health 
status *1 
Age group (yrs)        
19 or less  33 28 (84.8) 30 (90.9) 30 (90.9) 20 (60.6) 29 (87.9) 63.6 ± 17.8
20 – 29 42 33 (78.6) 41 (97.6) 34 (81.0) 22 (52.4) 29 (69.0) 58.1 ± 15.5
30 – 39 49 39 (79.6) 47 (95.9) 42 (85.7) 21 (42.9) 40 (81.6) 61.2 ± 15.6
40 – 49 64 51 (79.7) 61 (95.3) 54 (84.4) 33 (51.6) 46 (71.9) 55.0 ± 16.0
50 – 59 52 33 (63.5) 44 (84.6) 34 (65.4) 16 (30.8) 39 (75.0) 54.6 ± 17.0
60 – 69 39 26 (66.7) 33 (84.6) 22 (56.4) 12 (30.8) 28 (71.8) 56.4 ± 20.4
70 or more 34 19 (55.9) 28 (82.4) 12 (35.3) 11 (32.4) 23 (67.6) 49.7 ± 14.9
Missing/refused 3  2 (66.7) 3 (100.0)  3 (100.0)  3 (100.0)    3 (100.0) 86.7 ± 23.1
Age of onset (yrs)  
9 or less 15 12 (80.0) 14 (93.3) 12 (80.0)  4 (26.7) 10 (66.7) 64.0 ± 10.6
10 – 19 92 71 (77.2) 84 (92.1) 77 (83.7) 44 (47.8) 70 (76.1) 57.6 ± 17.1
20 – 29 58 41 (70.7) 52 (89.7) 39 (67.2) 31 (53.4) 43 (74.1) 57.9 ± 18.2
30 – 39 51 41 (80.4) 45 (88.2) 38 (74.5) 15 (29.4) 36 (70.6) 57.3 ± 15.8
40 – 49 34 25 (73.5) 31 (91.2) 28 (82.4) 19 (55.9) 28 (82.4) 53.5 ± 19.1
50 or more 29 20 (69.0) 28 (96.6) 17 (58.6)  5 (17.2) 23 (79.3) 56.9 ± 18.1
Missing/refused 37 21 (56.8) 33 (89.2) 22 (59.5) 20 (54.1) 27 (73.0) 55.1 ± 18.5
 
(Continued on the next page) 
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Table 22 (Continued).  
 N Mobility Self-care *5 Usual activities
*3 *4 
  Pain / 
discomfort *3 
*5 
Anxiety / 
depression 
Overall health 
status *3 *4 
Education (yrs)        
2 or less 157 106 (67.5) 136 (86.7) 100 (63.7) 54 (34.4) 108 (68.8) 53.1 ± 16.8
3 – 4 33 23 (69.7) 31 (93.9) 26 (78.8) 15 (45.5) 26 (78.8) 59.4 ± 18.2
5 – 6 40 32 (80.0) 38 (95.0) 33 (82.5) 25 (62.5) 35 (75.0) 60.5 ± 15.7
7 – 10 40 33 (82.5) 39 (97.5) 36 (90.0) 20 (50.0) 32 (80.0) 62.0 ± 14.2
11 or more 37 31 (83.8) 35 (94.6) 30 (81.1) 19 (51.4) 28 (75.7) 60.5 ± 18.8
Missing/refused 9 6 (66.7) 8 (88.9) 8 (88.9) 5 (55.6) 8 (88.9) 68.9 ± 21.5
Occupation  
Farmer 44 34 (77.3) 39 (88.6) 34 (77.3) 19 (43.2) 33 (75.0) 55.2 ± 17.0
Seller at home 66 45 (68.2) 59 (89.4) 42 (63.6) 25 (37.9) 49 (74.2) 55.0 ± 15.5
Seller at market 52 36 (69.2) 48 (92.3) 40 (76.9) 19 (36.5) 37 (71.2) 59.2 ± 16.4
Tailor/seamstress 17 15 (88.2) 15 (88.2) 14 (82.4) 12 (70.6) 14 (82.4) 58.2 ± 18.1
Unemployed 90 57 (63.3) 80 (88.9) 59 (65.6) 40 (44.4) 68 (75.6) 52.6 ± 18.1
Other 64 54 (84.4) 61 (95.3) 56 (87.5) 34 (53.1) 50 (78.1) 64.2 ± 17.4
Illness knowledge  
Insect bite 31 21 (67.7) 28 (90.3) 22 (71.0) 8 (25.8) 22 (71.0) 58.4 ± 13.9
Magic 33 21 (63.6) 26 (78.8) 19 (57.6) 7 (21.2) 18 (54.5) 53.9 ± 17.1
Sprain 30 23 (76.7) 25 (83.3) 22 (73.3) 10 (33.3) 20 (66.7) 58.7 ± 14.8
Chill 43 31 (72.1) 39 (90.7) 30 (69.8) 13 (30.2) 32 (74.4) 51.9 ± 13.7
Other 41 29 (70.7) 34 (82.9) 27 (65.9) 15 (36.6) 29 (70.7) 52.7 ± 16.7
Don’t know 177 133 (75.1) 169 (95.5) 138 (78.0) 93 (52.5) 141 (79.7) 58.0 ± 18.8
 
(Continued on the next page) 
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Table 22 (Continued).  
 N Mobility *6 *7 Self-care Usual activities
*6 *7 
 Pain / 
discomfort *7 
Anxiety / 
depression 
Overall health 
status *6 
Daily income 
(gde) 
    
25 or less 33 25 (75.8) 27 (81.8) 20 (60.6) 14 (42.4) 24 (72.7) 54.5 ± 17.0
26 – 50 28 22 (78.6) 26 (92.9) 22 (78.6) 12 (42.9) 18 (64.3) 53.2 ± 19.3
51 – 100 29 21 (72.4) 26 (89.7) 21 (72.4) 11 (37.9) 21 (72.4) 52.8 ± 17.1
101 – 200 25 20 (80.0) 23 (92.0) 20 (80.0)  9 (36.0) 19 (76.0) 58.4 ± 14.9
201 – 400 29 23 (79.3) 29 (100.0) 24 (82.8) 16 (55.2) 23 (79.3) 59.7 ± 15.9
401 or more 28 20 (71.4) 27 (96.4) 23 (82.1)  9 (32.1) 21 (75.0) 58.9 ± 15.9
Missing/refused 144 100 (69.4) 129 (89.6) 103 (71.5) 67 (46.5) 111 (77.1) 58.3 ± 17.9
Stage of right leg        
Normal 43 40 (93.0) 41 (95.3) 39 (90.7) 25 (64.1) 34 (79.1) 67.4 ± 16.0
Stage 1 106 80 (75.5) 96 (90.6) 81 (76.4) 50 (47.2) 79 (74.5) 56.1 ± 15.5
Stage 2 84 60 (71.4) 80 (95.2) 64 (76.2) 35 (41.7) 65 (77.4) 57.3 ± 14.1
Stage 3 52 34 (65.4) 44 (84.6) 29 (55.8) 15 (28.8) 38 (73.1) 51.9 ± 17.5
Stage 4 or more 29 15 (51.7) 24 (82.8) 19 (65.5) 12 (41.4) 19 (65.5) 55.9 ± 26.1
Missing/NA 2 2 (100.0) 2 (100.0) 1 (50.0) 1 (50.0) 2 (100.0)         35.0 ± 7.1 
Stage of left leg  
Normal 26 21 (80.8) 25 (96.2) 24 (92.3) 18 (69.2) 20 (76.9) 61.2 ± 21.4
Stage 1 71 61 (85.9) 70 (98.6) 60 (84.5) 37 (52.1) 60 (84.5) 56.8 ± 14.4
Stage 2 125 88 (70.4) 109 (87.2) 91 (72.8) 51 (40.8) 84 (67.2) 57.8 ± 17.3
Stage 3 58 38 (65.5) 51 (87.9) 39 (67.2) 17 (29.3) 46 (79.3) 53.6 ± 16.3
Stage 4 or more 34 21 (61.8) 30 (88.2) 18 (52.9) 14 (41.1) 25 (73.5) 59.7 ± 20.1
Missing/NA 2 2 (100.0) 2 (100.0) 1 (50.0) 1 (50.0) 2 (100.0)         30.0 ± 0.0 
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Figure 6. Other Socio-demographic Variables vs. Overall Health Status by EuroQol. 
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Figure 6 (Continued). 
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Figure 6 (Continued). 
EQ-VAS (stage of illness)
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CES-D 
 Table 23 shows the total scores on the CES-D scale. The mean score and its 
standard deviation were 13.2 and 9.5, respectively. For gender comparison, females were 
more likely to have higher score than males (T=1.95, df=314, p=0.05), but regional 
differences were more marked (F=58.03, df=2, 312, p<0.01). Especially, people living in 
La Plaine had much higher depression scores than those from the other areas. Since 
people with a total score of 16 or above are generally considered as a depressive case 
(Eaton et al., 2003), Table 20 also shows the proportion of respondents scoring above 16. 
More than one-third of the total sample had a score of 16 or more. The score of people in 
La Plaine was prominently higher than the comparison groups.  
 Total CES-D scores and the proportion of depressive cases in relation to other 
socio-demographic variables are shown in Table 24. There were no significant statistical 
differences in both scores and depressive cases for current age, age of onset, income, 
educational level, and knowledge of the illness. Only the stage of the illness was strongly 
associated with depression scores (p-values < 0.05); however, no linear or systematic 
variation was observed. 
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Table 23. Gender, Town vs. Total CES-D Score (mean ± SD, (Range)) and the 
Proportion of the Score Indicating Depressive Cases (n (% N)) (*: 1 missing, 
**: different among towns (p<0.05)). 
Gender Town *  Total 
(N=315) Male 
(N=61) 
Female 
(N=255) 
Arcahaie 
(N=120) 
Cabaret 
(N=72) 
La Plaine 
(N=123) 
CES-D score 
 ** 
13.2 ± 9.5 
(0 – 41) 
11.1 ± 8.4 
(0 – 27) 
13.7 ± 9.7 
(0 – 41) 
9.3 ± 7.0 
(0 – 33) 
9.1 ± 6.7 
(0 – 24) 
19.4±9.8 
(0– 41) 
below 16  198 (62.6) 42 (68.9) 156 (61.2) 102 (85.0) 58 (80.6) 37 (30.1) 
16 or more 118 (37.3) 19 (31.2) 99 (38.9) 18 (15.0) 14 (19.4) 86 (69.9) 
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Table 24. Other Socio-demographic Variables vs. Total CES-D Score (mean ± SD) and 
the Proportion of the Score Indicating Depressive Cases (n (% N)) (*: p<0.05 
for both score and depression level). 
 N Score Depress
ion 
level 
 N Score Depress
ion 
level 
Age group (yrs) Occupation 
19 or less 33 10.9 ± 9.1 12(36.4) Farmer 44 10.8 ± 7.5 9 (20.5)
20 – 29 42 12.3 ± 8.7 14(33.3) Sell – home 66 15.7 ± 10.6 31(47.0)
30 – 39 49 14.4 ± 9.9 19(38.8) Sell – market 52 12.3 ± 10.4 16(30.8)
40 – 49 64 12.6 ± 8.7 21(32.8) Tailor 17 14.3 ± 8.5 6 (35.3)
50 – 59 52 11.9 ± 8.6 15(28.8) Other 64 12.9 ± 9.4 29(45.3)
60 – 69 39 13.6 ± 9.9 18(50.0) Unemployed 90 13.7 ± 9.1 35(38.9)
70 or more 34 16.3 ±11.2 17(50.0)   
Missing 3 24.3 ±16.5 2 (66.7) Illness knowledge 
   Insect bite 31 12.2 ± 9.9 11 (35.5)
Age of onset (yrs) Magic 33 11.6 ± 7.4 10 (30.3)
9 or less 15 13.7 ± 9.0 6 (40.0) Sprain 30 11.9 ± 7.4 10 (33.3)
10 – 19 92 11.2 ± 8.4 26(28.3) Chill 43 11.6 ± 9.0 14 (32.6)
20 – 29 58 15.3 ± 9.6 27(46.6) Other 41 10.5 ± 7.7 10 (24.4)
30 – 39 51 13.4 ± 8.9 19(37.3) Don’t know 177 14.6 ± 10.3 76 (42.9)
40 – 49 34 11.8 ±10.1 11(32.4)   
50 or more 29 14.3 ±11.0 12(41.4) Stage of right leg * 
Missing 37 14.9 ±10.8 17(45.9) Normal 43 15.2 ± 10.3 20 (46.5)
   Stage 1 106 12.4 ± 8.6 34 (32.1)
Daily income (gde) Stage 2 84 10.3 ± 9.2 22 (26.2)
25 or less 33 15.4 ± 7.3 16(48.5) Stage 3 52 14.7 ± 9.7 23 (44.2)
26 – 50 28 12.9 ± 8.5 8(28.6) Stage 4 plus 29 18.8 ± 9.3 18 (62.1)
51 – 100 29 12.9 ± 9.4 10(34.5) Missing 2 16.5 ± 3.5 1 (50.0)
101 – 200 25 11.4 ±10.8 9(36.0)   
201 – 400 29 13.0 ±11.6 9(31.0) Stage of left leg * 
401 or more 28 14.1 ±12.3 11(39.3) Normal 26 14.7 ± 11.2 14 (53.9)
Missing 144 13.0 ± 8.9 55(38.2) Stage 1 71 12.3 ± 7.6 20 (28.2)
   Stage 2 125 11.1 ± 8.7 38 (30.4)
Education (yrs) Stage 3 58 13.7 ± 10.3 20 (17.0)
2 or less 157 13.0 ± 8.9 58(36.9) Stage 4 plus 34 21.1 ± 9.7 26 (76.5)
3 – 4 33 11.9 ±10.7 11(33.3) Missing 2 11.5 ± 3.5  0 (0.0) 
5 – 6 40 14.1 ± 9.2 15(37.5)     
7 – 10 40 12.6 ±11.1 17(42.5)     
11 or more 37 13.6 ± 8.3 12(32.4)     
Missing 9 18.3 ±13.3 5 (55.6)     
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CDC Healthy Days 
 Table 25 and Figure 7 present the self-rated general health status as measured by 
the CDC Healthy Days questionnaire. Slightly more than half (52.8 %) of the respondents 
felt they maintained at least a good health status, and 88 % thought their condition was 
fair or above. There were no significant gender differences, but more people in La Plaine 
fell into excellent or fair health conditions than others (χ2=35.21, df=8, p<0.01). 
 Table 26 shows the number of unhealthy days reported for each health condition. 
The first four health categories derived from the core questions which asked general 
unhealthy days in the past 30 days (physically unhealthy days, mentally unhealthy days, 
activity limitation days, overall unhealthy days in past 30 days). The average physically 
and mentally unhealthy days recorded 5 to 6 days; in contrast, fewer activity limitation 
days were reported. Overall unhealthy days in past 30 days are the combination of both 
physically and mentally unhealthy days in the 30-day period. The average unhealthy days 
was 9.9 days. There were no significant gender differences or regional differences; 
however, females tended to experience more overall unhealthy days in general but p-
value of the statistical test slightly exceeded at α = 0.05 (T=1.81, df=299, p=0.07). 
Likewise, residents of La Plaine were likely to report more mentally unhealthy days 
(F=2.39, df=2, 306, p=0.09). The result of mentally unhealthy days was similar to the 
outcome of CES-D score. 
 Additional five health categories focus on more specific health conditions in the 
same manner (pain days, depression days, anxiety days, sleepless days, vitality days). 
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None of the unhealthy days among all respondents exceeded more than a week. There 
were no significant statistical differences by gender, but females were more likely to 
report more frequent days in pain (T=1.95, df=310, p=0.05). Also, no significant regional 
differences were observed, but the differences between Cabaret and La Plaine were more 
likely to be obvious in depression days and anxiety day (p-values ≤ 0.11). There were no 
significant differences in pain day by locality.  
 Table 27 illustrates the details of reported activity limitation. About half of 
respondents thought their activities were limited due to their health impairments. There 
were no significant differences for gender or region. The rest of the questions were 
answered only by them. Due to an error in data collection, the major health problem had 
multiple answers per respondent instead of a single response, which is required by the 
CDC’s guidelines. Therefore, the rest of questionnaire can be regarded as a general 
activity limitation instead of a single health problem. Slightly over three-fourths (75.5 %) 
of respondents reported a problem with arthritis, and over one-half (52.8 %) reported 
having lymphedema. The other problems mainly included headache and stomachache, 
but the arthritis and lymphedema were more common health problems. There were 
significant impairment differences across gender (χ2=9.12, df=3, p=0.03) and towns 
(χ2=13.90, df=6, p=0.03). Particularly, males voiced more complaints about lymphedema 
but less about other problems such as walking or high blood pressure. 
 Additional activity limitation indicators are shown in Table 27. The average 
length of activity limitation due to a major cause of impairment or health problem was 
5.8 years. The length ranged from a minimum of one week up to 48 years. About 45 % of 
those who had activity limitations had difficulty in their routine care, but the personal 
care limitation was less serious. In any case, neither gender nor regional differences were 
found.  
 
Table 25. Gender, Town vs. Self-rated Health Status by CDC Healthy Days (n (% N), *: 
1 missing, **: difference among towns (p<0.05)). 
Gender Town * **  Total 
(N = 316) Male  
(N = 61) 
Female  
(N=255) 
Arcahaie 
(N=120) 
Cabaret 
 (N=72) 
La Plaine 
(N=123) 
Excellent     9 (2.9)   1 (1.6)   8 (3.2)   0 (0)   0 (0)   9 (7.3) 
Very good   38 (12.1) 10 (16.4) 28 (11.0) 14 (11.8)   4 (5.6) 20 (16.3) 
Good 119 (37.8) 27 (44.3) 92 (36.2) 55 (46.2) 35 (48.6) 29 (23.6) 
Fair 111 (35.2) 16 (26.2) 95 (37.4) 37 (31.1) 21 (29.2) 53 (43.1) 
Poor   36 (11.4)   7 (11.5) 29 (11.4) 11 (9.2) 12 (16.7) 12 (9.8) 
Do not 
know 
    2 (0.6)   0 (0)   2 (0.8)   2 (1.7)   0 (0)   0 (0) 
 
Figure 7. Gender, Town vs. Self-rated Health Status by CDC Healthy Days. 
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Table 26. Gender, Town vs. Healthy and Unhealthy Days (mean ± SD, all ranges are 0 - 30). 
 Gender Town   Total
 Male  Female  Arcahaie  Cabaret  La Plaine  
Physically unhealthy days 5.5 ± 7.1 4.7 ± 7.1 5.7 ± 7.1 5.4 ± 8.0 6.5 ± 7.3 5.0 ± 5.9 
Mentally unhealthy days 5.3 ± 7.4 4.1 ± 7.9 5.6 ± 7.3 4.4 ± 6.9 4.8 ± 6.9 6.4 ± 7.8 
Activity limitation days 3.8 ± 5.6 3.0 ± 5.5 4.0 ± 5.6 3.4 ± 5.8 4.5 ± 6.7 3.8 ± 4.8 
Unhealthy days in past 30 days 9.9 ± 9.9 7.8 ± 10.1 10.4 ± 9.8 8.5 ± 10.0 10.7 ± 10.2 10.5 ± 9.5 
Pain days 5.0 ± 6.5 3.6 ± 6.1 5.4 ± 6.6 4.8 ± 6.7 5.9 ± 7.5 4.8 ± 5.8 
Depression days 5.0 ± 7.0 3.8 ± 6.5 5.3 ± 7.1 5.1 ± 7.1 3.7 ± 5.9 5.9 ± 7.4 
Anxiety days 4.8 ± 6.8 3.5 ± 5.7 5.1 ± 7.0 4.4 ± 6.2 3.8 ± 5.5 5.8 ± 8.9 
Sleepless days 4.7 ± 6.7 4.5 ± 7.2 4.8 ± 6.6 4.4 ± 6.6 3.9 ± 6.5 5.5 ± 6.9 
Vitality days 6.3 ± 8.5 5.4 ± 8.2 6.5 ± 8.5 5.1 ± 7.7 7.0 ± 9.8 6.9 ± 8.0 
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Table 27. Gender, Town vs. Major Cause of Impairment or Health Problem (#: 1 missing, *: different between gender (p<0.05), **: 
different among towns (p<0.05)). 
Gender  Town #  Total 
(N=316) Male  
(N=61) 
Female  
(N=255) 
Arcahaie  
(N=120) 
Cabaret 
 (N=72) 
La Plaine 
(N=123) 
Activity limitation (n (% N)) ** 163 (51.6) 28 (45.9) 135 (52.9) 56 (46.7) 40 (55.6) 66 (53.7) 
Arthritis 122 (74.8) 19 (67.9) 103 (76.3) 38 (67.9) 31 (77.5) 53 (80.3) 
Back or neck problem   23 (14.1)   3 (10.7)   20 (14.8) 12 (21.4)   2 (5.0)   8 (12.1) 
Fractures, bone/joint injury   21 (12.9)   2 (7.1)   19 (14.1) 10 (17.9)   2 (5.0)   8 (12.1) 
Problem walking   25 (15.3)   1 (3.6)   24 (17.8) 10 (17.9)   2 (5.0) 13 (19.7) 
High blood pressure   23 (14.1)   1 (3.6)   22 (16.3)   6 (10.7)   3 (7.5) 14 (21.2) 
Depression/anxiety/emotional problem   20 (12.3)   3 (10.7)   17 (12.6)   6 (10.7)   6 (15.0)   8 (12.1) 
Lymphedema   84 (51.5) 20 (71.4)   60 (44.4) 37 (66.1) 25 (62.5) 21 (31.8) 
Health 
problem 
(n (% per 
activity 
limitation)
) * ** 
Other problem 121 (74.2) 21 (75.0) 100 (74.1) 45 (80.4) 26 (65.0) 49 (74.2) 
Length of activity limitation due to health problems 
(mean year ± SD (Range: days - years)) 
  5.8 ± 9.0 
(7 – 48) 
7.4 ± 11.2 
(10 – 45) 
5.5 ± 8.5 
(7 – 48) 
5.8 ± 8.6 
(7 – 35) 
7.5 ± 12.9 
(14 – 48) 
4.7 ± 5.9 
(7 – 27) 
Personal care for activity limitation 
(n (% per activity limitation)) 
  39 (23.9)   9 (33.3)   30 (22.4) 13 (24.1) 12 (30.0) 14 (21.2) 
Routine care for activity limitation 
(n (% per activity limitation)) 
  73 (44.8) 12 (42.9)   61 (45.5) 22 (39.3) 16 (40.0) 35 (53.9) 
 
 101
 102
 The next three tables (Table 28 – Table 30) describe the association of the CDC 
Healthy Days measures with other socio-demographic variables. Table 28 reports self-
rated health status and core unhealthy days. The self-rated health status indicates the 
number of people who described their health condition as good or above. The self-rated 
health condition was strongly associated with age (χ2=31.88, df=6, p<0.01), educational 
level (χ2=22.87, df=4, p<0.01), and income level (χ2=11.85, df=5, p=0.04). People’s 
health condition was more likely to be poor as they got older. Also, those completing 
higher levels of education seemed to be healthier, as did people with higher income 
levels. Stage of leg was also associated with general health status (p-values < 0.01). 
Though no systematic pattern was observed by age of onset, those with higher stages of 
illness tended to report lower general health status. Age of onset, occupation, and 
knowledge of the illness were not significantly associated with self-rated health. The 
details of the self-rated health status are summarized graphically in Figure 8. The 
relationships between unhealthy days and the variables of interest were dependent on the 
variables. Physically unhealthy days were significantly associated with age of onset 
solely (F=3.13, df=5, 263, p=0.01). Activity limitation days were associated with 
education (F=2.56, df=4, 298, p=0.04). On the other hand, mentally unhealthy days 
varied by age group (F=2.61, df=6, 300, p=0.02) and stage of left leg (F=2.41, df=4, 303, 
p=0.05), and overall unhealthy days were significantly different within age groups 
(F=2.99, df=6, 292, p=0.01), age of onset (F=2.52, df=5, 259, p=0.03), and educational 
level only (F=2.72, df=4, 287, p=0.03). 
 Table 29 reports the results from five specific statements (pain, depression, 
anxiety, sleeplessness, vitality) and demographic variables. Compared with four 
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unhealthy day indicators, the socio-demographic variables seem to be less important. 
Significant differences were found only in anxiety days for the stage of left leg (F=4.43, 
df=4, 154, p<0.01).  
 Table 30 corresponds to activity limitation indicators in Table 24. Because of the 
small number of responses for health problems in Table 24, only arthritis, lymphedema, 
and other problem were left in the category. The rest of the health problems were 
summarized as “other2”. Generally, the health problems were less likely to be an 
important influence on activity limitation. Only the number of respondents who indicated 
any activity limitation was significantly different for age group, age of onset, educational 
level, occupation, and stage of right leg (all p-values < 0.05). Length of activity 
limitation, personal care, and routine care were not significantly different among the 
variables, except for personal care vs. education level and stage of left leg (p-values < 
0.05). Similarly, the type of health problem was not significantly different within the 
socio-demographic variables. In general, perhaps due to the purpose of this research, 
arthritis and lymphedema were amongst the major problems reported among patients. 
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Table 28. Other Socio-demographic Variables vs. Self-rated Health Condition (n (% N)) 
and Unhealthy Days (mean ± SD) (*1: different among agegroup, *2: different 
among age of onset, *3: different among daily income, *4: different among 
educational level, *5: different among right leg, *6: different among left leg (all 
p<0.05)). 
Unhealthy days  N Health 
condition 
*1 *2 *3 
*4  
Physical 
*2 
Mental *1 Activities 
*4 
Overall *1 
*2 *4 
Age group (yrs)       
19 or less 32 28 (87.5) 3.5 ± 6.3 1.9 ± 5.1 1.3 ± 3.2 4.8 ± 8.3 
20 – 29 42 27 (64.3) 6.0 ± 8.2 4.5 ± 7.3 4.0 ± 6.0 8.6 ± 9.8 
30 – 39 49 27 (55.1) 5.9 ± 6.7 5.7 ± 7.3 4.0 ± 5.1 10.7 ± 9.9 
40 - 49 64 28 (43.8) 5.7 ± 7.4 5.8 ± 7.0 4.3 ± 6.3 10.7 ± 10.0
50 - 59 52 27 (54.0) 4.1 ± 4.7 5.1 ± 7.0 3.3 ± 5.4 9.3 ± 9.4 
60 – 69 39 19 (48.7) 4.9 ± 6.3 5.0 ± 7.2 3.9 ± 4.8 9.4 ± 9.6 
70 or more 34 8 (23.5) 8.6 ± 9.1 9.0 ± 10.1 5.7 ± 7.0 14.7 ± 11.0
Missing/refused 3 1 (33.3) 5.3 ± 3.9 4.3 ± 4.0 2.7 ± 2.5 11.8 ± 1.8 
Age of onset 
(yrs) 
      
9 or less 15 11 (73.3) 1.8 ± 2.7 3.3 ± 8.1 1.1 ± 2.1 3.1 ± 5.3 
10 – 19 91 53 (58.2) 4.9 ± 6.6 4.4 ± 6.8 3.3 ± 5.4 8.4 ± 9.7 
20 – 29 58 30 (51.7) 6.5 ± 8.0 5.6 ± 7.8 4.6 ± 5.9 10.6 ± 10.0
30 – 39 51 30 (61.2) 3.8 ± 4.7 6.1 ± 8.9 3.0 ± 4.8 9.3 ± 9.6 
40 – 49 34 18 (52.9) 5.6 ± 7.3 4.6 ± 4.6 5.0 ± 7.1 9.7 ± 9.8 
50 or more 29 14 (48.3) 9.0 ± 9.3 6.9 ± 8.0 4.4 ± 4.6 13.7 ± 10.7
Missing/refused 37 10 (27.0) 6.2 ± 6.9 6.6 ± 7.7 4.5 ± 6.5 12.7 ± 10.2
Daily income 
(gde) 
     
25 or less 33 13 (39.4) 6.6 ± 7.4 6.7 ± 7.5 5.4 ± 5.9 11.3 ± 9.8 
26 – 50 28 8 (28.6) 4.2 ± 4.7 8.1 ± 11.3 2.9 ± 4.2 11.2 ± 11.9
51 – 100 29 15 (55.6) 4.4 ± 6.4 3.8 ± 3.7 3.5 ± 5.9 8.4 ± 9.3 
101 – 200 25 15 (60.0) 5.8 ± 5.3 5.0 ± 6.8 3.1 ± 3.9 10.5 ± 9.8 
201 – 400 29 18 (62.1) 6.4 ± 8.5 5.8 ± 8.3 5.1 ± 6.4 10.2 ± 10.5
401 or more 28 18 (64.3) 6.5 ± 8.5 5.9 ± 8.2 4.8 ± 6.8 11.1 ± 10.6
Missing/refused 143 79 (55.3) 5.3 ± 7.2 4.6 ± 6.7 3.4 ± 5.5 9.1 ± 9.5 
Education (yrs)      
2 or less 157 63 (40.7) 6.4 ± 7.5 6.2 ± 7.9 4.6 ± 6.3 11.5 ± 10.1
3 – 4 33 19 (57.6) 5.5 ± 6.6 5.8 ± 6.6 3.8 ± 4.1 10.7 ± 10.0
5 – 6 40 25 (62.5) 4.1 ± 6.2 4.7 ± 7.9 2.7 ± 4.7 7.2 ± 9.4 
7 – 10 40 28 (70.0) 4.1 ± 5.7 3.6 ± 5.7 2.2 ± 4.2 7.1 ± 9.3 
11 or more 36 27 (75.0) 5.7 ± 7.9 4.0 ± 6.4 2.6 ± 3.6 8.5 ± 9.4 
Missing/refused 9 4 (44.4) 2.3 ± 2.8 5.2 ± 9.8 7.2 ± 9.8  6.7 ± 10.1 
 
(Continued on the next page)
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Table 28 (Continued).  
Unhealthy days  N Health 
condition 
*5 *6 
Physical Mental *5 
*6 
Activities Overall *6 
Occupation       
Farmer 43 22 (51.2) 7.1 ± 8.6 5.8 ± 8.9 4.3 ± 6.1 11.3 ± 11.4 
Seller at home 65 29 (44.6) 5.7 ± 6.4 6.3 ± 7.9 3.9 ± 5.1 11.2 ± 10.1 
Seller at market 52 28 (53.9) 4.9 ± 5.6 4.3 ± 5.1 4.8 ± 6.3   9.0 ± 8.7 
tailor/seamstress 17 9 (52.9) 3.8 ± 4.8 5.9 ± 8.1 2.8 ± 4.2   9.1 ± 9.8 
Unemployed 90 43 (47.8) 6.4 ± 8.0 5.8 ± 7.4 4.2 ± 6.3 11.1 ± 10.1 
Other 63 43 (68.3) 4.1 ± 7.0 3.9 ± 6.9 2.2 ± 3.9   6.8 ± 9.1 
Illness 
knowledge 
      
Insect bite 31 21 (67.7) 8.6 ± 8.3  9.6 ± 10.8 4.5 ± 6.3 15.4 ± 12.4
Magic 31 16 (51.6) 9.2 ± 5.8 6.4 ± 8.4 6.8 ± 6.8 14.5 ± 10.0
Sprain 29 15 (51.7) 2.8 ± 3.2 4.7 ± 8.1 1.8 ± 2.3 7.2 ± 8.8 
Chill 43 21 (48.9) 8.4 ± 7.3 7.3 ± 8.8 4.7 ± 3.5 14.7 ± 9.2 
Other 41 25 (61.0) 9.8 ± 8.7 7.4 ± 7.8 7.5 ± 6.8 15.7 ± 11.2
Don’t know 177 90 (50.9) 7.7 ± 8.5 7.1 ± 8.1 5.9 ± 7.2 13.3 ± 10.4
Stage of right 
leg 
     
Normal 43 28 (65.1) 3.5 ± 3.3 4.6 ± 7.4 1.8 ± 2.3 7.8 ± 8.5 
Stage 1 106 61 (57.5) 6.1 ± 8.5 5.1 ± 7.4 4.2 ± 6.1   9.9 ± 10.5
Stage 2 83 53 (63.9) 5.2 ± 6.5 4.1 ± 5.2 4.2 ± 6.2 9.2 ± 9.5 
Stage 3 52 16 (30.8) 7.0 ± 7.4 7.7 ± 9.0 3.2 ± 4.5 13.0 ± 10.6
Stage 4 or more 29 8 (27.6) 4.4 ± 6.1 5.6 ± 8.0 5.5 ± 6.7 8.0 ± 8.1 
Missing/NA 2 0 (0) 4.0 ± 5.7 19.0 ±15.6 1.0 ± 1.4  23.0 ± 9.9 
Stage of left leg      
Normal 26 15 (57.7)  9.0 ±10.4 8.0 ± 8.0 5.9 ± 6.1 14.5 ± 11.4
Stage 1 71 40 (56.4) 5.4 ± 6.8 5.0 ± 7.0 3.8 ± 5.2 9.7 ± 9.9 
Stage 2 124 77 (62.1) 5.7 ± 7.7 4.3 ± 6.9 4.0 ± 6.6   9.0 ± 10.2
Stage 3 58 25 (43.1) 4.4 ± 4.5 5.1 ± 7.2 2.9 ± 3.7 9.0 ± 8.3 
Stage 4 or more 34 9 (27.0) 4.6 ± 5.0 7.7 ± 8.6 3.4 ± 4.4 9.0 ± 8.3 
Missing/NA 2 0 (0) 4.0 ± 5.7 17.0 ±18.4 1.5 ± 2.1 21.0 ± 12.7
 
Figure 8. Other Socio-demographic Variables vs. Self-rated Health Status by CDC 
Healthy Days (good or above). 
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Figure 8 (Continued). 
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Figure 8 (Continued). 
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Table 29. Other Socio-demographic Variables vs. Unhealthy/healthy Days (mean ± SD) 
(*: different among left leg (p<0.05). 
 Pain days Depressio
n days  
Anxiety 
days 
Sleepless 
days 
Vitality 
days  
Age group (yrs)      
19 or less 2.4 ± 4.9 2.3 ± 5.9 1.8 ± 3.3 2.6 ± 5.0 3.1 ± 6.7 
20 – 29 5.7 ± 7.1 5.9 ± 8.1 5.7 ± 8.1 5.3 ± 7.3 7.1 ± 9.7 
30 – 39 5.7 ± 6.7 5.7 ± 8.5 5.2 ± 7.7 5.2 ± 7.4 6.2 ± 7.9 
40 - 49 5.5 ± 7.1 5.0 ± 6.5 4.9 ± 7.0 4.2 ± 6.6 6.7 ± 8.6 
50 - 59 4.5 ± 5.8 4.7 ± 5.6 5.1 ± 6.4 4.7 ± 6.8 4.4 ± 6.2 
60 – 69 4.2 ± 5.0 3.8 ± 4.8 4.0 ± 4.9 5.6 ± 6.8 7.9 ± 8.9 
70 or more 6.9 ± 7.8 8.0 ± 8.5 6.3 ± 7.6 5.8 ± 6.4 9.7 ± 10.3 
Missing/refused 3.2 ± 3.0 0.8 ± 1.4 5.0 ± 8.7 3.7 ± 3.5 0.3 ± 0.6 
Age of onset (yrs)      
9 or less 2.4 ± 3.4 5.1 ± 8.6 5.6 ± 8.7 5.9 ± 8.6 4.2 ± 6.0 
10 – 19 4.5 ± 6.1 4.2 ± 6.4 4.0 ± 6.5 4.5 ± 6.6 6.4 ± 9.1 
20 – 29 4.6 ± 6.4 4.8 ± 7.6 5.1 ± 6.9 4.9 ± 7.5 6.5 ± 8.9 
30 – 39 4.6 ± 6.0 4.8 ± 6.7 5.1 ± 7.7 4.0 ± 5.6 4.3 ± 5.8 
40 – 49 6.4 ± 7.9 5.5 ± 8.0 4.6 ± 6.4 4.9 ± 7.9 6.6 ± 9.2 
50 or more 5.7 ± 6.5 6.9 ± 6.9 5.9 ± 6.3 6.6 ± 7.1 9.0 ± 9.3 
Missing/refused 7.0 ± 7.8 5.9 ± 6.6 5.0 ± 6.2 4.0 ± 4.6 7.2 ± 8.4 
Daily income (gde)      
25 or less 5.2 ± 5.4 5.8 ± 8.0 5.3 ± 6.7 4.0 ± 6.3 9.1 ± 11.1 
26 – 50 5.9 ± 7.2 3.8 ± 4.7 5.4 ± 8.1 4.8 ± 6.4 5.6 ± 8.1 
51 – 100 4.3 ± 6.3 3.9 ± 4.7 3.8 ± 4.7 4.9 ± 7.0 5.6 ± 7.3 
101 – 200 5.9 ± 5.4 5.1 ± 5.1 4.4 ± 4.7 6.3 ± 6.2 5.9 ± 5.2 
201 – 400 6.7 ± 8.3 5.5 ± 8.1 6.3 ± 8.2 7.9 ± 10.1 6.0 ± 7.6 
401 or more 7.1 ± 8.6 4.7 ± 9.6 6.2 ± 8.5 5.4 ± 7.1 6.6 ± 8.5 
Missing/refused 4.1 ± 5.9 4.9 ± 7.1 4.3 ± 6.6 3.9 ± 5.8 6.0 ± 8.7 
Education (yrs)      
2 or less 5.6 ± 6.6 5.8 ± 7.1 5.0 ± 6.2 4.7 ± 6.6 7.5 ± 9.1 
3 – 4 4.7 ± 6.4 4.9 ± 7.5 5.7 ± 7.2 6.9 ± 9.0 6.3 ± 8.9 
5 – 6 4.6 ± 4.7 4.5 ± 6.3 4.7 ± 7.2 4.6 ± 6.6 4.7 ± 5.7 
7 – 10 3.4 ± 5.3 3.5 ± 6.1 4.7 ± 8.2 4.3 ± 7.2 4.8 ± 6.9 
11 or more 4.3 ± 6.2 4.6 ± 8.1 3.3 ± 7.1 3.2 ± 4.8 4.9 ± 9.5 
Missing/refused 8.2 ± 10.1 4.0 ± 5.8 4.2 ± 5.2 5.7 ± 3.2 5.8 ± 6.1 
Occupation      
Farmer 4.9 ± 7.0 4.6 ± 8.0 3.6 ± 5.8 4.1 ± 7.1 4.8 ± 8.1 
Seller at home 5.9 ± 5.9 5.4 ± 6.4 5.4 ± 6.7 5.3 ± 7.0 7.1 ± 7.8 
Seller at market 6.2 ± 6.9 4.9 ± 5.2 5.1 ± 5.4 5.5 ± 7.5 5.7 ± 7.5 
Tailor/seamstress 2.9 ± 3.5 3.8 ± 6.1 5.5 ± 8.3 5.4 ± 7.6 6.0 ± 7.5 
Unemployed 4.9 ± 6.5 6.4 ± 8.0 5.4 ± 7.6 4.7 ± 6.5 8.3 ± 10.1 
Other 3.7 ± 6.7 3.9 ± 6.9 3.6 ± 7.0 4.1 ± 5.9 4.5 ± 7.7 
(Continued on the next page)
 110
 
Table 29 (Continued). 
 Pain days Depression 
days 
Anxiety 
days *  
Sleepless 
days 
Vitality 
days  
Illness 
knowledge 
     
Insect bite 6.8 ± 7.3 9.1 ± 9.9 9.4 ± 9.8 7.4 ± 9.3 7.4 ± 8.5 
Magic 6.7 ± 6.7 8.8 ± 8.8 5.5 ± 6.1 6.8 ± 9.3 12.7 ± 11.5 
Sprain 3.4 ± 3.1 2.4 ± 2.6 4.6 ± 7.9 1.8 ± 2.7 4.1 ± 4.4 
Chill 6.9 ± 6.5 8.2 ± 9.1 5.3 ± 6.7 5.9 ± 6.7  10.9 ± 9.5 
Other 9.7 ± 8.9 7.2 ± 8.3 7.1 ± 8.3 7.7 ± 8.8 10.2 ± 10.1 
Don’t know 6.7 ± 7.1 6.6 ± 8.1 5.9 ± 7.7 5.9 ± 7.5   9.0 ± 10.0 
Stage of right leg      
Normal 3.5 ± 4.1 4.3 ± 6.3 3.4 ± 4.0 4.0 ± 4.5 5.2 ± 7.4 
Stage 1 5.0 ± 6.6 4.4 ± 7.1 3.8 ± 6.2 4.1 ± 7.2 6.0 ± 8.9 
Stage 2 5.4 ± 7.0 5.1 ± 6.2 4.5 ± 5.9 5.0 ± 6.2 5.4 ± 7.0 
Stage 3 6.1 ± 7.9 5.8 ± 7.6 7.1 ± 9.4 6.3 ± 7.9 8.7 ± 9.9 
Stage 4 or more 4.6 ± 4.9 6.2 ± 7.8 6.8 ± 9.4 5.2 ± 6.9 6.3 ± 8.1 
Missing/NA 4.5 ± 4.9 16.0 ± 19.8 12.5 ± 13.4 1.0 ± 1.4 22.5 ± 10.6 
Stage of left leg      
Normal 6.1 ± 8.3 7.5 ± 8.0 8.8 ± 9.1 7.0 ± 7.9 8.5 ± 9.8 
Stage 1 4.6 ± 5.0 5.0 ± 7.5 3.1 ± 3.7 2.9 ± 5.5   6.8 ± 10.3 
Stage 2 5.2 ± 7.2 4.3 ± 6.4 4.3 ± 6.7 4.8 ± 6.6 5.6 ± 7.5 
Stage 3 4.3 ± 4.4 4.6 ± 5.6 4.6 ± 6.2 5.9 ± 7.3 5.6 ± 7.4 
Stage 4 or more 6.0 ± 4.4 6.2 ± 8.3 6.7 ± 9.1 5.0 ± 7.0 6.5 ± 7.4 
Missing/NA 3.0 ± 2.8 16.0 ± 19.8 12.0 ± 14.1 1.0 ± 1.4 19.0 ± 15.6 
 
 
Table 30. Other Socio-demographic Variables vs. Major Cause of Impairment or Health Problem (Other problem and other2 indicate 
the sum of the health problems so that the proportion of AL may exceed 1, *: different in activity limitation (p<0.05), **: 
different in personal care (p<0.05)). 
Health problem (n (% per Activity limitation (AL)))  Activity 
limitation 
(n (%total)) 
Arthritis 
 
Lymphedema 
 
Other 
problem 
Other2 
Year of 
activity 
limitation 
(mean ± SD) 
Personal 
care 
(n (% AL)) 
Routine  
care 
(n (% AL)) 
Age group (yrs) *        
19 or less 8 (24.2) 6 (75.0)    2 (25.0)   6 (75.0) 7 (87.5) 1.5 ± 1.0 1 (12.5) 3 (37.5)
20 – 29 20 (47.6) 14 (70.0)    9 (45.0) 13 (65.0) 9 (45.0) 2.9 ± 3.9 2 (10.0) 5 (25.0)
30 – 39 22 (44.9) 19 (86.4)    6 (27.3) 11 (50.0) 8 (36.4) 3.7 ± 5.1 4 (13.6) 8 (36.4)
40 – 49 32 (50.0) 18 (56.3) 17 (53.1) 30 (93.8) 17 (53.1)   8.2 ± 11.0 10 (31.3) 13 (40.6)
50 – 59 28 (53.8) 22 (78.6) 19 (67.9) 16 (57.1) 27 (96.4) 7.8 ± 9.5 8 (28.6) 12 (42.9)
60 – 69 24 (61.5) 20 (83.3) 14 (58.3) 14 (58.3) 17 (70.8)   8.3 ± 13.4 7 (29.2) 12 (50.0)
70 or more 28 (82.4) 23 (82.1) 16 (57.1)   31 (110.7) 27 (96.4) 4.2 ± 5.9 8 (28.6) 20 (71.4)
Missing/refused 1 (33.3)    0 (0)     1 (100.0)     0 (0) 0 (0) 1.0 ± 0.0   0 (0)    0 (0) 
Age of onset (yrs) *      
9 or less 3 (20.0) 3 (100.0)   1 (33.3)   2 (66.7) 1 (33.3) 6.7 ± 7.0    0 (0)    0 (0) 
10 – 19 39 (42.4) 25 (64.1) 23 (59.0) 29 (74.4) 23 (59.0)   8.6 ± 12.9 9 (23.1) 16 (41.0)
20 – 29 32 (55.2) 25 (78.1) 18 (56.3) 23 (71.9) 28 (87.5)   7.0 ± 10.1 8 (25.0) 16 (50.0)
30 – 39 20 (39.2) 14 (70.0) 10 (50.0) 15 (75.0) 9 (45.0) 6.6 ± 7.6 5 (25.0) 8 (40.0)
40 – 49 22 (64.7) 16 (72.7)   6 (27.3) 16 (72.7) 18 (81.8) 2.6 ± 3.1 5 (22.7) 10 (45.5)
50 or more 21 (72.4) 19 (90.5) 10 (47.6) 18 (85.7) 15 (71.4) 4.1 ± 5.4 3 (14.3) 9 (42.9)
Missing/refused 26 (70.3) 20 (76.9) 16 (61.5) 18 (69.2) 18 (69.2) 3.4 ± 5.7 9 (34.6) 14 (53.9)
 
(Continued on the next page) 
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Table 30 (Continued).  
Health problem (n (% per Activity limitation (AL)))  Activity 
limitation 
(n (% 
total)) 
Arthritis Lymphedema Other 
problem 
Other2 
Year of 
activity 
limitation 
(mean ± 
SD) 
Personal 
care 
(n (% AL)) 
Routine 
care 
(n (% AL)) 
Education (yrs) * **        
2 or less 99 (63.1) 72 (72.7) 57 (57.6) 79 (79.8) 73 (73.7)   6.5 ± 10.1 33 (33.3) 50 (50.5)
3 – 4 17 (51.5) 14 (82.4) 10 (58.9)   8 (47.1) 14 (82.4)   7.1 ± 10.2 3 (17.7) 9 (52.9)
5 – 6 18 (45.0) 11 (61.1)   8 (44.4) 18 (100.0) 10 (55.6) 5.2 ± 7.6      1 (5.6) 3 (16.7)
7 – 10 12 (30.0) 11 (91.7)   3 (25.0)   6 (50.0)   6 (50.0) 1.8 ± 2.0 2 (16.7) 5 (45.5)
11 or more 13 (35.1) 11 (84.6)   6 (46.2) 10 (76.9) 10 (76.9) 3.9 ± 3.0   0 (0) 4 (30.8)
Missing/refused 4 (44.4)    4 (100.0)       0 (0)   0 (0)   1 (25.0) 6.5 ± 5.9   0 (0) 2 (50.0)
Occupation *       
Farmer 20 (45.5) 13 (65.0) 12 (60.0) 15 (75.0) 11 (55.0)   7.0 ± 11.3 6 (30.0) 7 (35.0)
Seller at home 42 (63.6) 34 (81.0) 23 (54.8) 30 (71.4) 32 (76.2) 6.1 ± 8.6 10 (24.4) 18 (42.9)
Seller at market 26 (50.0) 19 (73.1) 15 (57.7) 12 (46.2) 16 (61.5) 6.2 ± 8.0 4 (15.4) 12 (46.2)
Tailor/seamstress 6 (35.3)    6 (100.0)   3 (50.0)   5 (83.3)   4 (66.7) 5.0 ± 5.3 1 (16.7) 1 (16.7)
Unemployed 62 (68.9) 43 (69.4) 30 (48.4) 59 (95.2) 55 (88.7) 5.6 ± 9.0 14 (22.6) 32 (51.6)
Other 18 (28.1) 16 (88.9)   7 (38.9)   8 (44.4)   5 (27.8) 4.1 ± 8.3 5 (27.8) 8 (44.4)
Illness knowledge      
Insect bite 17 (54.8) 12 (70.6)   8 (47.1) 15 (88.2) 15 (88.2) 5.6 ± 6.9 5 (29.4) 10 (58.8)
Magic 13 (39.4)   9 (69.2)   9 (69.2) 12 (92.3) 15 (115.4) 4.5 ± 5.6 3 (23.1) 6 (46.2)
Sprain 13 (48.2)   9 (69.2)   8 (61.5) 18 (138.5) 11 (84.6)    10.1 ± 9.7 3 (23.1) 3 (23.1)
Chill 27 (62.8) 21 (77.8) 19 (70.4) 17 (63.0) 11 (40.7)   4.9 ± 10.9 7 (25.9) 14 (51.9)
Other 21 (51.2) 19 (90.5) 14 (66.7) 16 (76.2) 17 (81.0) 4.3 ± 9.9 8 (38.1) 10 (47.6)
Don’t know 94 (53.1) 69 (73.4) 40 (42.6) 69 (73.4) 68 (72.3) 5.5 ± 8.4 18 (19.1) 39 (41.5)
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Table 30 (Continued).  
Health problem (n (% per Activity limitation (AL)))  Activity 
limitation 
(n (% 
total))  
Arthritis Lymphedema Other 
problem 
Other2 
Year of 
activity 
limitation 
(mean ± 
SD) 
Personal 
care 
(n (% AL)) 
Routine 
care 
(n (% AL)) 
Daily income (gde)      
25 or less 17 (51.5)   9 (52.9)   8 (47.1) 17 (100.0) 10 (58.9) 5.2 ± 7.9 1 (5.9)  4 (23.5) 
26 – 50 15 (53.6) 12 (80.0) 12 (80.0)   9 (60.0) 11 (73.3) 10.8 ± 13.0  5 (33.3)  5 (33.3) 
51 – 100 11 (37.9) 11 (100.0)   8 (72.7) 11 (100.0) 16 (145.5) 4.4 ± 4.9  2 (18.2)  5 (45.5) 
101 – 200 15 (60.0) 13 (86.7)   6 (40.0)   1 (6.7) 4 (26.7)   5.5 ± 11.4  5 (33.3)  8 (53.3) 
201 – 400 15 (51.7) 12 (80.0)   6 (40.0) 12 (80.0) 2 (13.3) 2.4 ± 5.4  3 (20.0)  7 (46.7) 
401 or more 11 (39.3) 10 (90.1)   6 (54.5)   9 (81.8) 6 (54.5) 2.8 ± 5.4  3 (27.3)  6 (54.5) 
Missing/refused 79 (54.9) 55 (69.6) 38 (48.1) 62 (78.5) 63 (79.7) 6.3 ± 8.9 20 (25.3) 38 (48.1) 
Stage of right leg *        
Normal 12 (27.9)   9 (75.0) 4 (33.3)   6 (50.0)   5 (41.7) 2.9 ± 4.2   2 (16.7)  6 (50.0) 
Stage 1 56 (52.8) 39 (69.6) 27 (48.2) 46 (82.1) 43 (76.8) 4.5 ± 7.8 11 (20.4) 17 (30.4) 
Stage 2 46 (54.8) 34 (73.9) 26 (56.5) 28 (60.9) 24 (52.2) 6.4 ± 9.9 14 (30.4) 24 (52.2) 
Stage 3 30 (57.7) 23 (76.7) 18 (60.0) 27 (90.0) 23 (76.7) 5.9 ± 7.2   5 (16.7) 16 (53.3) 
Stage 4 or more 17 (58.6) 16 (94.1)  9 (52.9)   8 (47.1) 12 (70.6) 10.6 ± 14.2   6 (37.5)  9 (56.3) 
Missing/NA    2 (100.0) 1 (50.0)       0 (0)   6 (300.0)   5 (250.0) 6.5 ± 4.9   1 (50.0)  1 (50.0) 
Stage of left leg **        
Normal 12 (46.2)   8 (66.7)  3 (25.0) 13 (108.3) 11 (91.7) 4.5 ± 5.8      0 (0)  5 (41.7) 
Stage 1 35 (49.3) 26 (74.3) 13 (37.1) 31 (88.6) 17 (48.6) 5.8 ± 9.9   4 (11.8) 12 (34.3) 
Stage 2 63 (50.4) 48 (76.2) 38 (60.3) 46 (73.0) 45 (71.4) 5.7 ± 9.5 21 (34.4) 27 (42.9) 
Stage 3 32 (55.2) 25 (78.1) 21 (65.6) 16 (50.0) 21 (65.6) 6.8 ± 9.7   6 (18.8) 19 (59.4) 
Stage 4 or more 19 (55.9) 15 (78.9)  8 (42.1) 11 (57.9) 17 (89.5) 5.7 ± 6.7   6 (31.6)  8 (44.5) 
Missing/NA    2 (100.0)   0 (0)  1 (50.0)   4 (200.0)   1 (50.0) 3.5 ± 0.7     2 (100.0)    2 (100.0) 
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Reliability and Validity 
The last research question, reliability and validity of the standardized instruments, 
is an important issue for lymphedema management in the Haitian context. Table 31 
shows the results of internal consistency reliability for the QOL instruments (EuroQol, 
CDC Healthy Days) and a subjective well-being assessment tool (CES-D). Prior to the 
analysis, the scores of EQ-VAS were reversed because EQ-VAS had a negative direction 
in relation to the items in EQ-5D. Some questions in CDC Healthy Days were excluded 
due to the non-directional measurements (e.g., major cause of impairment or health 
problem). Also, all missing values and ambiguous responses were ignored prior to 
calculation. Overall, all measurements have at least acceptable inter-rater reliability 
(alpha > 0.70). 
Table 31. Internal Consistency Reliability in QOL Scales and CES-D. 
 N Cronbach coefficient alpha 
EuroQol  306 0.72 
CES-D 280 0.85 
CDC Healthy Days 281 0.87 
Core questions only 298 0.71 
 
 
 In order to examine the criterion-related validity, the results of three scales were 
compared by correlational analysis. Correlational analysis was also used for the analysis 
of convergent and discriminant validity. Table 32 shows the results of validity analyses. 
The rows consist of the appropriate CDC Healthy Days health topics, while the columns 
correspond to the EuroQol five-dimensioned health categories. The CES-D score was 
added in both rows and columns for convenience. For criterion-related validity, EuroQol 
 115
questionnaires were fairly associated with CDC Healthy Days. Particularly, five health 
dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) in 
EuroQol were strongly associated with CDC Healthy Days self-rated health condition (all 
p<0.01), and three core health questionnaires (physically unhealthy days, mentally 
unhealthy days, activity limitation days) in CDC Healthy Days were also significantly 
associated with EuroQol overall healthy status (all p<0.01). Likewise, EuroQol agreed 
with CDC Healthy Days in terms of physical health, activity limitation, and 
overall/general health status (all p<0.05), and disagreed with each other in the other 
discordant domains. These outcomes indicate satisfactory convergent and discriminant 
validity. However, the mental health indicators in EuroQol had non-significant, weak 
relationships with those of both CES-D and CDC Healthy Days, even though the other 
two forms had slightly less strong but statistically significant relationships.
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Table 32. Correlations between Representative Questions in QOL Instruments and CES-
D (*: p<0.05, **: p<0.01). 
 Mobility Self-
care 
Usual 
activitie
s 
Pain / 
discomf
ort 
Anxiety 
/ 
depressi
on 
Overall 
health 
CES-D 
CES_D 0.12 * 0.12 0.15 ** -0.08 0.01 - 0.15 
**  
- 
Self-rated 
health 
0.26 ** 0.25 ** 0.32 ** 0.28 ** 0.19 ** 0.57 ** 0.20 ** 
Physically 
unhealthy 
days 
0.10 -0.00 0.11 * 0.14 * 0.13 * 0.28 ** 0.08 
Mentally 
unhealthy 
days 
0.05 -0.01 0.13 * 0.05 0.07 0.21 ** 0.24 ** 
Activity 
limitation 
(AL) days 
0.10 0.07 0.14 * 0.13 * 0.18 ** 0.21 ** 0.10 
Any AL -0.30 ** -0.04 -0.35 ** -0.27 ** -0.16 **  - 0.41 
** 
-0.12 * 
Length of 
AL 
0.02 0.24 ** 0.15 -0.10 0.07 - 0.04 0.45 ** 
Personal 
care for AL 
-0.26 ** -0.31 ** -0.36 ** -0.26 ** -0.17 * - 0.02 0.09 
Routine 
care for AL 
-0.31 ** -0.16 * -0.29 ** -0.25 ** -0.10 - 0.05 0.01 
Pain days 0.06 0.03 0.03 0.12 * 0.14 * 0.26 ** 0.01 
Depression 
days 
0.15 ** 0.00 0.12 * 0.07 0.07 0.18 ** 0.21 ** 
Anxiety 
days 
0.17 ** 0.03 0.09 0.11 * 0.06 0.10 0.19 ** 
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Chapter Five 
Discussion and Conclusion 
Morbidity control of lymphatic filariasis is one of the most important public health 
issues in Haiti. In order to increase QOL among Haitian lymphedema patients due to LF as 
well as contribute to eradicate LF worldwide, it is critical to implement appropriate control 
strategies in endemic areas. This thesis aimed to observe the association among 
filariasis-related variables among lymphedema patients in three rural Haitian towns and 
assess QOL among affected persons by using established QOL instruments. Particularly, 
attention was given to gender differences in the impact of the disease on people’s daily 
lives. There were numerous significant findings in the results of data analysis. 
 
 
Regional Differences 
In general characteristics of lymphedema patients, there are significant differences 
among the three communities, Arcahaie, Cabaret, and La Plaine. Though lymphedema 
conditions in Arcahaie are very similar to those in Cabaret, people in La Plaine experienced 
more severe symptoms than in other areas. Although sample characteristics are slightly 
different among regions, the results confirm the finding by Dreyer et al. (1998) that the 
characteristics of filariasis vary by geographic region.  
Regional differences are more obvious for illness history. No consistent 
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symptomatic conditions were observed among towns. Although the interview relied on 
patients’ recall, there were significant differences among the three communities in the first 
impression of the illness and the first symptom noticed. This different illness history might 
influence perception and knowledge of the disease and future prevention, treatment, and 
control. In particular, since lymphedema treatment requires sustained intensive efforts, it is 
critical to understand the background and perception of the disease prior to introducing the 
prevention and treatment regimen at the local level. For example, people in La Plaine were 
more likely to utilize health services and routine health care practices. This is likely 
explained by the greater accessibility to the capital. Since there are many medical services 
available in Port-au-Prince and its suburbs in comparison with other cities, residents in La 
Plaine tend to talk to health professionals more often. Overall, they were more concerned 
about leg treatment and took care of their legs more frequently with confidence. 
Particularly, they reported washing legs, use of massage, and avoiding walking on bare feet 
more often than people in the other zones. Maintaining hygiene is one of the most critical 
practices for LF morbidity control. Therefore, considering these facts, the introduction of a 
morbidity control program in La Plaine would likely be received well. On the other hand, 
people in Arcahaie seem more conservative regarding leg treatments. More people prefer 
to visit a traditional healer and use herbal remedies. Their knowledge of the illness is more 
related to traditional cultural and spiritual dimensions. However, though knowledge of the 
illness is a fundamental key to the future prevention of the disease, the results reflect poor 
understanding of the disease nationwide (Coreil et al., 1998; Eberhard et al., 1996). 
Therefore, it would be effective to plan and implement morbidity control regimens on a 
regional basis.
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Gender Perspective 
The sample design was based on non-probability sampling, but the gender 
proportion was consistent with previous findings. In Haiti, women suffer from 
lymphedema 5 – 10 times more often than men (Lammie et al., 1993), and there were 4.2 
times more females than males in the sample so that the gender comparison in this thesis 
can be representative of the general lymphedema conditions in Haiti. However, overall 
gender differences were less pronounced than regional variation. Significant gender 
differences were found in aspects of acute attacks, but there was no statistically significant 
discordance in illness history or knowledge of the illness. Therefore, in terms of 
lymphedema, gender differences can be accorded comparatively low priority in these 
Haitian towns.  
 
 
Lymphedema Condition and Its Related Variables 
The lymphedema conditions among people in three Haitian communities are 
consistent with the previous findings in other countries. Dreyer et al. (2002) mention that 
many lymphedema cases fall within stage 3 or less, which indicates shallow skin folds or 
swollen legs. In three towns, nearly two-thirds of people were diagnosed as falling within 
the first two stages, and about 90 % were in the first three stages. More severe conditions 
were found among people in La Plaine. Because the area of La Plaine experiences frequent 
flooding, residents are more likely to be exposes to mosquito-favorable environments. 
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However, the differences across towns were not significant. These results are also similar 
to findings in another Haitian town, Leogane (Dahl, 2001). Therefore, the conditions of 
lymphedema in these towns appear to reflect a general lymphedema profile.  
Socio-demographic variables had a partial association with lymphedema 
conditions. In this analysis, age group was strongly associated with lymphedema 
characteristics. In both foot size and stage of the illness, lymphedema conditions worsened 
as people became older, with a peak around age 50. This supports the relationship between 
age and lymphedema conditions in numerous studies from other parts of the world 
(Gasarasi et al., 2000; Gyapong et al., 1996b; Hyma et al., 1989; King & Freedman, 2001; 
Shriram et al., 2002; Weerasooriya et al., 2001). In contrast, other variables of interest such 
as gender, SES (occupation, income, and education), knowledge of the illness, and history 
of acute attacks were poorly associated with lymphedema conditions. This is probably due 
to the type of study design, a cross-sectional study, which makes it difficult to establish a 
causal relationship due to the collection of data at a single point in time. In the LF literature, 
these variables may be the potential indicators of the lymphedema conditions more or less. 
Therefore, in order to find out the clear relationship, it would be necessary to conduct more 
thorough and prospective research in the future. 
 
 
Health-related Behavior 
Health-related behaviors are critical in establishing an effective preventive and 
control strategy for LF. In this thesis, health-related behaviors were assessed as seeking 
care for leg treatment, taking precautions with one’s legs, self-care practices for legs which 
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are currently done or can be done in the future, and confidence in leg care (self-efficacy). 
The proportion of people who indicated choosing herbal remedies for treatment and 
engaging in self-care practices is substantially high. Although no scientific benefit of 
herbal remedies is known for lymphedema, more than 40 % of people usually use them for 
their treatment and self-care practices. This suggests that traditional therapy for LF is still 
common and widespread in the study setting. However, Western medicine is reported as an 
alternative choice. Seeing health professionals and purchasing pharmaceutical medicine 
are practiced in the communities, although availability is still limited due to the small rural 
community far from the capital and the prohibitive cost of medicine. In addition, regional 
differences are evident. Traditional medicine is more widely practiced in Arcahaie, but 
Western medicine is more common in La Plaine, probably due to the higher accessibility to 
the metropolitan area. Also, the confidence of self-care practice for legs is significantly 
different among towns. More people in La Plaine are very confident in their leg care. 
Therefore, since the treatment and prevention strategy of lymphedema is generally based 
on the Western regimen, the regional characteristics of health-related behaviors would 
influence acceptability of future interventions.  
Socio-demographic variables rather than the regional perspective appear to be less 
important determinants of health-related behaviors. Gender, age group, age of onset, 
income, and occupation were not significantly associated with current or future self-care 
for legs or self-efficacy. Only educational level and knowledge of the illness were related 
to future possible self-care practice. However, knowledge of the illness was quite low so 
that it would be possible to promote self-care practices by improving illness knowledge. 
Reports from other countries indicate that poor LF knowledge significantly contributes to 
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high risk behaviors as well as exacerbates the disease (Ahorlu et al., 1999; Eberhard et al., 
1996; Gyapong et al., 1996a; Rauyajin et al., 1995). Therefore, assessment of the effect of 
health education about LF would be beneficial for future morbidity control strategies. 
 
 
Quality of Life and Subjective Well-being Scales 
Reliability and Validity 
The other noteworthy finding of the research is the successful introduction of the 
QOL instruments for evaluation of the impact of lymphedema on people’s lives. Since 
there has been little focused research to assess QOL in LF populations, two different QOL 
measurements (EuroQol and CDC Healthy Days) and the CES-D as a mental health 
indicator were used in Haitian lymphedema cases. Reliability of the instruments was 
established. Since the instruments are considered reliable when the internal consistency 
coefficient or Cronbach alpha falls at 0.70 or above, and all the instruments reached at least 
0.71 or more. This indicates that the scales are able to measure a consistent aspect of LF in 
Haiti.  
In contrast, it is usually more difficult to demonstrate the cross-cultural validity of 
instruments. In this thesis, criterion-related validity and construct validity were assessed. 
Criterion-related validity was acceptable but not really strong. The health domain in the 
EuroQol was correlated with similar outcomes in the CDC Healthy Days, except for 
mental health indicators. In particular, overall health status in the EuroQol was strongly 
associated with self-rated health status in the CDC Healthy Days scale. The other health 
domains also showed similar results in both questionnaires. However, mental health 
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indicators were poorly associated with QOL measures. Particularly, the EuroQol mental 
health domain (anxiety/depression) was problematic, probably due to the simplicity of the 
questionnaires. On the other hand, the CDC Healthy Days instrument has a few items 
regarding mental health, and the CES-D is entirely focused on mental health assessment. 
Scores for the two instruments were significantly correlated. Therefore, both the EuroQol 
and CDC Healthy Days would be acceptable for evaluating lymphedema conditions, but in 
terms of mental health, CDC Healthy Days would provide a more valid tool.  
On the other hand, construct validity established more reasonable evidence for 
validity of the instruments. Dahl (2001) reported that lymphedema patients in Haiti 
experienced limited physical activities due to acute attacks. Nearly 95 % of respondents 
had acute attacks in the previous year, and more than 50 % of them reported activity 
limitations especially due to arthritis and lymphedema in the CDC Healthy Days 
instrument. Bandyopadhyay (1996) and Coreil et al. (1998) indicate that women with 
abnormal physical features due to lymphedema experience mental and psychological stress. 
Although no gender differences were found in mental health indicators in any of the QOL 
instruments, respondents in La Plaine, where there are 6.8 times more females than males 
in the sample, showed significantly worse mental health scores in two of three instruments. 
Thus, construct validity is somewhat demonstrated.  
Related to construct validity, convergent and discriminant validity were also 
assessed. The results showed that the multiple health indicators in different domains could 
operate consistently at least at acceptable levels, except for the mental health indicators 
mentioned in criterion-related validity. Although the correlation coefficients among 
convergent domains are slightly lower that expected, most of the matched pairs indicated a 
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significant relationship between them. Likewise, most of discriminant pairs showed no 
significant relationship. Therefore, the QOL instruments are fairly applicable in assessing 
lymphedema patients in Haiti, but further investigation would be beneficial.  
 
 
Outcome of the Scales vs. Socio-demographic Variables 
The results of QOL instruments show significant relationships with 
socio-demographic variables. Like lymphedema conditions and health-related behaviors, 
regional differences are strongly associated with the results of QOL instruments. Though 
the significant relationship between towns and EuroQol mental health indicators is 
questionable due to poor validity of the instrument discussed above, the relationship in 
CES-D and CDC Healthy Days is significant. In the CES-D, those in La Plaine 
experienced significantly more severe mental health symptoms than the other areas, and a 
similar tendency was observed in the CDC Healthy Days scores. Particularly, the outcomes 
in CDC Healthy Days indicate apparent regional differences between La Plaine and the 
other towns for the other health domains. Also, both EuroQol and CDC’s general health 
condition indicators showed significant differences among these three towns.  
Other socio-demographic variables were also associated with QOL outcomes. The 
most significant relationship was found with age. As in general healthy populations, 
physical health conditions including activity limitations are strongly correlated with age. 
As the age of the patients increases, the scores for physical health conditions and activity 
limitations in EuroQol and CDC Healthy Days showed a negative relationship. Noteworthy, 
the tendency was most obvious in usual activities, pain/discomfort, and overall health 
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status in EuroQol, and overall health status and activity limitation in CDC Healthy Days. 
Some other mental health indicators are also associated with age group, but the results are 
inconsistent. Thus, age would be a potential indicator of health status among lymphedema 
patients. 
Additional variables such as age of onset, educational level, occupation, and 
knowledge and stage of the illness were also potential indicators of health status, but the 
results were variable. Though gender, income, and knowledge of the illness seem to be less 
important to evaluate health conditions among lymphedema patients, age of onset, 
educational level, and occupation were significantly associated with indicators of physical 
health and activity limitations. In age of onset, for example, those who had the first 
symptom in early life seem to have better health status and less activity limitation. 
Similarly, as people complete higher education, their health status and activity limitation 
appear to be better. Regarding occupation, unemployed people are more likely to have poor 
health status and more activity limitation. Though it is difficult to identify which type of 
occupation influences health status probably due to the imbalanced sample among job 
categories, tailor/seamstress seems to be healthier than others.  
Stage of the illness is another variable associated with QOL outcomes. In addition 
to the relationship with physical health and activity limitation, stage of the illness seems to 
be a good mental health indicator among lymphedema patients. In both CES-D and CDC 
Healthy Days, there were significant differences in scores across the stage levels. However, 
there is no tendency that people at higher stages of the illness have worse mental health 
conditions than those at lower. The results indicate that people with normal leg conditions 
had very poor mental health status, similar to stage 4 or more. This might imply that their 
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mental health is influenced by additional factors in their lives. Although the condition of 
lymphedema may be associated with mental health, there is poor control of possible 
confounders due to the characteristics of the study. Thus, further investigation would be 
valuable.  
Overall, the generic QOL instruments were useful in evaluating the health 
conditions among lymphedema patients. Without the analysis of QOL, it was found that 
only regional differences and age groups were significant determinants. However, by 
analyzing the results of QOL instruments, other socio-demographic variables appeared to 
be potential correlates of lymphedema patients’ health, especially physical health and 
activity limitation. Though no comparison with people who have normal health status was 
made, the results of the QOL instruments suggest it would be beneficial to look at such a 
comparison group. That additional information would help design effective prevention, 
treatment, and morbidity control strategies.  
 
 
Limitation 
There are several limitations on this research. The first one is the sampling method. 
Since non-probability sampling was chosen, there are possible biases in sample 
characteristics. The common one is selection bias. Since it was difficult to select a member 
of the study group probabilistically, the possibility of sample misrepresentation was unable 
to be excluded throughout the study. Particularly, in comparison with estimated total 
population in each community, the area of La Plaine might be overrepresentative in the 
sample. However, sample characteristics in this thesis were more likely to be very similar 
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to previous studies (eg. Eberhard et al., 1996; Lammie et al., 1993), even though several 
minor disparities such as gender ratio among three towns might have skewed the outcomes 
and their interpretation. Other limitations due to non-probability sampling are 
susceptibility to confounding and weak external validity. Due to the inability of 
randomization, it might be difficult to rule out potential explanations and generalize the 
results to and/or across communities. Therefore, since population characteristics were 
unavailable in these regions, further studies will need to support the findings in this study. 
Also, regarding the data collection, interviewer bias might be a critical factor. Since 
the data were collected by five trained interviewers in three different locations in a short 
period of time, there were some discrepancies in the dataset and deviation from the 
protocol of data collection. Particularly, the faulty administration of one of CDC Healthy 
Days questionnaires made it difficult to follow the guidelines of the analysis and made the 
outcomes less useful. Therefore, careful attention to the data collecting process is essential. 
The second limitation stems from the purpose of the dataset. The data came from an 
ongoing project called Evaluation of Support Groups in the Management of Lymphedema 
Caused by Lymphatic Filariasis. Although this thesis is aimed at the description of 
lymphedema conditions in new areas of Haiti, the dataset has already been designed as a 
baseline survey for evaluating a planned support group intervention. This is appropriate for 
the preparation and introduction of morbidity control in the study community, but some 
important variables might be excluded for the purpose of the description of general 
filariasis conditions. In order to obtain more universal information in the new areas, it 
would be necessary to conduct the primary data collection at the neutral position. 
The third limitation is the method of analysis. The purpose of the data analysis was 
 128
descriptive rather than analytical so that the socio-demographic variables were analyzed 
one by one. This thesis concluded that the gender difference seemed to be less important, 
but no gender variation within three different towns was examined. Also, other variables 
which had no association with lymphedema conditions might be potential confounders. 
Thus, more complex analyses such as multiple regression analysis would be required for 
deeper analysis. In this thesis, however, data collection was at a single point of time so it is 
difficult to determine the causal relationships between variables. Therefore, the results of 
this thesis can be viewed as a preliminary assessment of QOL among lymphedema patients 
in Haiti. 
 
 
Conclusion 
 Lymphedema conditions due to LF in three rural towns in Haiti are explained by 
several interesting variables. Regional variation was noteworthy. Generally, people in La 
Plaine reported more severe symptoms than those in other communities. This was 
indicated by foot examination and scores on the QOL instruments. Particularly, physical 
health status and activity limitation were significantly different among towns. Also, 
health-related behaviors varied across communities. Traditional medicine was more 
common in Arcahaie, and use of Western medicine was higher in La Plaine. These findings 
should help design a culturally competent morbidity control strategy at the local level. 
Likewise, age is an important aspect of public health interventions among lymphedema 
patients, especially in the treatment of legs. Other variables might be potential indicators 
for lymphedema control, but their effects seem to be limited. Thus, further investigation 
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would be valuable. 
 Lastly, the standardized QOL instruments are useful tools to evaluate health 
conditions among lymphedema patients. They showed the influence of the 
socio-demographic variables on the health conditions among patients, particularly on 
physical health condition and activity limitation. Mental health condition seems to be less 
important, but additional study would be helpful. The reliability and validity of the 
instruments in this population are acceptable. Though more careful attention to validity of 
the EuroQol mental health indicators is needed, general applications of the instruments for 
lymphedema patients are appropriate. Thus, the information obtained in this research will 
contribute to the development of morbidity control programs in these areas. 
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Appendix A: Lymphedema Stages (Dreyer et al., 2002). 
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 Appendix B: Filariasis Baseline Evaluation Survey – Arcahaie. 
 
Anket de Baz Pou Filaryoz – Akaye 
 
(Filariasis Baseline Evaluation Survey – Arcahaie) 
 
Dat anket la (Date of survey) _____________________________2003 
 
Nom ankete a (Name of interviewer) ____________________________________ 
 
Nom enfomate a (Name of respondent) __________________________________ 
 
Eske-w kann vizite Klinik Gwopye nan l’Hôpital Ste. Croix déjà?   Wi    Non   (si Wi, pa ranpli kesyonè a) 
 
Demografik  (Demographics) 
 
Lokalite (address)_________________________________________________________ 
 
Sex (Gender)      Fiy (Female) ________ Gason (Male) ______ 
 
Ki laj ou? (How old are you?)  _________ 
 
Eske ou marye/plase/ etc.?  (Are you married/co-habiting, etc.?) ___________ 
[1– marye  2– plase  3– viv avek  4– renmen  5– fyanse  6– selibate  7– separe ou divose  98– Lot, di kisa]   
 
[1- married  2- plase  3-live together  4- in relationship 5- engaged 6- single 7- separated or divorced  98- 
Other, explain] 
 
Kombyen pitit you gen kap viv kounye a  (How many living children do you have?) _________ 
 
Ki laj premye la genyen?  ____ ans     Ki laj denye la genyen?     ____ans 
(How old is the oldest child?)   (How old is the youngest child?) 
 
Kombyen petit ale lekol? _______    (How many of your children go/went to school?) 
 
Nan ki relijon ou mache (What is your religion?)  ______________ 
[1- katolik  2- protestan  3-  vodouyizan  4- pa gen relijon  98- lot, di kisa]   
[1- Catholic  2- Protestant  3- Voudouiste 4-  No religion  5-  Other, explain] 
 
Kisa ou ap fe pou viv/ki metye ou genyen? _________________ 
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 (What do you do for a living/what is your occupation?) 
 
[1- kiltivate  2- komesan nan lakay  3 - komesan nan marche   4 - Couture  5 - Lot travay  6 - Pa gen travay   
98- Lot, di kisa] 
[1- farmer  2-  seller at home 3 – seller at market  4 – tailor/ seamstress   5- Other work  4- Unemployed  
98- Other, explain] 
 
 
 
Normalman, kombyen jou ou travay nan seman?   _____ jou pa semane 
 
Kombyen kòb ou kabap fè? _____ Gdes  ο pa jou          ο pa semane        ο pa mwa 
 
Kombyen ane ou te fe nan lekol?  _______________  
[How many years of school did you complete?] 
 
Eske ou konn li ak ekri?  (Can you read and write?)  wi (Y)  _______ non (N) _______ 
 
Eske genyen nan kay la?  (Do you have the following in your house?) 
 
Radyo (radio) ________ Office/china/gade manje/armoire (Storage chest) ________ 
 
Salon (living room) ________ Bicyclette/motocyclette (Bicycle/motor cycle) ________ 
 
 
Istwa de maladi (Illness history)
 
Ki laj ou te genyen le ou te premye santi maladi ya? ________________ 
(What age were you when you first became aware of the illness?) 
 
Kisa ou ta panse ou te genyen? ________________ 
(What did you think you had?) 
 
1-Fredite  2- Ekzema  3-Glan  4- Poud maji  5- Piki insek  6-Ansent  7- Antoch  8- Yon 
maladi  9- Gwopye  10- Filariose  11- Pakonnen  12- Lot bagay, di kisa 
 
(1-Chill  2- Eczema  3- Gland  4- Magical powder  5- Insect bite  6- Pregnancy 7- 
Sprain  8- An illness  9- Big foot  10- Filariasis  11- Don’t know  12- Other, explain) 
 
Ki premye sintom ou te remake pou maladi sa a? 1- pye a anfle  2- doule  3- glann  4 
- fyev   
5 - tet fe mal     6 - pye a cho   7- Lot, di kisa  
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_________________________________________ 
 
 
(What was the first symptom you noticed?  1- foot swollen  2- pain   3- swollen gland   
4 - fever  5 - headache   
6 - foot hot   7- Other, explain) 
 
Kisa ou te fe pou jwenn soulajman?  Eksplike nou sa.  1- Kay ougan  2- Remed fey    
3-  pommade    4-  mete med fey  5- Tikwi/Sansi   6- Mete glacé   7- Medicaman 
famasi  8- Lot bagay, di kisa ________________________ 
 
(What did you do to treat the illness?  1- Traditional healer  2- Herbal remedy  3-  
Pommade  4-  Herbal leaves on leg   5- Cupping/leeches  6- put ice on leg  7-
Pharmaceutical medicine  8- Other, explain) 
 
Kijan de prekosyon ou pran ak pye ou? Di mwen tou sa ou fe pou li.  _______________ 
_______________________________________________________________________ 
(What precautions do you take with your foot?  Tell me everything you do for it.) 
 
Eske ou konn ki sa atak la-ye?  Eske ou kapab di’m, s’il vous plait. (Pa bezwen ekrit 
anyen)  
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Anné ki sot pase, konbyen atak ou te genyen?  ___________ 
(During the past year, how many acute attacks did you have?) 
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 Atak #1 Atak #2 Atak #3 
Nan ki mwa ou te 
genyen atak-sa? 
 
Mwa ____________ 
 
Mwa ____________ 
 
Mwa ____________ 
Konbyen jou atak-
sa te dire? 
 
______ Jou 
 
______ Jou 
 
______ Jou 
Eske gen kote ou te 
ale pou jwenn 
tretman? 
 
Di ki kote ou te ale.   
 
ο Klinik _________________ 
ο Kay Medsen Fey _________ 
ο Kay Ougan ____________ 
ο  Ajan de Sante ___________ 
ο Lot kote, di ki kote  
___________________ 
ο Okenn kote  
ο Klinik _________________ 
ο Kay Medsen Fey _________ 
ο Kay Ougan ____________ 
ο  Ajan de Sante ___________ 
ο Lot kote, di ki kote  
___________________ 
ο Okenn kote 
ο Klinik _________________ 
ο Kay Medsen Fey 
_________ 
ο Kay Ougan ____________
ο  Ajan de Sante 
___________ 
ο Lot kote, di ki kote  
___________________ 
ο Okenn kote 
Kombyen jou ou te 
tan avan ale la?  
Pou ki sa? 
 
____ Jou 
ο Mwen pa’t tan 
ο P’at gen kòb 
____ Jou 
ο Mwen pa’t tan 
ο P’at gen kòb 
____ Jou 
ο Mwen pa’t tan 
ο P’at gen kòb 
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Si ou pa’t ale okenn 
kote, pou ki sa? 
ο Malade – p’at kapab soti 
ο Pa renmen tretman 
ο Pa bezwen ale – mwen ka fè 
tretman lakay mwen 
ο Lot __________________ 
ο Malade – p’at kapab soti 
ο Pa renmen tretman 
ο Pa bezwen ale – mwen ka fè 
tretman lakay mwen 
ο Lot __________________ 
ο Malade – p’at kapab soti 
ο Pa renmen tretman 
ο Pa bezwen ale – mwen ka 
fè tretman lakay mwen 
ο Lot __________________ 
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Kombyen fwa ou te 
ale la pou meme 
atak? 
 
______ Fwa 
 
______ Fwa 
 
______ Fwa 
Eske moun’n konn 
ale ak ou? 
 
 
ο Non       ο Wi 
Si Wi, ki moun?
_____________ 
 Si Wi, ki moun? _____________ 
Kijan de travay li fe? 
______________________ 
ο Non       ο Wi 
Kijan de travay li fe? 
_________________________ 
ο Non       ο Wi 
Si Wi, ki moun? 
_____________ 
Kijan de travay li fe? 
_________________________
 Atak #1 Atak #2 Atak #3 
Kombyen tan wap 
pran pou kabap 
rive la? 
______ Minutes ______ Minutes ______ Minutes  
Eske ou te bezwen 
peye transportasyon 
pou ale la? 
ο Non       ο Wi 
Si wi, $ _____ Gdes chak moun 
ο Non       ο Wi 
Si wi, $ _____ Gdes chak moun 
ο Non       ο Wi 
Si wi, $ _____ Gdes chak 
moun 
Kijan de tretman ou 
te jwenn nan 
lokalite-sa? 
 
Di kombyen kòb ou 
te peye pou chak 
tretman ou te 
Ki medikaman?
_____________ 
ο Piki, $ ______ Gdes 
ο Medikaman, $ _____ Gdes 
 Ki medikaman? _____________ 
ο Piki, $ ______ Gdes 
ο Medikaman, $ _____ Gdes 
ο Piki, $ ______ Gdes 
ο Medikaman, $ _____ Gdes 
Ki medikaman? 
_____________ 
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jwenn. 
 
ο Med fey, $ _____ Gdes 
ο Tikwi/ Sansi,  $ _____ Gdes 
ο Pommade, $ _____ Gdes 
ο Mesaj, $ ______ Gdes 
ο Bandaj, $ ______ Gdes 
ο Tès, $ ______ Gdes 
Ki tès? ________________ 
ο  Lot, di ki sa 
______________ 
ο Med fey, $ _____ Gdes 
ο Tikwi/ Sansi,  $ _____ Gdes 
ο Pommade, $ _____ Gdes 
ο Mesaj, $ ______ Gdes 
ο Bandaj, $ ______ Gdes 
ο Tès, $ ______ Gdes 
Ki tès? ________________ 
ο  Lot, di ki sa _______________
ο Med fey, $ _____ Gdes 
ο Tikwi/ Sansi,  $ _____ 
Gdes 
ο Pommade, $ _____ Gdes 
ο Mesaj, $ ______ Gdes 
ο Bandaj, $ ______ Gdes 
ο Tès, $ ______ Gdes 
Ki tès? ________________ 
ο  Lot, di ki sa 
_______________ 
Kombyen tan ou te 
fè la pou jwenn 
tretman? 
 
______ Minutes 
 
______ Minutes 
 
______ Minutes 
Kombyen kòb ou te 
peye pou 
konsiltasyon? 
 
Eske se pou chak 
  
                           ο Chak fwa 
_______ Gdes    ο Total 
 
                    ο Chak fwa 
_______ Gdes    ο Total 
 
                    ο Chak fwa 
_______ Gdes    ο Total 
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vizit ou byen pou 
total? 
 Atak #1 Atak #2 Atak #3 
Ki sa ou te fè lakay 
ou pou atak sa? 
 
Si ou te bezwen 
achete bagay pou 
tretman sa lakay ou, 
di kombyen kòb ou 
te peye. 
ο Bwe medikaman 
Ki medikaman?
_____________ 
 Ki medikaman? _____________ 
Pou kombyen jou? ___ jou 
Kombyen kòb? $ ______ Gdes 
ο Mete med fey 
ο Mete pomade 
Kombyen kòb? $ ______ Gdes 
ο Lave pye ____ fwa chak jou 
ο Leve pye 
ο Mete konpres fre nan janm 
ο Priye 
ο Anyen 
ο Bwe medikaman 
Pou kombyen jou? ___ jou 
Kombyen kòb? $ ______ Gdes 
ο Mete med fey 
ο Mete pomade 
Kombyen kòb? $ ______ Gdes 
ο Lave pye ____ fwa chak jou 
ο Leve pye 
ο Mete konpres fre nan janm 
ο Priye 
ο Anyen 
ο Bwe medikaman 
Ki medikaman? 
_____________ 
Pou kombyen jou? ___ jou 
Kombyen kòb? $ ______ 
Gdes 
ο Mete med fey 
ο Mete pomade 
Kombyen kòb? $ ______ 
Gdes 
ο Lave pye ____ fwa chak 
jou 
ο Leve pye 
ο Mete konpres fre nan 
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ο Lot, di ki sa _____________ 
Kombyen kòb? $ ______ Gdes 
ο Lot, di ki sa _____________ 
Kombyen kòb? $ ______ Gdes 
janm 
ο Priye 
ο Anyen 
ο Lot, di ki sa 
_____________ 
Kombyen kòb? $ ______ 
Gdes 
Eske ou pa’t genyen 
moun’n ki te édé ou 
ak tretman pou 
atak-sa? 
 
 
 
 
 
ο Non       ο Wi 
Ki moun? _______________ 
Kijan de travay li fe? 
______________________ 
ο Non       ο Wi 
Ki moun? _______________ 
Kijan de travay li fe? 
______________________ 
ο Non       ο Wi 
Ki moun? _______________ 
Kijan de travay li fe? 
______________________ 
 Atak #1 Atak #2 Atak #3 
Eske ou te kapab 
travay pendan ou te 
genyen atak-sa? 
ο Non       ο Wi 
Si Non, pou kombyen jou ou 
pat ka travay? ______ jou 
ο Non       ο Wi 
Si Non, pou kombyen jou ou pat 
ka travay? ______ jou 
ο Non       ο Wi 
Si Non, pou kombyen jou ou 
pat ka travay? ______ jou 
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Eske anné ki sot pase-a, ou te acheté materiel paske ou gen gwo pye (pa pendan atak-yo)?  ο Non       ο Wi 
Si Wi, ki sa ou te acheté? ο Souliye/Sandal Kombyen kòb? $ ______ Gdes 
ο Pomade  Kombyen kòb? $ ______ Gdes  
ο Bandage       Kombyen kòb? $ ______ Gdes  
ο Ti ban        Kombyen kòb? $ ______ Gdes  
ο Kivet          Kombyen kòb? $ ______ Gdes  
ο Lot, di sa ____________  Kombyen kòb? $ ______ Gdes 
 
Eske semain ki sot pasé ou te: 
 Lavé rad?    ο Non       ο Wi       Si Wi, _______ fwa 
Alé nan maché?   ο Non       ο Wi       Si Wi, _______ fwa 
Alé van’n?    ο Non       ο Wi       Si Wi, _______ fwa 
Alé leglise?    ο Non       ο Wi       Si Wi, _______ fwa 
Alé fonksyone lekol pou pitit-w? ο Non       ο Wi       Si Wi, _______ fwa 
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Examen de pye a  (Foot exam)
 
 
Mesi jam malad la (Leg measurements) 
       Pye dwat ( R)  Pye goch (L) 
1- Do pye (foot) (10 cm from toe)  __________  __________ 
2- Chevill (ankle) (10 cm from floor)  __________  __________ 
3- Jam (leg) (20 cm from floor)   __________ 
 __________ 
 
Staj maladi a (Stage of illness)    __________  __________ 
 
Presence des lesions (Lesions present)  Oui /Non  ________       ________ 
 
Si Wi, lokalite lesion-la _________________________________________________ 
 
Lesyon fongal (entry lesions)  (indicate on the drawing where all entry lesions are, 
especially those between the toes) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Konesyans maladi a (Knowledge about the illness)
 
Eske ou ka di nou kisa ki bay maladi sa a?  (Can you tell me what causes this 
illness?)  
 
1- Piki insek  2- Maji  3- Antoch/frappe pye  4- Ve  5- Fredi  6- Mank de vitamin 
7-Lot, di  kisa 
 
[1-Insect bite  2- Magic  3- Sprain/injure foot  4- Worms  5- Chill  6- Vitamin 
deficiency  7- Other, explain] 
 
What kinds of care can help your gwopye?  (Circle all that patient says) 
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1- Hygiene/washing  2- Wear shoes  3- Permanganate  4- Crème 5- Elevation  6- 
Massage  7-  Exercise  8- Bandage  9- Medicine  10- Nothing  11 – Other, explain 
 
Are there things you can do to help prevent acute attacks?  No _____ 
Yes ______ (If yes:)  What can you do? 
 
1- Hygiene/washing  2- Wear shoes  3- Permanganate  4- Crème 5- Elevation  6- 
Massage  7-  Exercise  8- Bandage  9- Medicine  10- Nothing  11 – Other, explain 
 
What can be done to provide relief during an acute attack?  (Circle all that patient 
says) 
 
1- Hygiene/washing  2- Wear shoes  3- Permanganate  4- Crème 5- Elevation  6- 
Massage  7-  Exercise  8- Bandage  9- Medicine  10- Nothing  11 – Other, explain 
 
Pratik ke malad fe li menm pou swenye pye a (Self-care practices for leg) 
 
Di mwen tou sa ou fe pou pye a ak fwekans (Tell me everything you do for your leg 
and how often). 
 
   Chak jou   Yon fwa/semen   Yon fwa/mwa    Mwens ke sa 
                                    (Daily)       (Once/week) (Once/month)   (Less often) 
 
1- Ijenn  ______ ______ ______ ______ 
2- Mete sandal ______ ______ ______ ______ 
3- Perman. ______ ______ ______ ______ 
4- Krèm  ______ ______ ______ ______ 
5- Elevasyon ______ ______ ______ ______ 
6- Masaj  ______ ______ ______ ______ 
7- Eksersis ______ ______ ______ ______ 
8- Bandaj  ______ ______ ______ ______ 
9- Medikaman ______ ______ ______ ______ 
10- Remed fey ______ ______ ______ ______ 
11- Pomad  ______ ______ ______ ______ 
12- Lot:_____ ______ ______ ______ ______ 
 
 
Self-efficacy
 
Ki lot bagay ou kapab fe pou pye-a ke ou pap fe kounye-a?  Fwekans? 
What other things can you do to help your leg that you do not currently do? 
Frequency? 
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   Chak jou   Yon fwa/semen   Yon fwa/mwa    Mwens ke sa 
                                    (Daily)       (Once/week) (Once/month)   (Less often) 
 
1-Ijenn  ______ ______ ______ ______ 
2-Mete sandal ______ ______ ______ ______ 
3-Perman. ______ ______ ______ ______ 
4-Krèm  ______ ______ ______ ______ 
5-Elevasyon ______ ______ ______ ______ 
6-Masaj  ______ ______ ______ ______ 
7-Eksersis  ______ ______ ______ ______ 
8-Bandaj  ______ ______ ______ ______ 
9-Medikaman ______ ______ ______ ______ 
10-Remed fey ______ ______ ______ ______ 
11-Pomad  ______ ______ ______ ______ 
12-Lot:_____ ______ ______ ______ ______ 
 
 
Eske ou gen konfyans nan kapasite pa-ou pou fe tout bagay posib pou pran swen 
pye-ou nan meye fason posib? 
How confident are you in your ability to do all things possible to take care of your 
leg the best way you can? 
 
1- Anpil confyans  2- Ti kras confyans  3- A penn confyans  4- Manke confyans  
5- Pa ditou konfyans 
1- Very confident  2- Somewhat confident  3- A little confident  4- Not very 
confident  5- Not at all confident 
 
Quality of Life
 
Euro-Qual – 5D 
 
By placing a check in one box in each group below, please indicate which statements best 
describe your own health state today. 
(Tanpri, pou chak gwoup nan paj sa a, tyeke nan ti kare yo pou ou ka fè nou konnen ki 
fraz ki esplike pi byen kijan sante ou ye jodi a☺ 
 
Mobility (Mouvman) 
 
I have no problems in walking about        
(Mwen pa gen pwoblèm pou m mache) 
 
I have some problems in walking about    
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(Mwen gen kèk pwoblèm pou m mache) 
 
I am confined to bed   
(Mwen oblije ret nan kabann toutan) 
 
 
Self-Care (Pwòpte kò w) 
  
I have no problems with self-care   
(Mwen pa gen pwoblèm pou m pwòpte tèt mwen  
pou kont mwen)    
 
I have some problems washing or dressing myself   
(Mwen gen ti pwoblèm pou m fè twalèt mwen, pou m benyen 
osnon pou m abiye pou kont mwen)  
 
I am unable to wash or dress myself   
(Mwen pa ka ni fè twalèt mwen, ni abiye m pou 
kont mwen) 
 
 
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
{Aktivite Ou Abitye Fè  (pa egzanp:  ale travay, etidye, fè travay nan kay, fè aktivite ak 
fanmi an osnon amizman)} 
 
I have no problems with performing my usual activities   
Mwen pa gen pwoblèm pou mwen fè aktivite mwen toujou abitye fè yo 
 
I have some problems with performing my usual activities   
(Mwen gen ti pwoblèm pou mwen fè aktivite mwen abitye fè yo) 
I am unable to perform my usual activities   
(Mwen pa kapab fè aktivite mwen te konn abitye fè yo ankò) 
 
 
Pain/Discomfort (Doulè ak malalèz) 
I have no pain or discomfort   
(Mwen pa gen doulè, mwen pa malalèz ak janm lan) 
 
I have moderate pain or discomfort   
(Mwen gen ti doulè epi mwen yon ti jan malalèz ak  janm lan) 
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I have extreme pain or discomfort   
(Mwen gen anpil doulè, mwen malalèz anpil ak janm lan) 
 
 
Anxiety/Depression (Enkyetid ak Dekourajman) 
I am not anxious or depressed   
(Mwen pa gen enkyetid; mwen pa dekouraje non plis) 
 
I am moderately anxious or depressed   
(Mwen gen yon ti enkyetid, mwen yon ti jan dekouraje) 
 
I am extremely anxious or depressed   
(Mwen gen anpil enkyetid; mwen dekouraje anpil) 
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To help people say how good or bad a health state is, we have drawn a scale (rather like a 
thermometer) on which the best state you can imagine is marked 100 and the worst state 
you can imagine is marked 0. 
(Pou ede moun jwenn yon fason pou yo ka esplike si sante yo anfòm osnon si sante yo pa 
anfòm, nou trase pakèt ba sa yo (ki sanble ak yon tèmomèt). Pi bon sante yon moun ka 
imajine rive sou liy san (100) epi lè sante a pa bon ditou li rive jouska liy 0 (zewo). 
We would like you to indicate on this scale how good or bad your own health is today, in 
your opinion.  Please do this by drawing a line from the box below to whichever point on 
the scale indicates how good or bad your health state is today. 
(Nou ta renmen ou di nou dapre pakèt ba  sa yo  kijan dapre ou sante ou anfòm osnon si li 
pa bon jodi a. Tanpri, trase yon liy apatid kare nwa sa a, jiska  pwen sou pakèt ba sa yo  
ki montre kijan sante ou bon osnon kijan li pa bon jodi a.) 
Best Imaginable Health State 
(Sante ki pi bon ou ka imajine) 
      100 
 
9 0 
 
8 0 
 
7 0 
 
6 0 
 
  5 0 
 
4 0 
 
3 0 
 
2 0 
 
1 0 
 
Your own Health State 
0  
Worst Imaginable Health State 
(Sante ki pi mal ou ka imajine) 
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Center for Epidemiologic Studies Depression Scale (CED-D), NIMH 
 
Below is a list of the ways you might have felt or behaved.  Please tell me how often you have felt this way during the past week. 
Make bwat ki pi byen montre jan ou te santi-ou oubyen jan ou te aji PANDAN SEMENN PASE-A 
 
During the Past Week 
 Rarely or none of 
the time (less than 
1 day) 
Raman. Ou, pa 
minm yon fwa 
(mwens ke yon 
jou) 
Some orr a little of 
the time (1-2 days) 
Kek fwa.  Ou, yon 
ti kras tan. (1 a 2 
jou) 
Occasionally 
or a moderate 
amount of 
time (3-4 days)
Ase souvan 
oubyen, yon 
kantite modere 
(3 a 4 jou) 
Most or all 
of the time 
(5-7 days) 
Pi fo Oubyen 
tout tan. (5 a 
7 jou) 
1.  I was bothered by things that  
     usually don’t bother me. 
     Kek bagay te deranje-m ki pa   
     abitye deranje-m 
    
2.  I did not feel like eating; my 
     appetite was poor. 
    Mwen pa’t santi-m mwen ta  
    manje Apeti-m te ba 
    
3.  I felt that I could not shake off 
     the blues even with help from 
my 
     family or friends. 
     Mwen pa’t santi-m te kapab 
     souke tristes mwen malgre 
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    fanmi-m ak sanmi-m yo ede-m 
4.  I felt I was just as good as other 
     people. 
    Mwen te santi-m byen menm jan 
    ak tout lot mounn. 
    
5.  I had trouble keeping my mind 
     on what I was doing. 
    Mwen te genyen difikilte 
     konsantre sou sa mwen’tap fe. 
    
6.  I felt depressed 
     Mwen te santi-m demoralize 
    
7.  I felt that everything I did was 
an 
    effort. 
    Mwen santi tout sa mwen fe se 
ak 
    gwo efo. 
 
 
    
 
 
Rarely or none of 
the time (less than 
1 day) 
Raman. Ou, pa 
minm yon fwa 
(mwens ke yon 
jou) 
Some orr a little of 
the time (1-2 days) 
Kek fwa.  Ou, yon 
ti kras tan. (1 a 2 
jou) 
Occasionally 
or a moderate 
amount of 
time (3-4 days)
Ase souvan 
oubyen, yon 
kantite modere 
(3 a 4 jou) 
Most or all 
of the time 
(5-7 days) 
Pi fo Oubyen 
tout tan. (5 a 
7 jou) 
8.  I felt hopeful about the future.     
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    Mwen santi mwen genyen espwa 
    avek avni mwen. 
9.  I though my life had been a 
     failure. 
    Mwen te panes la vi-m te yon 
    gwo echek. 
    
10.  I felt fearful. 
      Mwen te santi mwen pe 
    
11.  My sleep was restless. 
       Mwen te san somey 
    
12.  I was happy. 
       Mwen te kontan. 
    
13.  I talked less than usual. 
       Mwen te pale mwens ke mwen 
       Abitye. 
    
14.  I felt lonely 
       Mwen te santi mwen poukont 
       Mwen. 
    
15.  People were unfriendly 
       Mwen te konn banmwen 
       tretman fret. 
    
16.  I enjoyed life. 
       Mwen te jwi lavi mwen. 
    
17.  I had crying spells. 
       Mwen te pran kriye yon paket 
       fwa. 
    
18.  I felt sad. 
       Mwen te santi mwen tris. 
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    19.  I felt that people dislike me. 
       Mwen te santi ke mounn pa’t 
       renmen mwen. 
20.  I could not get “going” 
       Mwen pa’t kapab souke ko’m 
       pou mwen demare. 
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CDC Healthy Days Questions 
 
1.  Eske-w ka di an jeneral kijan sante-w ye: (would you say that in general your helath 
is:) 
 
 Read responses 1a-e. 
 
 a. Ekselan 
 b. tre byen 
 c. byen 
d. pa mal ou 
 e. mal. 
 f Mwen pa konen / Mwen pa si 
 g. Refuse 
 
Pa li repons pou kesyon swivan. (Do not read the responses for the following questions) 
 
2.  Kounye-a nap panse a sante ko ou, maladi ko ou ak aksidan ladan tou, konbyen 
jou nan mwa ki sot pase sante ko ou pat byen?   (Now thinking about your 
physical health, which includes physical illness and injury, for how many days 
during the past 30 days was your physical health not good?) 
 
 a. Nomb jou ____Number of days ____ 
 b. Ayen____       None____ 
 c. Pa konnen ____Don’t know____ 
 d. Refuse____  Refused____ 
 
3. Kounye-a nap panse a maladi nan tet, maladi stres, depresyon, e pwoblem avek 
emosyon, konbyen jou nan mwa ki sot pase ya ou te malad nan tet?  (Now 
thinking about your mental health, which includes stress, depression, and 
problems with emotions, for how many days during the past 30 days was your 
mental health not good?) 
 
 a. Nomb jou ____Number of days ____ 
 b. Ayen____       None____ 
 c. Pa konnen ____Don’t know____ 
 d. Refuse____  Refused____ 
 
4. Nan mwa ki sot pase a, konbyen jou maladi ko ou ak maladi tet fe ou pa kab fe 
aktivite-w abitye fe, tankou okipe tet ou, travay, ak amizman?  (During the past 30 
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days, for about how many days did poor physical or mental health keep you from 
doing your usual activities, such as self-care, work, or recreation?) 
 a. Nomb jou ____Number of days ____ 
 b. Ayen____       None____ 
 c. Pa konnen ____Don’t know____ 
 d. Refuse____  Refused____ 
Kesyon kap ven you se sou limitasyon ou kap genyen chak jou nan lavi-w. (The next 
questions are about  limitations you may have in your daily life). 
 
1.   Eske ou limite nan aktivite-w paske ou domaje oubyen gen pwoblem sante?  (Are 
you limited in any way in any activities because of any impairment or health 
problem?) 
 
 a.  Wi     (Yes) 
 b. Non – ale nan Kesyon 6 (No – go to question 6) 
 c.  Pa konnen – Ale nan kesyon 6 (Don’t know – go to question 6) 
 d. Refuse – Ale nan kesyon 6 (Refused – go to question 6) 
 
2.  Ki domaj oubyen pwoblenm sante presipal ou gen ki fe ou pa kap fe aktivite?  
(What is the MAJOR impairment or health problem that limits your activities?)  
DO NOT READ.  SELECT ONLY ONE CATEGORY. 
 
 a. arthrit (arthritis) 
 b. pwoblem avek do oubyen kou (back or neck problems) 
 c. fwakti, mal zo (fractures, bone/joint injury) 
 d.  pwoblem mashe (problems walking) 
 e. pwoblem avek respiration (lung/breathing problem) 
 f. difikilti koute (hearing problem) 
 g. pwoblem avek je (eye / vision problem) 
 h. maladi ke (heart problem) 
 i. maladi atak “stroke”  (stroke problem) 
 j. tansyon (high blood pressure) 
 k diabet/sik (diabetes) 
 l. kanse (cancer) 
 m. depression / anxiety / emotional problems 
 n. gwo pye (lymphedema) 
 o. lot pwoblem (other problem) ___________________________________ 
 p. Pa konnen (Don’t know) 
 q. Refuse (Refused) 
 
3.   Kombyen tan sa genyen depi ou gen domaj presipal sa? (For how long have your 
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activities been limited because of your major impairment or health problem?)  PA 
LI REPONS. MAKE SA LI DI.  (DO NOT READ.  CODE APPROPRIATE 
UNIT OF TIME.) 
 
 a. _____ jou (days) 
 b. _____ semann (weeks) 
 c. _____ mwa (months) 
 d. _____ ane (years) 
 e. Pa konnen (Don’t know) 
 f. Refuse (Refused) 
 
4.  Poutet domaj oubyen pwoblem sante, eske ou beswen lot moun okipe ou, tankou 
pou manje, benyen, mete rad sou ou, ou pou mache nan kay la? (Because of any 
impairment or health problem, do you need the help of other persons with your 
PERSONAL CARE needs, such as eating, bathing, dressing, or getting around the 
house)? 
 
 a. Wi (Yes) 
 b. Non (No) 
 c. Pa konnen (Don’t know) 
 d. Refuse (Refused) 
 
 
5.   Poutet ou domaje oubyen pwoblem sante, eske ou beswen ed pou fe aktivite chak 
jou-w, tankou menaj nan kay, komes, fe pwovizyon, oubyen soti pou fe lot bagay? 
(Because of any impairment or health problems, do you need the help of other 
persons in handling your ROUTINE needs, such as everyday household chores, 
doing necessary business, shopping, or getting around for other purposes?) 
 
 a. Wi (Yes) 
 b. Non (No) 
 c. Pa konnen (Don’t know) 
 d. Refuse (Refused) 
 
 
6. Nan trant jou ki sot pase yo konbyen jou ko’w te fe telman mal li te di pou ou fe 
acktivite nomal tankou okipe tet ou, travay, ou rekreyasyon?  (During the past 30 
days, for about how many days did PAIN make it hard for you to do your usual 
activities, such as self-care, work, or recreation?) 
 
 a. ______ Nomb jou (number of days) 
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 b. Ayen (None) 
 c. Pa konnen (Don’t know) 
 d. Refuse (Refused) 
 
7.   Nan trant jou ki sot pase-a konbyen fwa ou te santi ke’w pa kontan, tris, ou 
chagren? (During the past 30 days, for about how many days have you feldt SAD, 
BLUE, or DEPRESSED?) 
 
 
 a. ______ Nomb jou (number of days) 
 b. Ayen (None) 
 c. Pa konnen (Don’t know) 
 d. Refuse (Refused) 
 
8. Nan trant jou ki sot pase-a konbyen fwa ou te santi ke pa kontan, enkye, tandi, ke 
pa pose?  (During the past 30 days, for about how many days have you felt 
WORRIED, TENSE, or ANXIOUS?)  
 
 
 a. ______ Nomb jou (number of days) 
 b. Ayen (None) 
 c. Pa konnen (Don’t know) 
 d. Refuse (Refused) 
 
9. Nan trant jou ki sot pase-a konbyen jou ou te santi ou pa pran ase repo oubyen ou 
pa ase domi? (During the past 30 days, for about how many days have you felt 
that you did not get ENOUGH REST OR SLEEP?)  
 
 a. ______ Nomb jou (number of days) 
 b. Ayen (None) 
 c. Pa konnen (Don’t know) 
 d. Refuse (Refused) 
 
10. Nan trant jou ki sot pase a konbyen jou ou te santi ou pat an fom oubyen avek 
anpil eneji? (During the past 30 days, for about how many days have you felt 
VERY HEALTHY AND FULL OF ENERGY?)    
 
 a. ______ Nomb jou (number of days) 
 b. Ayen (None) 
 c. Pa konnen (Don’t know) 
 d. Refuse (Refused)
 
 
Appendix C: Map of Port-au-Prince Area. 
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